kidney

INTERNATIONAL

Volume 35, 1989

Editor Emeritus
Roscoe R. Robinson, Nashville

Editor
Thomas E. Andreoli, Little Rock

Associate Editors
Claude Amiel, Paris
James P. Knochel, Dallas

Consulting Editors
J. S. Cameron, London
Ramzi Cotran, Boston
William G. Couser, Seattle
Gerhard Giebisch, New Haven
Nishio Honda, Hamamatsu
Wilhelm Kriz, Heidelberg
François Morel, Paris
Pierre Verroust, Paris

Editorial Board
Vittorio E. Andreucci, Naples
Robert C. Atkins, Melbourne
Knut Aukland, Bergen
Peter Bàlint, Budapest
Rashad Barsoum, Guiza
Jonas Bergstrom, Stockholm
Ori S. Better, Haifa
Roland C. Blantz, San Diego
Jean-Philippe Bonjour, Geneva
Vittorio Bonomini, Bologna
Barry M. Brenner, Boston
Ruth E. Bulger, Washington, D.C.
Anthony R. Clarkson, North Terrace
Jack W. Coburn, Los Angeles
Giuseppe D'Amico, Milan
Vincent W. Dennis, Durham
Evert J. Dorhout Mees, Utrecht
Ratislav Dzúrik, Bratislava
Marilyn G. Farquhar, New Haven
Thomas F. Ferris, Minneapolis
Carmelo Giordano, Naples
Richard J. Glassock, Torrance
Jared J. Grantham, Kansas City
J. P. Grünfeld, Paris
Renée Habib, Paris
Steven C. Hebert, Boston
Lee W. Henderson, Round Lake
Robert H. Heptinstall, Baltimore
Jaime Herrera-Acosta, Mexico City
Klaus Hierholzer, Berlin
Malcolm A. Holliday, San Francisco
Harry Jacobson, Nashville
Rex L. Jamison, Rochester, NY
Colin I. Johnston, Melbourne
D. N. S. Kerr, London
Saulo Klahr, St. Louis
Horst Klinkmann, Rostock
Franklyn G. Knox, Rochester, MN
Franciszek Kokot, Katowice
Rajiv Kumar, Rochester, MN
Kiyoshi Kurokawa, Tokyo
Neil A. Kurtzman, Lubbock
Paul H. Lambert, Geneva
David Z. Levine, Ottawa
Guy Lemieux, Montreal
Francisco Llach, Oklahoma City
Robert G. Luke, Cincinnati
Manuel Martinez-Maldonado, San Juan
Shaul G. Massry, Los Angeles
Alfred F. Michael, Minneapolis
Paul Michielsen, Louvain
William E. Mitch, Atlanta
John F. Moorhead, London
T. J. Neale, Wellington
Karl D. Nolph, Columbia
Tadeusz Orlowski, Warsaw
D. Keith Peters, London
Mordecai M. Popovtzer, Jerusalem
Jaime Borrero Ramirez, Medellin
Jose L. Rodicio, Madrid
Robert W. Schrier, Denver
Jay H. Stein, San Antonio
Liliane Striker, Bethesda
Wadi N. Suki, Houston
Richard L. Tannen, Ann Arbor
Gilbert Thiel, Basel
C. Craig Tisher, Gainesville
Karl J. Ullrich, Frankfurt
Heinz Valtin, Hanover
Clark D. West, Cincinnati
Guillermo Whittembury, Caracas
Curtis B. Wilson, La Jolla

Manuscript Editor
Shellie Newell, Little Rock

Editorial Assistant
Joni Owens, Little Rock

Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1989 by International Society of Nephrology

Author Index For Volume 35

Aarons I (abst) 741, 751
Abarzua M (abst) 170, 420
Abboud CN (abst) 355
Abboud HE (abst) 295, 308
Abdella P (abst) 313, 382
Abdulnour-Nakhoul S (abst) 476
Abe H (abst) 327, 328, 471
Abe K *See* Ito S et al 1138
Abels RI (abst) 193, 229
Abitbol C (abst) 219, 267, 385
Aboolian A (abst) 168, 175, 182
Abraham NG (abst) 446, 448
Abraham P (abst) 243
Abraham PA (abst) 198, 236, 301
Abrahamson DR (abst) 357, 360, 504
Abramow M (abst) 280, 305
Abrams SML (abst) 220
Abrams SML *See* Baker LRI et al 661
Abramson RG (abst) 432, 451
Abrass CK (abst) 339
Abreo K (abst) 397
Abu-Alfa A (abst) 422
Abu-Hamdan D (abst) 399
Abu-Hamdan DK (abst) 198
Abu-Jawdeh G (abst) 422
Abuelo JG (abst) 204
Acara M (abst) 432
Acchiardo S (abst) 237, 259
Adachi K *See* Kobayashi S et al 1405
Adam K (abst) 1439
Adam WR (abst) 741
Adams JS (abst) 276
Adams ND (abst) 380
Adamson JW (abst) 190, 193, 193, 246
Adelberg EA (abst) 156, 164
Adhikari M (abst) 909, 909, 910, 914
Adler A (abst) 399
Adler AJ (abst) 380
Adler S (abst) 202, 204, 207, 339, 401, 422
Adler S *See* Stahl RAK et al 1161
Adler SG (abst) 195
Adler SG *See* Ferdows M et al 783
Admiraal P (abst) 1429
Adorati M (abst) 758
Adrogue HJ (abst) 214, 214
Afendakis N (abst) 1443, 1443
Agarwal A (abst) 213
Agrafiotis A (abst) 1436, 1436, 1436, 1443
Agrawal A (abst) 243
Ahmed S (abst) 221
Airaghi C (abst) 759
Aizawa S (abst) 418
Ajam M (abst) 237, 247, 255, 260
Ajemian R (abst) 404
Ajemian RC (abst) 294
Akabas MH (abst) 160
Akano N *See* Yoshioka K et al 1203
Akashi Y (abst) 368, 372, 374, 376
Akiba T (abst) 217, 237, 252
Akmal M (abst) 422, 427
Al-Awqati Q (abst) 160, 465
Al-Khateeb M (abst) 212
Al-Muzairai IA, Innes A, Hillis A, Stewart KN, Bone JM, Catto GRD, Macleod AM: Renal transplantation: Cyclosporin A and antibody development after donor-specific transfusion 1057
Albertazzi A (abst) 405, 755
Albertyn L (abst) 744
Albini B (abst) 356
Albrechtsen D (abst) 513
Albrightson-Winslow C (abst) 339
Alcock M (abst) 744
Alevizou V (abst) 1440, 1441, 1443
Alexander EA (abst) 463, 464, 501
Alexander JW (abst) 515
Alexander RW (abst) 516
Alexander S (abst) 268
Alexiewicz JM (abst) 193, 389
Alexopoulos E (abst) 1440, 1440
Alexopoulos J (abst) 1441
Alfieri R (abst) 192
Alfred HJ (abst) 237
Alfrey A (abst) 479
Alfrey AC (abst) 398
Alfrey PS (abst) 253
Alfrey PS *See* Lanese DM et al 1409
Algrim C (abst) 274
Ali A (abst) 321
Allen B (abst) 742
Allen GG (abst) 751
Allen GG, Barratt LJ: An in vivo study of voltage-dependent renal tubular acidosis induced by amiloride 1107
Allen HM (abst) 206
Allen JC (abst) 306
Allen RD (abst) 738, 745, 745
Allis JL *See* Endre ZH et al 1249
Allison NL (abst) 249
Allon M (abst) 206, 211, 215, 238
Alper SL (abst) 150, 152
Alpern RJ (abst) 301, 450, 455, 461
Alpers C (abst) 350
Alpers CE (abst) 339
Alpert H (abst) 415
Alpert HC *See* Gouvea WL et al 1041
Alpert MA (abst) 238
Altman A (abst) 356
Altmann P (abst) 189, 192
Alvarez RJ (abst) 308
Alvestrand A *See* Lindholm B et al 1219
Alvo M (abst) 214
Amato D (abst) 336
Ameer B (abst) 337
Amerling R (abst) 308
Amiel C (abst) 154, 171, 444, 476
Amin A (abst) 400, 404

Aminian A (abst) 741
Ammann H (abst) 442
Amore A *See* Roccatello D et al 622
Anagnostopoulos T (abst) 461
Anania MC (abst) 318
Anania MC *See* Pugliese F et al 817
Anassis P (abst) 1440, 1446
Anastasio P (abst) 189, 192, 468
Andersen RC (abst) 523
Anderson C (abst) 505
Anderson H (abst) 274
Anderson J (abst) 220
Anderson P (abst) 422
Anderson RJ (abst) 171, 175, 400
Anderson S (abst) 284, 290, 314, 422
Ando Y (abst) 305
Andreoli SP (abst) 400
Andreoli SP, Cohen M: Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD 1330
Andres G *See* Brentjens JR 954
Andres GA *See* Rees AJ et al 921
Andress DL (abst) 258, 376, 518
Andreucci VE (abst) 754
Andrews GK (abst) 311
Andrews PI (abst) 749
Androulakis G (abst) 1439
Ang KS (abst) 191, 204, 238, 241
Angra S (abst) 523
Antiga L (abst) 336
Antignac C, Gubler M-C, Leverger G, Broyer M, Habib R, Lacoste M, Beziau A, Naizot C: Delayed renal failure with extensive mesangiolysis following bone marrow transplantation 1336
Antignani A (abst) 209, 220, 239, 269
Antoniadis A (abst) 1436
Antoniou A (abst) 1438
Antonovych T (abst) 408, 424
Anzalone D (abst) 240
Aono F (abst) 268
Aperia A (abst) 314, 323, 478
Aperia A *See* Hannerz L et al 1133
Apostolidis N (abst) 1444
Apostolopoulos A (abst) 1442, 1442
Apostolopoulos D (abst) 1441
Appel G *See* D'Agati V et al 1358
Appel GB (abst) 210, 211
Appel RG (abst) 277
Arakawa M (abst) 150, 357
Arant BS Jr (abst) 473
Arbeit L (abst) 256, 508
Arbeit LA (abst) 401
Ardaillou R (abst) 290, 309, 318, 405
Ardaillou R *See* Baud L et al 1111
Ardito T (abst) 407
Arisz L (abst) 470
Arisz L *See* Krediet RT et al 1064
Arkema A (abst) 345
Arnold PE (abst) 403
Aron DC (abst) 308
Aronoff GR (abst) 220, 279
Aronson PS (abst) 158, 164, 464, 478, 488, 498
Arruda JAL (abst) 224, 319, 455, 456, 462, 464
Arthus MF (abst) 202, 206
Artis AK (abst) 238
Aruz F (abst) 493
Arvanitis D (abst) 1437
Asano Y (abst) 489
Ashida T (abst) 327, 328, 471
Ashley CC (abst) 396
Ashwood ER (abst) 419
Asinger RW (abst) 236
Asmus G (abst) 388
Assan R (abst) 404
Assmann K (abst) 1434
Assmann KJ (abst) 353
Assmann KJM (abst) 340, 341
Assounga AGH (abst) 238
Atkins R (abst) 753
Atkins RC (abst) 742, 743, 743, 744, 745, 747
Atkinson D (abst) 421
Ault BH (abst) 368
Aurell M (abst) 298
Ausiello D (abst) 165
Ausiello DA (abst) 152, 154
Austin JN (abst) 239
Ave TD (abst) 401
Aveledo L (abst) 400
Aventaggiato L *See* Schena FP et al 875
Avioli R *See* Blair HC et al 1119
Avison MJ (abst) 449, 492
Avner ED (abst) 423
Avram MM (abst) 209, 220, 239, 269
Awazu M (abst) 278
Axelsen R (abst) 747
Aynedjiam H (abst) 433
Aynedjian H (abst) 425
Ayus JC (abst) 214
Azar S (abst) 430
Azar S *See* Mauer SM et al 48
Azar SH (abst) 322
Baack B (abst) 506
Bab I (abst) 379
Babino H (abst) 466
Bacallao R (abst) 186, 188
Bacay A (abst) 179
Bacay AC (abst) 207
Bach JF (abst) 404
Backer A (abst) 314
Bacle F *See* Haeffner-Cavaillon N et al 1212
Badalamenti J (abst) 170, 360
Badr KF (abst) 174, 291, 296, 298, 308, 312, 339, 364
Bagby S (abst) 322
Bagchus WM (abst) 340, 345
Baggio B (abst) 754
Baglioni C (abst) 310
Bagnis C *See* Bruno M et al 1189
Bahner U (abst) 278, 281, 417
Bailey RR (abst) 739
Bailey S (abst) 222
Baillou C (abst) 245
Bailly C (abst) 444, 476
Baines AD (abst) 401
Baird B (abst) 150, 388, 411
Baird H (abst) 740
Bakaletz AP (abst) 344
Baker B (abst) 212
Baker L, Dahlem S, Goldfarb S, Kern EFO, Stanley CA, Egler J, Olshan JS, Heyman S: Hyperfiltration and renal disease in glycogen storage disease, type I 1345
Baker LRI (abst) 220, 395, 518

Baker LRI, Abrams SML, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH: $1,25(OH)_2D_3$ administration in moderate renal failure: A prospective double-blind trial 661
Baker P (abst) 350, 359, 362
Baker PJ *See* Schulze M et al 60
Baker PJ *See* Stahl RAK et al 1161
Bakir AA (abst) 221
Bakker WW (abst) 221, 359, 1429, 1433
Balakrishanan K (abst) 515
Balaskas E (abst) 1445
Balcke P (abst) 225, 294, 321, 383, 509
Baldet P (abst) 238
Ballardie FW (abst) 372
Baller JFW (abst) 221, 1429
Ballerman BJ (abst) 278
Ballermann BJ (abst) 177, 285, 316, 320, 432
Ballocchi S (abst) 757, 757, 757
Baltzan MA (abst) 504
Baltzan RB (abst) 504
Baluarte HJ (abst) 410, 515, 523
Bamji M (abst) 368
Bandari B (abst) 380
Bank N (abst) 210, 425, 433
Bankir L (abst) 449
Banks RO (abst) 309
Bansal VK (abst) 322
Barac-Nieto M (abst) 380, 385, 437
Barajas L (abst) 319
Barak H (abst) 271
Baranowski R (abst) 289
Baranowski RL (abst) 278, 289
Barba L (abst) 504
Barbarano L (abst) 759
Barber WH (abst) 516, 517
Barcelli UO (abst) 423
Barcelon FS (abst) 168
Bardin T (abst) 267
Barfuss DW (abst) 492, 500
Barkley G (abst) 262
Barlee V (abst) 241
Barnas U (abst) 316
Barnes J (abst) 176
Barnes JL (abst) 340
Barnett R (abst) 279, 401, 508
Baronti A (abst) 755
Barratt LJ (abst) 751, 751, 753
Barratt LJ *See* Allen GG 1107
Barre PE (abst) 258
Barrero J (abst) 214
Barrett KJ (abst) 346
Barrett PQ (abst) 279, 300
Barry J (abst) 521
Barsotti G (abst) 758
Barth RH (abst) 239
Barthel AM (abst) 241
Bartkus C (abst) 520
Bartosh S (abst) 410
Bascoul S (abst) 238
Bashore T (abst) 231
Basile C (abst) 267
Baskin GB (abst) 339
Bass AS (abst) 477
Bassallo G (abst) 757
Bastl CP (abst) 169, 182, 446, 477
Bastos MG (abst) 506
Batlle DC (abst) 323, 329, 332, 462
Batsford S (abst) 365
Battaglia C (abst) 472
Batuman V (abst) 150
Baud L (abst) 309, 318
Baud L, Oudinet J-P, Bens M, Noe L, Peraldi M-N, Rondeau R, Etienne J, Ardaillou R: Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide 1111
Baudin G (abst) 263
Baudouin B (abst) 160, 164, 166
Bauer JH (abst) 303
Bauer KD *See* Carone FA et al 1351
Baum M (abst) 450, 462
Baumal R *See* Thorner P et al 843
Baumgartner D (abst) 1431
Bausewein K (abst) 282
Baxter R (abst) 436
Bay WH (abst) 221
Bayer T (abst) 285, 423
Baylis C (abst) 423, 472
Bayliss J (abst) 398
Bayrou B (abst) 257
Baz M *See* Monti JP et al 871
Bazzato G (abst) 221, 239, 270, 334
Beach D (abst) 423
Bear J (abst) 206
Beaumont K (abst) 477, 490
Beck GJ (abst) 201
Beck JC (abst) 451
Beck R (abst) 909
Becker GJ (abst) 749
Beckman B (abst) 288
Beckner ME (abst) 265
Bedford L (abst) 396
Bedogna V (abst) 336
Bedoya LA (abst) 302
Behar M (abst) 340, 502
Behme T (abst) 254
Behrens MT (abst) 442
Beier E *See* Szabo A et al 1049
Beierwaltes WH *See* Ito S et al 1138
Beilin LJ (abst) 748
Belechri AM (abst) 1444
Bell JL (abst) 240
Bell PD (abst) 309
Bellini L (abst) 192
Bello-Reuss E (abst) 477
Belloni A (abst) 508
Bellorin-Font E (abst) 396, 400
Benabe JE (abst) 493
Benazzi E (abst) 759
Bendayam R (abst) 493
Benedict C (abst) 333
Benet LZ (abst) 507
Benetsanakis N (abst) 1441
Bengele HH (abst) 501
Bennett C (abst) 442
Bennett G (abst) 739
Bennett L (abst) 223
Bennett PH *See* Kunzelman CL et al 681
Bennett W (abst) 521
Bennett WM (abst) 203, 222, 369, 405, 510, 738, 748, 748
Bens M *See* Baud L et al 1111
Benson B (abst) 295
Benson L (abst) 444

Bentzel CJ (abst) 151
Benvenisty AI (abst) 512
Benz RL (abst) 323
Berden J (abst) 1434
Berden JHM (abst) 341
Berekos K (abst) 1444
Bergamo R *See* Hirschberg R et al 865
Berger M (abst) 313
Bergonzi G (abst) 757, 757, 757
Bergstein JM, Riley M: Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction 14
Bergstrom J (abst) 274, 519
Bergström J *See* Lindholm B et al 1219
Berk AJ (abst) 183
Berk M (abst) 329
Berke A (abst) 263
Berkley V (abst) 240
Berkseth R (abst) 243, 251
Berl T (abst) 168, 230
Berl T *See* Teitelbaum I et al 647
Berlyne G (abst) 399
Berlyne GM (abst) 239, 380
Bernard DB (abst) 235, 272
Bernard LM (abst) 501
Bernard R (abst) 467
Bernardini J (abst) 275
Berndt TJ (abst) 389
Bernheim J (abst) 272, 286, 287, 296
Berns AS (abst) 414
Bernstein KE (abst) 298
Bernstein S (abst) 493
Berrocal FJR *See* Martínez-Zorzano VS et al 1295
Berry C (abst) 481
Bertani T (abst) 424, 436
Bertelli R (abst) 760
Berteloot A (abst) 449, 450
Bertolatus JA (abst) 401
Bertorello A (abst) 323, 478
Bertrand W (abst) 181
Berty R (abst) 202, 401
Besarab A (abst) 240, 240, 445, 520
Betts CR (abst) 172
Beutler JJ *See* Boer WH et al 1183
Bevilacqua M (abst) 754
Bezazi-Papakonstantinou E (abst) 1447
Beziau A *See* Antignac C et al 1336
Bhagavan H (abst) 275
Bhagavan HN (abst) 276
Bhusnurmath SR (abst) 334
Bianchi AM (abst) 755
Bianchi G (abst) 325
Bibiano L (abst) 754
Bichara M (abst) 389, 458, 459, 460
Bichet DG (abst) 202, 206
Bidani A (abst) 323, 428
Bieta A (abst) 1436
Biguzas M (abst) 738, 746
Billis A (abst) 1436, 1440, 1441
Billis AG (abst) 1437, 1437, 1439, 1442, 1442, 1445, 1445, 1446
Bills T (abst) 421
Bilo HJG (abst) 516, 1432
Bingham C (abst) 322, 430
Birch D (abst) 222
Birch F (abst) 289
Bird JE (abst) 402
Bird JE, Evan AP, Peterson OW, Blantz RC: Early events in ischemic renal failure in the rat: Effects of antioxidant therapy 1282
Birmingham D (abst) 341, 354
Birnir B (abst) 151
Bitter-Suermann D (abst) 365
Bjorch S (abst) 298
Blackburn JG *See* Hazen-Martin DJ et al 31
Blaine EH (abst) 287
Blair HC, Finch JL, Avioli R, Crouch EC, Slatopolsky E, Teitelbaum SL: Micromolar aluminum levels reduce ^{3}H-thymidine incorporation by cell line UMR 106-01 1119
Blair J (abst) 189, 192
Blanchard I (abst) 204
Bland PS (abst) 249
Blantz RC (abst) 402, 406, 467, 467, 475
Blantz RC *See* Bird JE et al 1282
Blasberg RG (abst) 269
Blaufox S (abst) 279
Blazer-Yost B (abst) 151
Blecher SR (abst) 205
Bleifer KH (abst) 229
Blendis L (abst) 284, 289
Bleta A (abst) 1444
Bletas A (abst) 745
Blifeld C (abst) 521
Bloch RD (abst) 388, 503
Bloom R (abst) 151, 426
Blum M *See* Steinhausen M et al 1151
Blumenfeld JB (abst) 496
Blumenthal S (abst) 478
Bobadilla J (abst) 406
Bobadilla N (abst) 336
Bobrow M (abst) 203
Bochicchio T (abst) 189
Bodt A (abst) 260
Boer WH (abst) 207, 1429
Boer WH, Koomans HA, Beutler JJ, Gaillard CA, Rabelink AJ, Mees EJD: Small intra- and large inter-individual variability in lithium clearance in humans 1183
Boeschoten EW *See* Krediet RT et al 1064
Bogman MJJT (abst) 1431
Bohle A (abst) 178, 371
Bohle A *See* Müller CA et al 116
Boineau FG (abst) 207
Boitard C (abst) 404
Bollag WB (abst) 300
Bolton WK (abst) 233, 361
Bomba M (abst) 511
Bomens M (abst) 186
Bommartini F (abst) 336
Bomsztyk K (abst) 384
Bonar SL (abst) 317
Bonduris D (abst) 464
Bonduris DN (abst) 453
Bone JM *See* Al-Muzairai IA et al 1057
Bonifati AM (abst) 759
Bonomini V (abst) 759
Bonventre JV (abst) 169, 170, 292, 412, 415
Boos C (abst) 159
Booz GW (abst) 495
Bora NS (abst) 374
Border W (abst) 341

Bordoni E (abst) 754
Borelli A (abst) 376
Borges RC (abst) 192
Borkan SC (abst) 443
Borke JL (abst) 381
Boron WF (abst) 172, 451, 454, 460
Borsatti A (abst) 754
Bosch FH (abst) 1429
Bosch JP (abst) 195, 222, 230, 241, 271
Bossaller C (abst) 447, 504
Bostrom TE (abst) 740
Botha JR (abst) 908, 909, 911
Boulanger Y (abst) 442, 449, 450
Boulpaep EL (abst) 476, 491
Bourdeau JE (abst) 387, 393
Bourgoignie JJ (abst) 258, 408, 424, 522
Bourke E (abst) 382
Bourne HR (abst) 178
Bouya PA (abst) 238
Bovbjerg RR (abst) 254, 512, 516
Bower JD (abst) 326
Boyarsky G (abst) 172
Boyce NW, Tipping PG, Holdsworth SR: Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis 778
Boyle A (abst) 222
Boyle AS (abst) 440
Boyle F (abst) 194
Braam B (abst) 470, 1432
Braden G (abst) 190, 222
Brady H (abst) 321
Brady HR (abst) 402, 480, 482
Brash A (abst) 298
Brater DC (abst) 432
Braun B (abst) 229
Bravo E (abst) 331
Bravo EL (abst) 509
Brazy PC (abst) 190
Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: Role of blood pressure 670
Brecher P (abst) 443
Breckon R (abst) 171, 175
Brem AS (abst) 493
Brenchley PEC (abst) 372
Brendolan A (abst) 261
Brennan N (abst) 267
Brennan S (abst) 443
Brenner BM (abst) 177, 282, 284, 285, 290, 314, 316, 320, 321, 422
Brenner RM (abst) 152
Brentjens J (abst) 760
Brentjens JR, Andres G: Interaction of antibodies with renal cell surface antigens 954
Bresater LE (abst) 298
Breyer JA (abst) 309, 319
Breyer M (abst) 293
Breyer MD (abst) 305, 308, 309, 319, 451, 485, 496
Brezis M (abst) 402
Brich DF (abst) 374
Briefel G (abst) 226
Brier ME (abst) 279
Briggs D (abst) 742
Briggs JD (abst) 1441, 1441, 1441
Briggs JP (abst) 299, 473
Brines ML (abst) 300
Brinker K (abst) 512
Brinkman K (abst) 1434
Brion LP (abst) 451
Brisette W (abst) 367
Brissenden JE (abst) 202
Brissot P (abst) 241
Bristoyannis G (abst) 1443
Brito E *See* Martinelli R et al 1227
Brock T (abst) 744
Brock TA (abst) 177
Brodsky WA (abst) 215
Bronsema DA (abst) 401
Brookins J (abst) 288
Brooks B (abst) 227
Brosius FC III (abst) 152
Brossa PC (abst) 759
Brouhard BH (abst) 474
Brown A (abst) 391
Brown A *See* Dusso A et al 860
Brown AD (abst) 750
Brown AJ (abst) 389
Brown AJ, Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Slatopolsky E: 1,25-$(OH)_2$D receptors are decreased in parathyroid glands from chronically uremic dogs 19
Brown AL (abst) 395
Brown CD (abst) 190, 246, 519
Brown D (abst) 150, 152, 187, 188, 503
Brown DM (abst) 352
Brown DM *See* Mauer SM et al 48
Brown EA (abst) 241
Brown GP (abst) 290
Brown J (abst) 274
Brown JA (abst) 274
Brown MA (abst) 750
Brown OE (abst) 375
Brown RC (abst) 394
Brown SA (abst) 424
Brown WS (abst) 257
Browne LE (abst) 483
Brownley R (abst) 278, 289, 289
Broyer M *See* Antignac C et al 1336
Bruggeman L (abst) 294
Bruijn JA (abst) 341, 1430
Brunati C (abst) 755
Bruno G (abst) 393
Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F: CAPD with an amino acid dialysis solution: A long-term, cross-over study 1189
Bruns FJ (abst) 204, 207
Brunson ME (abst) 515
Bryer A (abst) 911
Bucci E (abst) 400
Buchsbaum B (abst) 390
Buckner FS (abst) 190
Budde K (abst) 342
Buettner TL (abst) 205
Buhler FR (abst) 325, 330, 511
Buhrle C (abst) 480
Bukoski RD (abst) 324
Buller HR (abst) 234
Bulley S (abst) 911
Bunchman TE (abst) 342, 520
Bunke M (abst) 402, 409
Burch W (abst) 436
Burckhardt G (abst) 452

Burdick JF (abst) ... 518
Burg M (abst) ... 499
Burg MB (abst) ... 499, 501
Burgwitz K (abst) ... 447, 504
Burhop KE (abst) ... 277
Burk L (abst) ... 237
Burke C (abst) ... 175, 444
Burke J (abst) ... 520
Burke JR (abst) ... 738, 749
Burke TJ (abst) ... 403, 409
Burnatowska-Hledin MA (abst) ... 310
Burnett JC Jr (abst) ... 287, 317, 420, 471
Burningham TH (abst) ... 232
Burns DK (abst) ... 212
Burns G (abst) ... 278, 289
Burns M (abst) ... 362
Burns MW (abst) ... 359
Burrell J (abst) ... 744
Bursten SL (abst) ... 169
Bushinsky DA (abst) ... 378, 379, 390
Bussolino F (abst) ... 310
Butkowski RJ, Wieslander J, Kleppel M, Michael AF, Fish AJ: Basement membrane collagen in the kidney: Regional localization of novel chains related to collagen IV ... 1195
Buttimore AL (abst) ... 739
Buttyan R *See* Sawczuk IS et al ... 1315
Byrne S (abst) ... 914
Cabezas JA *See* Martínez-Zorzano VS et al ... 1295
Cada EM (abst) ... 316
Cadnapaphornchai P (abst) ... 403
Caflisch CR (abst) ... 452
Calderon P (abst) ... 280
Callard P *See* Meyrier A et al ... 696
Calleja C (abst) ... 189
Callus M (abst) ... 740
Calne RY (abst) ... 1439, 1440, 1440
Calvet JP (abst) ... 311
Cam G (abst) ... 191, 204, 241
Camargo MJF (abst) ... 324
Cameron R (abst) ... 340
Camp M (abst) ... 215
Campbell HT (abst) ... 241
Campbell P (abst) ... 289
Campbell PI (abst) ... 381
Campbell RA (abst) ... 403
Campbell T (abst) ... 172
Campbell WG (abst) ... 526
Campfield T (abst) ... 222
Campos S (abst) ... 403, 421
Camussi G (abst) ... 310, 760
Canadian CAPD Clinical Trials Group (abst) ... 268
Canadian Erythropoietin Study Group (abst) ... 195, 196
Canaud B (abst) ... 238
Canavese C (abst) ... 758, 759
Candiano G (abst) ... 760
Canessa ML *See* Kelly RA et al ... 595
Cantafio S (abst) ... 246
Cantaluppi A (abst) ... 342
Cantaluppi A *See* Bruno M et al ... 1189
Cantiello HF (abst) ... 325
Cantley LC (abst) ... 184
Cantor ES (abst) ... 222
Capasso G (abst) ... 189, 452, 468, 490, 755
Capdevila J (abst) ... 174, 293, 298, 312
Capdevila JH (abst) ... 290
Capitanio MA (abst) ... 515
Capodicasa G (abst) ... 189, 468
Capparelli A (abst) ... 152
Cappelli P (abst) ... 405
Cappellini MD (abst) ... 755
Capponi E (abst) ... 754
Caprioli RC *See* Jonas AJ et al ... 99
Caramelo C (abst) ... 307, 307, 324, 333
Carbon C (abst) ... 409, 412
Carbone L *See* D'Agati V et al ... 1358
Cardamone I (abst) ... 757
Cardella C (abst) ... 208
Cardella CJ (abst) ... 523, 526
Carey HB (abst) ... 228, 267
Carey RM (abst) ... 280, 299, 300
Carey S (abst) ... 342
Caride A (abst) ... 381
Carley M (abst) ... 446
Carmichael D (abst) ... 390
Carneiro AV (abst) ... 452
Carney SL (abst) ... 750
Caro J (abst) ... 445
Caron MG (abst) ... 163
Carone F (abst) ... 357, 359
Carone FA, Hollenberg PF, Nakamura S, Punyarit P, Glogowski W, Flouret G: Tubular basement membrane change occurs pari passu with the development of cyst formation ... 1034
Carone FA, Nakamura S, Schumacher BS, Punyarit P, Bauer KD: Cyst-derived cells do not exhibit accelerated growth or features of transformed cells in vitro ... 1351
Carozzi C (abst) ... 342
Carpenter CB (abst) ... 505, 507, 508
Carpentier-Alti P (abst) ... 194
Carr M (abst) ... 203
Carretero OA *See* Ito S et al ... 1138
Carroll HJ (abst) ... 218
Carroll MJ (abst) ... 395
Carson P (abst) ... 741
Carthy J (abst) ... 360
Carty J (abst) ... 350
Caruana RJ (abst) ... 241, 242
Caruso C (abst) ... 399
Caruso G (abst) ... 424
Caruso M (abst) ... 756
Carvalho ME (abst) ... 403, 421
Carvounis CP (abst) ... 493
Casagrande P (abst) ... 336
Casanova S (abst) ... 756
Casarosa L (abst) ... 755
Cassel D (abst) ... 158
Cassingena R (abst) ... 164, 166
Castellazzo A (abst) ... 428
Castellino P (abst) ... 756
Caterson R (abst) ... 739, 740, 742, 752
Cato A (abst) ... 242
Cattell V (abst) ... 343
Cattell WR (abst) ... 395
Catto GRD *See* Al-Muzairai IA et al ... 1057
Cattran DC (abst) ... 208
Cavaillon J-M *See* Haeffner-Cavaillon N et al ... 1212
Cavalli G *See* Roccatello D et al ... 622
Cavallo T (abst) ... 343, 347
Celsi G (abst) ... 223
Celsi G *See* Hannerz L et al ... 1133

Censon A (abst) 759
Cernacek P (abst) 284
Cervenka J (abst) 335
Chabardes D (abst) 494
Chagnac A (abst) 424
Chaimovitz C (abst) 216
Chakrabarti EK (abst) 275
Chan JCM (abst) 194
Chan L (abst) 239, 330, 463, 498, 511
Chan L *See* Shapiro JI et al 830
Chance B (abst) 438
Chander P (abst) 213, 313, 368
Chandra M (abst) 223
Chang H (abst) 177, 313
Chansel D (abst) 290
Chantler C (abst) 203, 742
Chantler C *See* Georgaki-Angelaki HN et al 84
Chao AC (abst) 491
Chao J *See* Xiong W et al 1324
Chao L *See* Xiong W et al 1324
Chapman A (abst) 203, 222
Chapman AB (abst) 440
Chapman J (abst) 268
Chapman JR (abst) 738, 745, 745
Charboneau JW (abst) 203, 204
Charland C (abst) 343, 347
Charlesworth JA (abst) 743
Charron R (abst) 208
Charuk JHM (abst) 164
Chasalow F (abst) 381
Chastang C (abst) 257
Chaudhari A (abst) 162, 279, 292, 293
Chaudhary BA (abst) 241
Check IJ (abst) 375
Cheema-Dhadli S (abst) 217
Cheigh J (abst) 191, 523
Chekal MA (abst) 304
Chen JM (abst) 490
Chen L (abst) 460
Chen TC (abst) 390
Chen Y-P *See* Stahl RAK et al 1161
Chen YT (abst) 212
Cheng J-T *See* D'Agati V et al 1358
Cheng JC (abst) 388
Cheng L (abst) 153, 167
Chesney RW (abst) 492
Cheung AK (abst) 242, 258, 517
Cheung AK, Parker CJ, Janatova J: Analysis of the complement C3 fragments associated with hemodialysis membranes 576
Cheung PT, Hammerman MR: Cytochalasin B binding to rabbit proximal tubular basolateral membranes 1290
Chevalier RL (abst) 280, 299, 300
Chiaramonte S (abst) 261
Chinea C (abst) 523
Chiodini P (abst) 223
Chirgwin K (abst) 242
Chita G (abst) 915
Cho KW *See* Lee DY et al 812
Chobanian MC (abst) 443
Choi Y *See* Lee HS et al 880
Chopra V (abst) 293
Chou CL (abst) 494
Chou SY (abst) 227
Chretien PB (abst) 362
Christiansen RG (abst) 252
Christodoulides S (abst) 1442
Christodoulidou C (abst) 1446
Christopher NG (abst) 910
Chrousos G (abst) 1446
Chugh KS (abst) 334
Chugh KS: Snake-bite-induced acute renal failure in India (Nephrology Forum) 891
Chung L (abst) 229
Churchill DN (abst) 268
Churchill P (abst) 472
Ciabattoni G (abst) 757
Cianci J (abst) 512
Ciancioni C *See* Haeffner-Cavaillon N et al 1212
Ciardella F (abst) 758
Ciccarelli M (abst) 755
Cieslinski DA (abst) 404, 408, 413
Cinotti GA (abst) 318, 759
Cinotti GA *See* Pugliese F et al 817
Cirami C (abst) 755
Cirillo M (abst) 754
Civati G (abst) 755
Civitelli R (abst) 175, 394
Clancy R (abst) 503
Clarey LE (abst) 290
Clark BA (abst) 280
Clark R (abst) 410
Clark WF (abst) 368
Clarke DL (abst) 181
Clarke HS (abst) 302
Clarkson A (abst) 741
Clarkson AR (abst) 751
Clausen C (abst) 461
Clausen T, Everts ME: Regulation of the Na,K-pump in skeletal muscle (Editorial Review) 1
Clayman M (abst) 358
Clayman MD (abst) 215, 363
Clayman P (abst) 176
Cleary J (abst) 244
Cleary MP (abst) 430
Cleary MP *See* Kasiske BL et al 40
Cleary TG (abst) 230
Clement J (abst) 1430
Clough J (abst) 369
Cloup B (abst) 204
Clyne D (abst) 242
Clyne DH (abst) 253
Coady MJ (abst) 151
Cobiac L (abst) 737
Coburn JW (abst) 258, 276, 378, 398, 399
Coburn JW *See* Kleinman KS 567
Cochineas C (abst) 747, 751
Cochineas CC (abst) 318
Cochran M (abst) 745, 753
Cockayne D (abst) 740
Cockfield SM (abst) 343
Cockrell S (abst) 259
Cocksedge B (abst) 742, 752
Coco M (abst) 425
Cody P (abst) 328
Coe FL (abst) 382, 385
Coffee K (abst) 326
Coffee M (abst) 343, 348, 1431
Coffey A (abst) 503
Coffey AK (abst) 494
Coffman TM (abst) 425, 505

Coffman TM, Ruiz P, Sanfilippo F, Klotman PE: Chronic thromboxane inhibition preserves function of rejecting rat renal allografts 24
Cogan E (abst) 280, 305
Cogan MG (abst) 452, 458
Coghlan JP (abst) 748, 750
Cohen AH (abst) 207
Cohen AJ (abst) 297, 425
Cohen BH (abst) 268
Cohen DJ (abst) 512
Cohen EP (abst) 191
Cohen HT (abst) 208
Cohen JJ (abst) 460
Cohen M *See* Andreoli SP 1330
Cohen PG (abst) 223
Cohen S (abst) 309
Cohen SL (abst) 223, 251
Cohen Solal M (abst) 377
Cohen Tervaert JW (abst) 208
Coimbra TM (abst) 404, 408
Colasanti G *See* D'Amico G et al 1004
Cole BR (abst) 205
Cole DEC (abst) 205
Cole E (abst) 208, 344, 505
Cole F (abst) 288
Cole J (abst) 394
Coleman DL (abst) 342
Coleman M *See* Felsenfeld AJ et al 1371
Coleman RA (abst) 212, 330
Coleman RE (abst) 232
Coleman TG (abst) 326
Coles GA (abst) 191, 273, 277
Collaborative Group of the Societe de Nephrologie (abst) 197
Collins A (abst) 242, 243, 251
Collins DM (abst) 425, 505
Collins JF (abst) 752
Collins RC (abst) 467, 475
Colman J (abst) 387, 452
Colombe BW (abst) 522
Colucci M (abst) 198
Colussi G (abst) 759
Cominotto R (abst) 755
Comp PC (abst) 226
Comstock T (abst) 261, 521
Condamin MC *See* Meyrier A et al 696
Condren TB (abst) 380
Conger JD (abst) 289, 404, 472
Conger JD, Falk SA, Yuan BH, Schrier RW: Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure 1126
Conley SB (abst) 527
Conley SB *See* Jonas AJ et al 99
Connor J *See* Sawczuk IS et al 1315
Conte G (abst) 754
Conti F (abst) 171
Contiguglia SR (abst) 239
Contreras A (abst) 406
Contreras I (abst) 400
Conz P (abst) 231
Cook T (abst) 343, 509
Cooke CR (abst) 300
Cooke NE (abst) 358
Coombs RG (abst) 468
Cooper K (abst) 228, 267
Cooper M (abst) 169
Cooperative Dialysis Study Group (abst) 255
Coovadia HM (abst) 909, 909, 910, 914
Copkney C (abst) 238
Copley JB (abst) 393
Coppo R *See* Roccatello D et al 622
Coppola S (abst) 189, 192, 468
Corbin AL (abst) 442
Cordonnier DJ (abst) 468
Cordova H (abst) 493
Correa J (abst) 436
Correa-Rotter R (abst) 268
Corry DB (abst) 324
Cortes J (abst) 406
Cortes P (abst) 450
Corteza Q (abst) 404
Corteza QB (abst) 362
Coruzzi P (abst) 317
Corver WE (abst) 341, 1430
Cosby RL *See* Shapiro JI et al 830
Coscarella G (abst) 189, 192
Coscarella T (abst) 468
Cosentino F (abst) 243
Cosio FG (abst) 162, 221, 341, 344, 351, 354, 373
Costa FJTDF (abst) 914
Costalat R (abst) 458, 460
Costantini F (abst) 364
Costello J (abst) 275
Costerton JW *See* Read RR et al 614
Costogianni G (abst) 1443
Cotran RS, Pober JS: Effects of cytokines on vascular endothelium: Their role in vascular and immune injury 969
Cotterell L (abst) 224, 521
Couser W (abst) 350, 362
Couser WG (abst) 359
Couser WG *See* Schulze M et al 60
Couser WG *See* Stahl RAK et al 1161
Cowell G (abst) 224
Cox E (abst) 1435
Cox M (abst) 151
Coyne DW (abst) 169
Crabos M (abst) 325
Craelius W (abst) 153
Cragoe E Jr. (abst) 490
Cragoe EJ Jr (abst) 156, 158, 186, 459
Cragoe EJ Jr. (abst) 160, 465
Cragoe EJ Jr. *See* Grantham JJ et al 1379
Cramer B (abst) 206
Crane C (abst) 260
Craven PA (abst) 170
Crevat A *See* Monti JP et al 871
Crews FT (abst) 316, 445
Cridland JS (abst) 909
Crippa G (abst) 757
Cripps JA (abst) 741
Croatt AJ (abst) 414
Crocker JFS (abst) 205
Crockett R (abst) 438
Cronin R (abst) 405, 411
Cross M (abst) 747
Crouch EC *See* Blair HC et al 1119
Crow JW (abst) 242
Crump J (abst) 262
Cruz C (abst) 269
Cucchi M (abst) 286
Culham CA (abst) 354

Cunningham E (abst) 525
Cunningham J (abst) 189, 192, 349, 356
Cupisti A (abst) 758
Cupples WA (abst) 468
Currie P (abst) 240
Curthoys NP (abst) 390
Curtis JJ (abst) 357, 512, 516, 517
Cusano AJ (abst) 208, 215, 217
Cushner HM (abst) 393
Cussen LJ (abst) 749, 751
Cuttler I (abst) 411
Cuzzola F (abst) 338, 755
Cybulsky AV (abst) 170, 360
Cybulsky AV *See* Salant DJ et al 976
Cyran J (abst) 150
Czekalski S (abst) 405
Dabbagh S (abst) 153
D'Agati V, Suh J-I, Carbone L, Cheng J-T, Appel G: Pathology of HIV-associated nephropathy: A detailed morphologic and comparative study 1358
Daha M (abst) 345
Daha MR (abst) 365, 520, 525, 1430, 1432, 1433
Daha MR *See* van den Wall Bake AWL et al 1400
Dahl D (abst) 443, 447
Dahl R (abst) 418
Dahlem S *See* Baker L et al 1345
Dal Canton A (abst) 754
Daly P (abst) 523
D'Amico G (abst) 756
D'Amico G, Colasanti G, Ferrario F, Sinico RA: Renal involvement in essential mixed cryoglobulinemia 1004
D'Amour P *See* Kaye M et al 1390
Daniel TO (abst) 170
Daniels L (abst) 737
Daniilidis M (abst) 1439, 1440
Danovitch G (abst) 513, 524
Danovitch GM (abst) 521
Dantes P (abst) 1437
Danthuluri NR (abst) 177
Danziger CH (abst) 513
Danziger MD (abst) 161
Dardamanis M (abst) 1444
Darvill A (abst) 372
Das K (abst) 310
Dasgupta MK (abst) 209
Dasgupta MK *See* Read RR et al 614
Dass PD (abst) 398
Datseris J (abst) 1445
Daugaard H (abst) 299
Daugirdas JT (abst) 237, 243, 247, 255, 257, 260, 271
Davaris P (abst) 1447
David-Neto E (abst) 376
Davidai GA (abst) 391
Davidman M (abst) 224
Davidson BA (abst) 183
Davidson CJ (abst) 231
Davidson RR (abst) 190
Davies DJ (abst) 743, 746
Davies M (abst) 344
Davies RW (abst) 425
Davillas N (abst) 1447
Davis CL (abst) 243
Davis GM (abst) 244, 326
Davis ID (abst) 344
Davis J (abst) 261, 277
Davis JA (abst) 170, 420, 473
Davison J (abst) 479
Davison JM (abst) 494
Dawborn JK (abst) 745, 753
Dawidson I (abst) 511
Dawn K (abst) 440
Dawson DB (abst) 203
Dawson KM (abst) 186
De Broe ME (abst) 192, 244
De Feo T (abst) 755
De Ferrari ME (abst) 759
De Guzman A (abst) 445
De Heer E (abst) 341, 345
de Heer E (abst) 1430
De Jong PE (abst) 213, 224, 227, 280, 283
de Jong PE (abst) 1432, 1434
de la Cadena MP *See* Martínez-Zorzano VS et al 1295
de Lima JG (abst) 748
De Martinville B (abst) 205
De Medina M (abst) 258
De Nicola L (abst) 754
De Rocha JRC (abst) 192
De Rouffignac C (abst) 444
De Santo NG (abst) 755
De Vries I (abst) 234
De Zeeuw D (abst) 224, 227, 280, 283, 327
de Zeeuw D (abst) 1432
Dean W (abst) 175
Deane S (abst) 738
Debieve MF (abst) 280
Deboer DK (abst) 273, 291
Debure A (abst) 257
Decandido S (abst) 182, 362
Déchaux M *See* Hannedouche T et al 95
Deci E (abst) 265
Deck LV (abst) 206
Deddens J (abst) 423
Dedrick RL (abst) 269
Deedy P (abst) 237
Deelder AM (abst) 1430
DeFronzo RA (abst) 756
Deguchi F (abst) 328
Deierhoi MH (abst) 516, 517
Dekan G (abst) 153, 164, 356
Del Pizzo R (abst) 490
Delahousse M (abst) 459
Delaney MM (abst) 364
Delaney VB (abst) 381, 382, 526
Delano BG (abst) 247
Delarue F (abst) 180, 185
Delarue F *See* Lacave R et al 806
Delgado A (abst) 404, 429
Delis V (abst) 1444
Delle Fave G (abst) 318
Delmez J (abst) 244, 264, 392
Delmore T (abst) 208
Delons S *See* Haeffner-Cavaillon N et al 1212
Demaeyer P (abst) 280
Demaine A (abst) 742
Denborough MA (abst) 752
Denis MC (abst) 468
Dennis VW (abst) 178, 180, 183, 391
Derkx F (abst) 1429
Derkx FHM (abst) 1435
Derubertis FR (abst) 170
Derveniotis B (abst) 1436

Desanto NG (abst) 189, 192, 468
Deschodt G (abst) 263, 270
Deschryver F (abst) 245
Desimone G (abst) 189, 192, 468
Desir GV (abst) 464, 478, 498
Detrisac CJ *See* Hazen-Martin DJ et al 31
Deuter G (abst) 196
Devecchi A (abst) 274
Devine P (abst) 173
Devita MV (abst) 216, 379
Devoto S (abst) 230
Dewan P (abst) 324
Dhakal MP (abst) 262
Dhanesha U (abst) 189
Dharmarajan TS (abst) 244
Di Carmine F (abst) 381
Di Paolo B (abst) 405, 755
Di Stefano A (abst) 444
Diamandopoulos A (abst) 1442, 1442, 1442
Diamond J (abst) 421
Diamond JR (abst) 426
Diamond LH (abst) 254
Diavidovitch-Consta H (abst) 1448
Diaz C (abst) 513
Diaz M (abst) 230
Dibona DR (abst) 501
Dibona GF (abst) 328
Dichiro JT (abst) 195
Dickerman R (abst) 512
Dickman KG (abst) 444
Diederich D (abst) 325, 330, 511
Diethelm AG (abst) 512, 516, 517
Dietler R (abst) 281
Digenis G (abst) 236, 1445
Digenis GE (abst) 1437, 1438
Digout S (abst) 205
Dijkstra C (abst) 345
Dillingham MA (abst) 175, 400, 444
Dillon JJ (abst) 513
Dimari SJ (abst) 429
Dimitrakopoulos K (abst) 1447
Dimitriadis A (abst) 1436
Ding G (abst) 187, 305
Dion JJ (abst) 257
Dipillo F (abst) 209, 220
Diprete DA (abst) 204
Discala VA (abst) 158, 497, 500, 502
Dishman E (abst) 290
Diskin CJ (abst) 265
Disney APS (abst) 738, 744
Diven W (abst) 153
Dix JA (abst) 154
Dixon BS (abst) 171, 175
Dixon TE (abst) 461
Djaldetti M (abst) 375
Dlugosz BA (abst) 525
Dobbie JW (abst) 469
Dodds RA (abst) 470
Doecke CJ (abst) 753
Dogliani M (abst) 759
Doi T (abst) 171
Doi T *See* Elliot S et al 1245
Doi T *See* Takeuchi E et al 638
Dolney AM (abst) 338
Dombros N (abst) 1445, 1445
Dombros NB (abst) 1438
Dominguez J (abst) 151, 386, 426
Don BR (abst) 216
Donatsch P (abst) 413
Donini U (abst) 756
Donker AJM (abst) 233, 503, 516, 1432
Donohoe JF (abst) 194
Donoso V *See* Grantham JJ et al 1379
Dontas A (abst) 1447
Dooper PMM (abst) 1431
Dorhout Mees E (abst) 436
Dorhout Mees EJ (abst) 207, 281, 283, 470
Dosquet P (abst) 245
Dossetor JB (abst) 518
Doumas L (abst) 1436
Douramani P (abst) 1439, 1441
Dousa TP (abst) 168, 306, 382, 389, 490, 494
Dowd T (abst) 380
Dowling J (abst) 743
Downes SJ (abst) 285
Downs MO (abst) 508
Drabik MJ (abst) 226
Draibe SA (abst) 522
Drakopoulos S (abst) 1439, 1440, 1440
Dreisbach A (abst) 150
Dreisbach AW (abst) 484
Drell D (abst) 230
Dreyling KW (abst) 291
Drinovec J (abst) 250
Drossos C (abst) 1445
Drouzas A (abst) 1442
Druce HM (abst) 317
Drueke T (abst) 245, 267
Druml W (abst) 225, 229
du Toit E (abst) 911
du Toit ED (abst) 911
Du XH (abst) 369
Dubb JW (abst) 249
Dube L (abst) 479
Dubinsky W (abst) 166
Dubose TD Jr (abst) 186, 452, 454
Dubovsky EV (abst) 517
Duchin K (abst) 245
Duggal P (abst) 220, 225, 235
Duggin GG (abst) 741
Dukakis D (abst) 236
Duley IT *See* Gabow PA et al 675
Dumann H (abst) 370
Dumler F (abst) 245, 256, 265, 450
Dunbar J (abst) 472
Duncan W (abst) 378
Dunea G (abst) 221
Dunham CB (abst) 178
Dunlay R (abst) 254, 261, 391, 426
Dunlay RW (abst) 215, 238
Dunn MJ (abst) 171, 184, 293, 295, 759
Dunn SR (abst) 426
Dunnill MS (abst) 745
Duque I (abst) 319
Durham JH (abst) 215, 453
Durr J (abst) 479
Durr J *See* Kim JK et al 799
Durr JA (abst) 217
Durrego P (abst) 400
Dusheiko G (abst) 909
Dussaule JC (abst) 405
Dussel R *See* Steinhausen M et al 1151

Dusso A (abst) 391, 392
Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Brown A, Martin K, Slatopolsky E: Metabolic clearance rate and production rate of calcitriol in uremia 860
Dusso A *See* Brown AJ et al 19
DvAddabo A (abst) 371
DvAgati V (abst) 210, 211, 364
DvHaese PC (abst) 244
Dworkin LD (abst) 427
Dworkin LD, Grosser M, Feiner HD, Ullian M, Parker M: Renal vascular effects of antihypertensive therapy in uninephrectomized SHR 790
Dwyer DF (abst) 752
Dwyer T (abst) 748
Dyck RF (abst) 504
Dzau VJ (abst) 302, 303
Early S (abst) 271
Eastman C (abst) 738
Eastman R (abst) 440
Eaton DC (abst) 483
Eaton P (abst) 292
Eaton R (abst) 296
Ebben J (abst) 251
Ebert J (abst) 296, 308, 364
Eberwein P *See* Read RR et al 614
Ebinger F (abst) 519
Eby B (abst) 387
Eche T (abst) 405
Eckstein R (abst) 740, 750
Economidou I (abst) 1437
Eddy A (abst) 345
Edelman A (abst) 160
Edelman I (abst) 161
Edred M (abst) 322
Edwards BS (abst) 420
Edwards JC (abst) 465
Egfjord M (abst) 299
Eggers PW (abst) 200
Egler J *See* Baker L et al 1345
Egrie J (abst) 246
Eide PA (abst) 396
Eilles C (abst) 282
Eisner GM (abst) 328
Ekblad U (abst) 323
Eklöf A-C *See* Hannerz L et al 1133
Eklof AC (abst) 325
Eklof O (abst) 194
Eknoyan G (abst) 214
El Gammal T (abst) 217
El Nahas AM (abst) 310, 315, 427, 440, 440
El-Dahr S (abst) 299
El-Hajjaoui ZR (abst) 186
El-Khatib MT (abst) 749
El-Sherif N (abst) 153
Elahi E (abst) 280
Elema JD (abst) 208, 340, 345, 1430
Elghozi JL *See* Hannedouche T et al 95
Elliasson K (abst) 232
Elliot S, Striker LJ, Doi T, Linehan WM, Striker GE: Hepatoma G2 conditioned medium facilitates early outgrowth of endothelial cells from isolated glomeruli (Technical Note) 1245
Elliott S (abst) 171
Ellis B (abst) 163
Ellis D (abst) 423
Ellis V (abst) 472
Ellison DH (abst) 479, 486
Elsen R *See* Monti JP et al 871
Elseviers MM (abst) 192
Elsperger KJ (abst) 236
Elzinga LW (abst) 203, 224, 369, 405, 738
Emancipator SN (abst) 342, 345, 347, 756, 760
Emery J (abst) 358
Emmerson BT (abst) 747, 749
Emmett M (abst) 219, 384
Emmons C (abst) 453
Endre ZH, Allis JL, Ratcliffe PJ, Radda GK: 87-Rubidium NMR: A novel method of measuring cation flux in intact kidney (Technical Note) 1249
Endres DB (abst) 376
Enia G (abst) 246
Enriquez MSV (abst) 406
Epley M (abst) 153
Epstein FH (abst) 280, 402, 448, 502
Epstein M (abst) 282, 291, 315, 323, 439
Epstein M *See* Wasserman J et al 1168
Epstein S (abst) 252
Ercolani L (abst) 154
Eres A (abst) 497
Erickson SJ (abst) 191
Ericsson F (abst) 519
Eriksson C (abst) 257
Erkelens D (abst) 436, 1433
Erkeling M (abst) 287
Erlanger BF (abst) 160
Erley CM (abst) 346, 388
Ertl G (abst) 282
Erturk E (abst) 302, 325, 509
Esber R (abst) 737
Eschbach JW (abst) 190, 193, 193, 246
Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin (Nephrology Forum) 134
Escoubet B (abst) 171
Espinosa A (abst) 406
Esposito C (abst) 754
Esquenazi V (abst) 415, 522
Estes D (abst) 211
Ethier JH (abst) 216
Etienne J *See* Baud L et al 1111
Ettenger RB (abst) 521
Eulitz M (abst) 308
Evan A *See* Grantham JJ et al 1379
Evan AP *See* Bird JE et al 1282
Evanoff GV (abst) 193
Evans BA (abst) 746
Evans R (abst) 249
Evans RW (abst) 246
Everett AD (abst) 300
Everts ME *See* Clausen T 1
Ewald U (abst) 1438
Faaber P (abst) 341, 1434
Faber MA (abst) 269
Fabijanski L (abst) 176
Fabris A (abst) 246, 261
Fadda GZ (abst) 427
Fain JS (abst) 225
Fairley K (abst) 222
Fairley KF (abst) 374, 739, 740, 742, 752
Fairley S (abst) 222
Fakhry I (abst) 277

Falardeau P (abst) 291, 368
Falck J (abst) 174, 295
Falk J (abst) 524
Falk RJ (abst) 346, 370
Falk SA *See* Conger JD et al 1126
Falsetti G (abst) 153
Fanestil DD (abst) 477, 490
Fanti P (abst) 215, 220, 377
Fanti P *See* Baker LRI et al 661
Fantone J (abst) 366
Fargin A (abst) 163
Farkas R (abst) 227
Farnham H (abst) 272
Farokhi F (abst) 292
Farquhar MG (abst) 153, 163, 164, 165, 356
Farrell P (abst) 744, 744, 753
Fassett RG (abst) 748
Fatica KJ (abst) 226
Fatone F (abst) 759
Fauchald P (abst) 513
Fauchet R (abst) 204
Faugere MC (abst) 220, 377
Faugere MC *See* Baker LRI et al 661
Faulkner M (abst) 225
Faull RJ (abst) 742
Faure M (abst) 468
Favero MS (abst) 255
Favus MJ (abst) 390
Fecondini L (abst) 231, 261
Fein PA (abst) 239, 269
Feindel C (abst) 523
Feiner HD (abst) 427
Feiner HD *See* Dworkin LD et al 790
Feinfeld DA (abst) 427
Feingold R *See* Winston JA et al 1175
Fejes-Toth G (abst) 486
Fekete P (abst) 526
Felder CC (abst) 172
Felder RA (abst) 329
Feldhoff P (abst) 175
Feldman GM (abst) 456, 495
Felsenfeld A (abst) 254, 261, 377, 379, 391, 426
Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llach F: Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease 1371
Fen Z (abst) 170
Fenves AZ (abst) 227
Ferdeghini M (abst) 758
Ferdows M, Golchini K, Adler SG, Kurtz I: Cl^-/base exchange in rat mesangial cells: Regulation of intracellular pH 783
Ferguson CW (abst) 200
Feriani M (abst) 246
Fernandez B (abst) 415
Fernando ON (abst) 525
Fernando R (abst) 433
Fernet M *See* Meyrier A et al 696
Ferng S (abst) 362
Ferrario F *See* D'Amico G et al 1004
Ferrario R (abst) 296
Ferraris P (abst) 757
Ferrer PL (abst) 267
Ferrier C (abst) 281
Ferti C (abst) 296
Fianco C (abst) 192
Fiel RJ (abst) 432
Field MJ (abst) 740
Fields ALA (abst) 217
Filburn CR (abst) 182, 184, 398, 399
Filley G (abst) 463
Finch CD (abst) 326
Finch J (abst) 264, 392
Finch JL *See* Blair HC et al 1119
Finco DR (abst) 167, 424
Fine LG (abst) 156, 176, 179, 207, 225, 420
Fine RN (abst) 269, 521
Fine SE (abst) 269
Fineman I (abst) 453
Finkelstein FO (abst) 228, 267
Finn WF (abst) 513
First MR (abst) 514, 515
Fischer JA (abst) 311
Fish AJ *See* Butkowski RJ et al 1195
Fisher DA (abst) 319
Fisher JW (abst) 288
Fisher KA (abst) 388, 503
Fishman P (abst) 375
Fitting K (abst) 366
Fitz AE (abst) 350
Fitzpatrick PM (abst) 204
Fitzwilliam JF *See* Brazy PC et al 670
Fivush B (abst) 416
Flatmark A (abst) 513
Fleming JT (abst) 476
Fleming JT *See* Steinhausen M et al 1151
Flessner MF (abst) 269
Fleuren GJ (abst) 341, 1430, 1430
Flinter F (abst) 203
Floege J (abst) 254, 263, 270, 297
Flouret G (abst) 359
Flouret G *See* Carone FA et al 1034
Flugge G (abst) 311
Fogo A (abst) 346, 410, 430, 434
Fogo A *See* Yoshida Y et al 654
Fokaeus E (abst) 1447
Foley WD (abst) 191
Fong IW (abst) 253
Fontana F (abst) 757, 757, 757
Fontoura BA (abst) 285
Fontoura BMA (abst) 281
Force T (abst) 412
Fordtran JS (abst) 384
Foreman J (abst) 444
Foreman JW (abst) 194
Fornasieri A (abst) 756
Forte L (abst) 394
Fortuen J (abst) 171
Foster MH (abst) 194, 346
Fouad F (abst) 240, 331
Foulks CJ (abst) 270
Fountoulakis A (abst) 1443
Fournier A (abst) 257, 377
Fox AW (abst) 428
Fox SD (abst) 267, 270, 274
Fracasso A (abst) 221, 239, 270, 334
Fracasso AR *See* Schena FP et al 875
Fraenkel MB (abst) 751, 753
Fraley DS (abst) 204, 207
Franco M (abst) 309
Francos G (abst) 520
Frangione B (abst) 373

Frank D (abst) 153
Frankel AH (abst) 505, 508
Frankenschmidt A (abst) 291
Franki N (abst) 187, 305
Franklin J (abst) 913
Franze L (abst) 750
Frascà MG (abst) 759
Freeman JW (abst) 748
Freiberg JM (abst) 443
Freidman E (abst) 526
Freilich S (abst) 265
Frergber M (abst) 214
Freundlich M (abst) 219
Frey BM (abst) 514, 514
Frey FJ (abst) 514, 514
Frey J (abst) 292, 296
Fried TA (abst) 479, 484
Fried TR (abst) 506
Friedenberg DS (abst) 154
Friediaender MM (abst) 397, 514
Friedlander G (abst) 154, 155, 166, 412
Friedler RM (abst) 377
Friedman EA (abst) 190, 242, 246, 247, 519
Friedrich F (abst) 180
Friedrich K (abst) 512
Friedrich T (abst) 506
Frindt G (abst) 480
Frisbie DD (abst) 354
Froment DH (abst) 398
Frutos MA (abst) 377
Fryckstedt J (abst) 311
Fryd DS (abst) 520
Fryer P (abst) 264
Frymoyer PA (abst) 347
Fu-Wen N (abst) 311
Fuchs E (abst) 311
Fuhro R (abst) 448
Fujihara CK (abst) 428, 442, 473
Fujii Y (abst) 299
Fujimi S (abst) 250
Fujise Y (abst) 417
Fujishima M (abst) 227, 250
Fujita T (abst) 372
Fujiwara Y (abst) 172
Fujiwara Y *See* Shin SH et al 1320
Fukagawa M (abst) 392
Fukatsu A (abst) 367
Fukuhara Y (abst) 406, 441
Fukunaga M (abst) 172
Fukunaga M *See* Shin SH et al 1320
Funk JE (abst) 250
Furlanetto R (abst) 151
Furlong TJ (abst) 155
Furman KI (abst) 908
Fürst P *See* Lindholm B et al 1219
Furuta T (abst) 321
Furuya H (abst) 489
Fuse Y (abst) 374
Fushimi K (abst) 495
Gabbai FB (abst) 406
Gaber AO (abst) 515
Gaber LW (abst) 515
Gabow P (abst) 203, 205, 206
Gabow PA (abst) 167, 310
Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease 675
Gaciong Z (abst) 193, 389
Gaffi G (abst) 754
Gafter U (abst) 271
Gagnon RF (abst) 201, 247, 271, 274, 275
Gaillard CA (abst) 281, 283, 1431, 1434
Gaillard CA *See* Boer WH et al 1183
Gainey MA (abst) 515
Galanis D (abst) 1436, 1442, 1442, 1446
Galdi P (abst) 276
Galla JH (abst) 361, 453, 454, 464
Gallery EDM (abst) 737
Gallice P *See* Monti JP et al 871
Gallo GR (abst) 373
Gallus AS (abst) 751
Galonsky R (abst) 247
Galvao CR (abst) 155, 408
Gamba G (abst) 406
Gambaro G (abst) 754
Gamelin L (abst) 419
Gamelin LM (abst) 421
Gandhi VC (abst) 237, 247, 255, 260
Ganousis L (abst) 479
Gans ROB (abst) 226
Ganten D (abst) 278
Ganz M (abst) 307
Ganz MB (abst) 172
Garbis S (abst) 1440
Garcia DL (abst) 422
Garcia J (abst) 172, 522
Garcia JC (abst) 394
Garcia JR (abst) 516
Garcia-Maldonado M (abst) 226
Garcia-Perez A (abst) 499
Gardenswartz MH (abst) 216
Gardner KD (abst) 369
Gardner PW (abst) 256, 264
Garella S (abst) 460
Garestier MC (abst) 171
Garg LC (abst) 316
Garneau L (abst) 483
Garovoy MR (abst) 507, 522
Garretson LT (abst) 162
Garrick R (abst) 292, 313
Garza RQ (abst) 407
Gassman JJ (abst) 197, 226
Gassner D (abst) 369
Gattone VH II (abst) 311
Gaudio KM (abst) 407, 418, 449
Gaughan W (abst) 240, 240
Gauthier B (abst) 381
Gauthier VJ (abst) 347
Gavalchin J (abst) 347
Gavellas G (abst) 408, 424
Gazit D (abst) 379
Gebreselassie W (abst) 276
Geer R (abst) 469
Geering K (abst) 155
Geerlings W (abst) 1434
Gehr T (abst) 495
Geibel J (abst) 454, 491
Geiger H (abst) 278, 281, 282, 417
Geissler K (abst) 321

Geniteau M (abst) 164, 166
Georgaki-Angelaki HN, Steed DB, Chantler C, Haycock GB: Renal function following acute renal failure in childhood: A long term follow-up study 84
George A (abst) 155
Georgiou P (abst) 1437
Gephardt GN (abst) 325
Gerbes AL (abst) 229
Gerepka R (abst) 268
Gerlag PGG (abst) 226
Germann PJ *See* Thaiss F et al 76
Germanos N (abst) 1439
Germenis A (abst) 1447
Gesek FA (abst) 445, 488
Gesualdo L (abst) 345, 347, 756, 760
Ghabra N (abst) 247, 260
Ghiggeri GM (abst) 760
Ghosh L (abst) 1436
Giachino O *See* Roccatello D et al 622
Giagides G (abst) 1436
Gibel L (abst) 506
Gibilaro SD (abst) 247
Gibson T (abst) 338
Giebisch G (abst) 402, 452, 454, 481, 488, 490, 491
Giebisch GH (abst) 491
Gierschik P (abst) 177
Gifford D (abst) 454
Gifford JD, Rutsky EA, Kirk KA, McDaniel HG: Control of serum potassium during fasting in patients with end-stage renal disease 90
Gilbert DN (abst) 748
Giles K (abst) 264
Gill JC (abst) 231
Gillis K (abst) 161
Gillum D (abst) 520
Gillum DM (abst) 378, 407, 513
Gimenez L (abst) 226
Ginevri F (abst) 760
Giocondi MC (abst) 155
Giordano C (abst) 756
Giordano DR (abst) 189, 192, 468, 755
Girone J (abst) 445
Glanzer K (abst) 285, 423
Glaros D (abst) 1438
Glas-Greenwalt P (abst) 235
Glass J (abst) 397
Glass WF II (abst) 156
Glassock R (abst) 422
Gleim GW (abst) 216
Glew R (abst) 202
Glicklich D (abst) 210
Glimcher LH (abst) 366
Glogowski W (abst) 359
Glogowski W *See* Carone FA et al 1034
Gluck S (abst) 150, 461, 463
Glurich I (abst) 356
Glynn M (abst) 344
Gnadinger MP (abst) 311
Gnionsahe A (abst) 404, 429
Goddard G (abst) 745
Goebel TK (abst) 249
Goel R (abst) 341, 354
Gogos CA (abst) 1442, 1442
Golchini K (abst) 173, 380, 484
Golchini K *See* Ferdows M et al 783
Gold P (abst) 1446
Goldberg H (abst) 505
Goldblat M (abst) 260
Goldenberg I (abst) 215
Goldfarb D (abst) 509
Goldfarb S (abst) 322, 428, 431, 435
Goldfarb S *See* Baker L et al 1345
Goldin H (abst) 497
Goldschmeding R (abst) 208, 1430
Goldstein DS (abst) 316
Goldstein MB (abst) 253
Goldstein SJ (abst) 252
Goldwasser P (abst) 209, 220, 239, 269
Golembieski A (abst) 403
Goligorsky M (abst) 177, 407
Goligorsky MS (abst) 173
Golper TA (abst) 738
Golub M (abst) 313
Gomez RA (abst) 280, 299, 300
Gomolka D (abst) 366
Gonwa T (abst) 512
Gonzalez G (abst) 400
Gonzalez OF (abst) 185
Gonzalez R (abst) 213
Gonzalez-Campoy JM, Romero JC, Knox FG: Escape from the sodium-retaining effects of mineralocorticoids: Role of ANF and intrarenal hormone systems (Editorial Review) 767
Good DW (abst) 452, 454
Goodfriend TL (abst) 443
Goodman A (abst) 292, 313
Goodman AI (abst) 446, 448
Goodman DJ (abst) 741
Goodman WG (abst) 276, 377, 378, 398, 399
Goodship T (abst) 349, 356
Goodwin J (abst) 506
Gordinho JJ (abst) 248
Gordon KF (abst) 337
Goren MP (abst) 515
Gorfien PC (abst) 412, 497
Gorin AB (abst) 214
Gotch F (abst) 248
Gotloib L (abst) 276
Gottesman MM (abst) 158
Gotz R (abst) 282, 392
Gouge S (abst) 378
Gougoux A (abst) 442, 447, 449, 450
Gouvea WL, Alpert HC, Kelley J, Pardo V, Vaamonde CA: Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats 1041
Gower PE (abst) 241
Goyal S (abst) 426
Graber M (abst) 173, 180
Gradu DBE (abst) 216
Graf H (abst) 316
Graham J (abst) 740
Granger JP (abst) 300, 488
Granholm NA (abst) 343, 347
Granolleras C (abst) 263
Granot Y (abst) 305
Grant SK *See* Read RR et al 614
Grantham J (abst) 487, 503
Grantham JA (abst) 495
Grantham JA *See* Grantham JJ et al 1379
Grantham JJ (abst) 280, 495

Grantham JJ, Uchic M, Cragoe EJ Jr., Kornhaus J, Grantham JA, Donoso V, Mangoo-Karim R, Evan A, McAteer J: Chemical modification of cell proliferation and fluid secretion in renal cysts 1379
Graor RA (abst) 333
Grapsa E (abst) 1437
Grauer GF (abst) 354
Graves K (abst) 333
Gray C (abst) 322
Gray RW *See* Lemann J Jr. et al 688
Grayzel A (abst) 210
Grazi G (abst) 755
Graziani L (abst) 754
Green B (abst) 911
Green J (abst) 156, 298, 459
Green M (abst) 744
Green W (abst) 248
Greene HL (abst) 421, 469
Greger R (abst) 444, 525
Grekas D (abst) 1436
Gretz N (abst) 355
Griffin K (abst) 323, 428
Griffiths SM (abst) 258
Griggs M (abst) 405, 411
Grinstein S (abst) 230
Griswold DE (abst) 339
Groc A *See* Meyrier A et al 696
Groene E (abst) 348
Groene HJ (abst) 348
Grogan W (abst) 189
Groggel GC (abst) 187, 348, 355
Gron D (abst) 256
Grond J (abst) 343, 348, 1431
Grone HJ (abst) 311
Gronich JH (abst) 292
Grooms P (abst) 391
Grooms P *See* Brown AJ et al 19
Grooms P *See* Dusso A et al 860
Grose J (abst) 291
Groslambert P (abst) 468
Gross C (abst) 229
Gross P (abst) 307, 480, 485
Grosser M (abst) 225
Grosser M *See* Dworkin LD et al 790
Grossman EB (abst) 480
Grosvenor M *See* Slomowitz LA et al 704
Grunewald RW (abst) 496
Grunfeld JP (abst) 404, 429
Grünfeld JP *See* Hannedouche T et al 95
Grutzmacher P (abst) 326
Gstraunthaler G (abst) 445
Guastoni C (abst) 755
Guay-Woodford LM (abst) 187
Gubler M-C *See* Antignac C et al 1336
Guerra E (abst) 408
Guerra MG *See* Roccatello D et al 622
Guggino SE (abst) 399
Guggino WB (abst) 166
Guidotti S (abst) 421
Gullans S (abst) 321
Gullans SR (abst) 152, 320, 402, 480, 482, 496
Gulmi FA (abst) 227
Gulyas KD (abst) 413
Gung A (abst) 248
Gunning M (abst) 282, 284, 290
Gunther RD (abst) 156
Guntupalli J (abst) 381, 382
Gupta A (abst) 334, 368
Gupta DK (abst) 237, 271
Gupta RK (abst) 380
Gupta S (abst) 292, 507
Gura V (abst) 396
Gurich RW (abst) 186, 454
Gurioli L (abst) 758
Gusmano R (abst) 760
Guthrie G Jr (abst) 329
Gutierrez A (abst) 519
Gutierrez GE (abst) 173
Gutjahr E (abst) 447, 504
Gutmann EJ (abst) 187
Guzelian P (abst) 189
Guzman NJ (abst) 445
Gyory AZ (abst) 318
Györy AZ (abst) 737
Gyory AZ (abst) 740, 747, 751
Ha B (abst) 419
Haag-Weber M (abst) 248
Haaijman JJ *See* van den Wall Bake AWL et al 1400
Haakenstad AO (abst) 348, 355
Habib R *See* Antignac C et al 1336
Hable M (abst) 248
Habscheid W (abst) 282
Habwe V (abst) 233, 271
Hack N (abst) 176
Haddoum F (abst) 245
Hadjikonstantinou V (abst) 1439
Hadro E (abst) 510
Haeffner-Cavaillon N, Cavaillon J-M, Ciancioni C, Bacle F, Delons S, Kazatchkine MD: In vivo induction of interleukin-1 during hemodialysis 1212
Haesemeyer RW (abst) 413
Haffejee AA (abst) 908, 908, 908
Hagan EA (abst) 266
Haggerty JG (abst) 156, 164
Hakim RM (abst) 248, 253
Halabe A (abst) 282
Hale G (abst) 741
Haley NR (abst) 190, 193, 193
Hall A (abst) 223
Hall JC (abst) 242
Hall JE (abst) 285, 326, 474
Hall P (abst) 749
Hall PM (abst) 197
Halla A (abst) 1438
Haller H (abst) 414
Halligan RD (abst) 306
Halloran PF (abst) 343, 524
Halperin M (abst) 216
Halperin ML (abst) 217
Halperin ML: How much "new" bicarbonate is formed in the distal nephron in the process of net acid excretion? (Editorial Review) 1277
Halstead M (abst) 505
Halstenson CE (abst) 198, 236
Hamberger B (abst) 257
Hamburger RJ (abst) 482
Hamer S (abst) 336
Hamm LL (abst) 459, 463, 466
Hammerman MR (abst) 181
Hammerman MR *See* Cheung PT 1290
Hamon C (abst) 189, 192
Hampel G (abst) 157

Hampl H (abst) 254, 429, 437
Hamzeh Y (abst) 212
Hand J (abst) 258
Handler JS (abst) 158
Handwerger BS (abst) 366
Hanevold C (abst) 410
Hanevold CD (abst) 515
Hanlon S (abst) 336
Hannan S (abst) 752
Hannedouche T (abst) 404, 429
Hannedouche T, Laude D, Déchaux M, Grünfeld JP, Elghozi JL: Plasma 5-hydroxyindoleacetic acid as an endogenous index of renal plasma flow 95
Hannerz L (abst) 223
Hannerz L, Celsi G, Eklöf A-C, Olling S, Wikstad I, Aperia A: Ascending pyelonephritis in young rats retards kidney growth 1133
Hanson G (abst) 251
Hanss BG (abst) 337
Hantzikonstantinou B (abst) 1436
Hara M (abst) 365
Haralson MA (abst) 349, 429
Haramati A (abst) 385, 392
Harden EA (abst) 515
Hardie IR (abst) 738
Harding GB (abst) 279
Hardman W (abst) 433, 446
Hardonk MJ (abst) 359, 1433
Hardy MA (abst) 512
Harendza S (abst) 348
Harford A (abst) 506
Hargovan N (abst) 910
Harnett JD (abst) 258
Harrington JT (abst) 194
Harrington R (abst) 180
Harris A (abst) 271
Harris DCH (abst) 737
Harris HW Jr (abst) 157, 187
Harris KPG (abst) 429, 461
Harris RC (abst) ... 158, 174, 278, 290, 305, 306, 308, 312, 349, 417
Harris WE (abst) 169
Harrison S (abst) 398
Hartich L (abst) 326
Hartsell A (abst) 312
Hartwig JH (abst) 188
Harvey D (abst) 332
Hasamear R (abst) 244
Haschemeyer R (abst) 523
Hashimoto Y (abst) 236, 469
Hassell J (abst) 294
Hassen F (abst) 910
Hatano M (abst) 355, 372
Hatseras S (abst) 224
Hatzikonstantinou M (abst) 1441
Hatzikonstantinou V (abst) 1440
Haupert GT Jr (abst) 157
Haverty T (abst) 308, 358, 428
Haverty TP (abst) 322, 349
Hawkey LA (abst) 411
Hawkins R (abst) 524
Hawthorne VM (abst) 194
Hay J (abst) 738, 739
Hayashi K (abst) 282, 291, 315, 323
Hayashi M (abst) 312
Haycock GB *See* Georgaki-Angelaki HN et al 84
Hayes C (abst) 395
Hayes J (abst) 745, 753
Haynes B (abst) 163
Hays R (abst) 320
Hays RM (abst) 187, 305
Hays SR (abst) 455
Hazelrig J (abst) 332
Hazen-Martin DJ, Sens MA, Detrisac CJ, Blackburn JG, Sens DA: Elevated glucose alters paracellular transport of cultured human proximal tubule cells 31
Heale WF (abst) 745
Hebert LA (abst) 221, 341, 354, 369
Hebert RL (abst) 496
Hebert SC (abst) 480, 489
Hediger MA (abst) 151, 496
Heeg JE (abst) 227
Heidbreder E (abst) 282, 392, 408
Heidland A (abst) 263, 278, 281, 282, 392, 408, 417
Heifets M (abst) 446
Heilig CW (abst) 152, 496
Heilman RL (abst) 209
Heim-Duthoy KL (abst) 517
Heinrich M (abst) 414
Held PJ (abst) 254, 512, 516, 522
Helderman JH (abst) 511
Hellwig B (abst) 329
Helmchen U (abst) 348
Helmchen U *See* Thaiss F et al 76
Helmchen UM (abst) 348
Hem GVD (abst) 1434
Hem SL *See* Fartridge NA et al 1413
Henderson J *See* Kaye M et al 1390
Henderson LW (abst) 240, 267, 270, 273, 274, 349
Henderson LW, Leypoldt JK: Unilateral nephrectomy and glomerular solute transport in the dog 589
Henderson RM (abst) 491
Hendriks GFJ (abst) 1431
Hene R (abst) 436
Hené R (abst) 1433
Hene RJ (abst) 207, 1429
Henkens C (abst) 1434
Henning P (abst) 737
Henrich W (abst) 301
Henry J (abst) 233
Hensen J (abst) 217
Hercz G (abst) 378
Herlitz H (abst) 298, 327
Hermann J (abst) 225, 235
Hernandez RE (abst) 387
Hernando L (abst) 319
Hernando L *See* Rodríguez-Puyol D et al 632
Herndon J (abst) 459
Herndon RM (abst) 218
Herndon RM *See* Sterns RH et al 69
Herrera GA (abst) 361, 516
Herrera-Acosta J (abst) 189, 336
Herschman HR (abst) 176
Herzlinger D (abst) 465
Herzog R (abst) 408
Hess B (abst) 382
Heuvel LVD (abst) 1434
Hewitson T (abst) 435
Heyman S *See* Baker L et al 1345
Hiatt RA (abst) 199
Hiehl K (abst) 363

Hiehle K (abst) 354
Hiemstra P (abst) 365
Hierholzer K (abst) 312
Higdon M (abst) 309
Hildebrandt DA (abst) 285, 474
Hill DJ (abst) 310, 315
Hill GL (abst) 752
Hill J (abst) 469
Hillis A *See* Al-Muzairai IA et al 1057
Hinary E (abst) 1442, 1442
Hinterberger W (abst) 321
Hiramatsu R (abst) 251
Hirsch DJ (abst) 202
Hirsch M (abst) 407
Hirschberg R (abst) 312
Hirschberg R, Rabb H, Bergamo R, Kopple JD: The delayed effect of growth hormone on renal function in humans 865
Hirszel P (abst) 275
Hirt D (abst) 293
Hise MK (abst) 430, 442
Hishida A *See* Kobayashi S et al 1405
Hitman G (abst) 349, 356
Hjemdahl P (abst) 475
Hlatky M (abst) 231
Hobbs R (abst) 525
Hoch BS (abst) 412, 497
Hodge E (abst) 525
Hodsman GP (abst) 740
Hoedemaeker PJ (abst) 341
Hoedemaeker PJ, Weening JJ: Relevance of experimental models for human nephropathology 1015
Hoek FJ *See* Krediet RT et al 1064
Hoffman A (abst) 283, 283
Hoffman WH (abst) 217
Hogendoorn P (abst) 345
Hogendoorn PCW (abst) 341, 1430
Hogg RJ (abst) 737
Hoilien C (abst) 410
Hoitsma AJ (abst) 1429
Hoke G *See* Sawczuk IS et al 1315
Holdaas H (abst) 513
Holdsworth MT (abst) 510
Holdsworth SR (abst) 741, 743, 747
Holdsworth SR *See* Boyce NW et al 778
Hollenberg P (abst) 359
Hollenberg PF *See* Carone FA et al 1034
Holley JL (abst) 270
Holley K (abst) 209
Holley KE (abst) 303
Hollmann R (abst) 281
Holloway M (abst) 276
Holmes C (abst) 249, 268, 273
Holstein-Rathlou NH (abst) 469
Holthofer H (abst) 157, 362, 439
Holthofer H *See* Wasserman J et al 1168
Holub B (abst) 368
Holz FG *See* Steinhausen M et al 1151
Homan van der Heide JJ (abst) 516
Homatas I (abst) 1436
Homatas J (abst) 1440, 1441
Homma S (abst) 306, 389, 494
Homma T (abst) 158, 174, 441
Honda N *See* Kobayashi S et al 1405
Honeyman T (abst) 315
Honeyman TW *See* Lee DY et al 812
Hong SY (abst) 358
Honrath U (abst) 288
Hood WB (abst) 230
Hooke DH (abst) 743
Hoorntje SJ (abst) 226
Hootkins R (abst) 227
Hoover RL (abst) 158, 349, 441
Hopfer SD (abst) 380
Hoppe A (abst) 382
Horak E (abst) 380
Hori K (abst) 227, 250
Horigan E (abst) 294
Horio M (abst) 158
Horl WH (abst) 248, 266
Horst R (abst) 276
Horvat R (abst) 159
Hosselet C (abst) 157
Hostetter TH (abst) 200, 434
Hotta O (abst) 372
Houser MT (abst) 209
Hout WM (abst) 308
Hovingh P (abst) 187
Howard A (abst) 378
Howarth G (abst) 741
Howden B (abst) 738, 745, 746
Hoy W (abst) 197
Hoy WE (abst) 374
Hoyer JR (abst) 363, 364
Hreniuk D (abst) 408
Hropot M (abst) 481
Hruby Z (abst) 527
Hruska K (abst) 407
Hruska KA (abst) 175, 394
Hsu A (abst) 358
Hsu CH (abst) 390, 395, 396
Hu MS (abst) 313, 382
Huang CL (abst) 174, 174
Huang D (abst) 441
Huang H (abst) 313
Huang ZQ (abst) 455
Huff M (abst) 368
Hugel U (abst) 384
Hughes ML (abst) 306
Hughson M (abst) 197
Hui R (abst) 291
Huisman RM (abst) 327
Hull A (abst) 512
Hultgard-Nilsso A (abst) 314
Hume B (abst) 390
Humes HD (abst) 404, 408, 413
Humphreys MH (abst) 327
Huneycutt-Calde L (abst) 346
Hunsicker LG (abst) 201
Hunter JB (abst) 231
Huntsberger TL (abst) 200
Huot SJ (abst) 158
Hura CE (abst) 470
Hurley BP (abst) 752
Hurst NP (abst) 744
Hurtubise PE (abst) 514, 515
Husted RF (abst) 481
Hutchinson FN (abst) 301
Hutchison FN (abst) 313, 431
Huxmann-Nageli D (abst) 249
Huysmans F (abst) 226
Hwang KH (abst) 408, 424

Hwang SD (abst) 199, 272
Hwang WS *See* Lau DCW et al 604
Hylander B (abst) 228, 242
Hymes LC (abst) 375, 516
Hyver S (abst) 249
Hyver S *See* Pallone TL et al 125
Iacone R (abst) 189, 468
Iatrou C (abst) 1444, 1445
Ibels L (abst) 740, 742, 744, 744, 750, 752
Ichikawa I (abst) ... 278, 306, 346, 410, 421, 430, 434, 441, 469
Ichikawa I *See* Yoshida Y et al 654
Ichinose N *See* Kobayashi S et al 1405
Idelson BA (abst) 272
Ideura T (abst) 236, 469
Igarashi P (abst) 158
Igarashi T (abst) 392
Ihle BU (abst) 739, 740
Iino Y (abst) 234, 288
Iitaka K (abst) 228
Ikoma M (abst) 430, 434
Ilson BE (abst) 249
Imada T (abst) 278
Imai M (abst) 457, 481, 492
Imanishi M (abst) 264, 327, 328, 471, 471
Imbert-Teboul M (abst) 476
Imboden J (abst) 174
Inagami T (abst) 278, 303, 308
Ing TS (abst) 237, 247, 255, 260, 271
Ingelfinger JR (abst) 302
Ingram P (abst) 411
Inman KC (abst) 493
Innes A *See* Al-Muzairai IA et al 1057
Inokuchi S (abst) 174
Inoue K (abst) 350, 358
Inoue T (abst) 264
Inzoli F (abst) 424
Isaacs L (abst) 909
Isales CM (abst) 279, 300
Iseki K (abst) 227, 250
Ishibashi K (abst) 481
Ishidate T (abst) 228
Ishimura E (abst) 350
Iskandar S (abst) 320
Islam S (abst) 257
Isozaki T (abst) 481
Istefan N (abst) 422
Ito S, Carretero OA, Abe K, Beierwaltes WH, Yoshinaga K: Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa 1138
Ivanovich P (abst) 250
Ives HE (abst) 174, 174, 330, 331
Iwahashi C (abst) 492
Jablonski P (abst) 738, 745, 746
Jackson B (abst) 750
Jackson J (abst) 292, 296
Jackson KL (abst) 200
Jackson M (abst) 259
Jackson R (abst) 313
Jackson RL (abst) 206
Jacobs A (abst) 409
Jacobs D (abst) 908, 909, 913, 914
Jacobs DWC (abst) 910
Jacobs WR (abst) 413
Jacobson H (abst) 293
Jacobson HR (abst) 305, 309, 319, 429, 451, 496
Jacobson S (abst) 194, 371
Jacoby M (abst) 497
Jacquot C (abst) 245
Jahn CH (abst) 321
Jaichenco J (abst) 276
Jain S (abst) 482
Jakobs KH (abst) 177
James S (abst) 911, 915, 915
Jamgotchian N (abst) 313
Jamiemson NY (abst) 1440
Jamison RL (abst) 476, 500
Janatova J (abst) 242, 258
Janatova J *See* Cheung AK et al 576
Janney RP (abst) 506
Janssen HP (abst) 1429
Janssen WMT (abst) 280, 283, 1432
Jarrell B (abst) 520
Jenkins RD (abst) 250
Jenner DA (abst) 748
Jenner L (abst) 344
Jennette JC (abst) 346, 370
Jennings M (abst) 159
Jeunink MF (abst) 340, 345
Jewell LD (abst) 209
Jimenez G (abst) 406
Jindal KK (abst) 253
Jirillo E *See* Schena FP et al 875
Jo OD (abst) 152
Joh K (abst) 418
Johnson A (abst) 203, 205, 206
Johnson AM *See* Gabow PA et al 675
Johnson GC (abst) 409, 417
Johnson HC (abst) 354
Johnson MA (abst) 336
Johnson ML (abst) 409
Johnson R (abst) 350, 362
Johnson RJ (abst) 359
Johnson RJ *See* Schulze M et al 60
Johnson RJ *See* Stahl RAK et al 1161
Johnston CI (abst) 740, 750
Joles JA (abst) 470, 1432
Joly V (abst) 409, 412
Jonas AJ, Lin SN, Conley SB, Schneider JA, Williams JC, Caprioli RC: Urine glyceraldehyde excretion is elevated in the renal Fanconi syndrome 99
Jonasson O (abst) 520
Jones DP (abst) 409
Jones GV (abst) 300
Jones H Jr (abst) 431
Jones P (abst) 512, 517
Jones Q (abst) 276
Jones R (abst) 205
Jones RM (abst) 745
Jones SL (abst) 470
Jones SY (abst) 328
Jonker GJ (abst) 327
Jonsson S (abst) 256
Jordan SC (abst) 350, 360
Jorgetti V (abst) 376
Jorkasky DK (abst) 249
Jose PA (abst) 172, 328
Josepovitz C (abst) 159, 163
Joshi S (abst) 466
Josimovic-Alase O (abst) 263
Juergensen PH (abst) 228
Julian BA (abst) 265, 368, 512, 516, 517

Julin CM (abst) 443
Julius M (abst) 194
Jungwirth A (abst) 410
Junor BJR (abst) 1441, 1441
Jureidini KF (abst) 737
Juul D (abst) 908
Kabat V (abst) 322, 430
Kablitz C (abst) 278, 289, 289
Kabouromiti G (abst) 1444
Kachadorian WA (abst) 158, 497
Kadam JRC (abst) 304
Kadowitz PJ (abst) 207
Kadwa AM (abst) 913
Kaehny M (abst) 175
Kaehny W (abst) 203, 205
Kaehny WD *See* Gabow PA et al 675
Kaever V (abst) 297
Kahf S (abst) 320, 348
Kahf S *See* Thaiss F et al 76
Kahn AM (abst) 306, 306
Kahn SB (abst) 318, 334
Kahn T (abst) 455
Kainer G (abst) 194, 749
Kaiser B (abst) 410, 523
Kaizu K (abst) 250
Kakavas I (abst) 1437
Kakavoulis T (abst) 1445, 1446
Kakizaki Y (abst) 747
Kala U (abst) 909, 913
Kala UK (abst) 910, 914
Kalef-Ezra J (abst) 1438
Kaleta MM (abst) 378
Kalinsky A (abst) 286
Kalivretakis N (abst) 1436
Kallenberg CGM (abst) 208, 213, 1430, 1434
Kallivretakis N (abst) 1437, 1446
Kalogera A (abst) 1446
Kalogeras K (abst) 1446
Kalogeropoulou K (abst) 1437
Kaloheretis P (abst) 1436
Kaloyanides GJ (abst) 159, 163, 401
Kamada T (abst) 172, 406, 441
Kamada T *See* Shin SH et al 1320
Kamata K (abst) 350, 358
Kamel K (abst) 217
Kanalas JJ (abst) 211, 351
Kaname S (abst) 392
Kandus A (abst) 250
Kanemitsu H (abst) 217
Kanfer A (abst) 405
Kant KS (abst) 210, 235
Kanwar Y (abst) 351
Kapellakis G (abst) 1439
Kaplan AA (abst) 228
Kapoor SC (abst) 196
Kapusta DR (abst) 328
Karabatsos A (abst) 1443, 1443, 1443, 1447
Karaghiannis A (abst) 1436
Karajiannis A (abst) 1443
Karanja N (abst) 328
Karantanas AH (abst) 1438
Karara A (abst) 290
Karayanis A (abst) 1445
Kark A (abst) 915
Karl I (abst) 407
Karlson K (abst) 483
Karlsson K (abst) 228
Karniski L (abst) 159
Karnovsky M (abst) 360
Karnovsky MJ (abst) 426
Karsenti E (abst) 186, 188
Karvountzis G (abst) 1446
Kashgarian M (abst) 343, 348, 350, 407, 418, 1431
Kashihara N (abst) 351
Kashtan CE (abst) 205
Kasinath BS (abst) 159, 162, 165, 208
Kasiske BL (abst) 293, 430, 434, 473, 517, 523
Kasiske BL, O'Donnell MP, Cleary MP, Keane WF, Phillips F: Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats 40
Kaskel F (abst) 508
Katirtzoglou A (abst) 1436, 1436, 1444, 1448
Katoh H (abst) 237
Katoh T (abst) 313
Katsarou A (abst) 1443
Katsiotis P (abst) 1438
Katz AI (abst) 299
Katz MA (abst) 266
Katz MA *See* Van Wyck DB et al 712
Katz MS (abst) 173
Katz SA (abst) 301, 434
Katzir Z (abst) 446, 514
Kaufman AM (abst) 455
Kaufman CE (abst) 226
Kaufman JS (abst) 482
Kavadias D (abst) 1437, 1439
Kaw D (abst) 455
Kawabe M (abst) 252
Kawachi H (abst) 351
Kawaguchi Y (abst) 184, 393
Kawai C (abst) 202, 357
Kawamura M (abst) 327, 328, 471
Kawano Y (abst) 264, 327, 328, 471, 471
Kawasaki K (abst) 352, 367
Kaye M, D'Amour P, Henderson J: Elective total parathyroidectomy without autotransplant in end-stage renal disease 1390
Kaysen GA (abst) 301, 425, 431
Kazatchkine MD *See* Haeffner-Cavaillon N et al 1212
Keane WF (abst) 293, 430, 434, 473
Keane WF *See* Kasiske BL et al 40
Kear FT (abst) 455
Kees-Folts D (abst) 351, 373
Keeton GR (abst) 911
Keiser HR (abst) 283, 283, 316
Kekos G (abst) 1439
Kellerman PS (abst) 410
Kelley J *See* Gouvea WL et al 1041
Kelley V (abst) 358
Kelley VE (abst) 366, 367, 506
Kelley VE *See* Strom TB 1026
Kellner D (abst) 403
Kelly C (abst) 358
Kelly CJ (abst) 349, 352
Kelly D (abst) 747, 751
Kelly J (abst) 745
Kelly MR (abst) 193
Kelly RA, Canessa ML, Steinman TI, Mitch WE: Hemodialysis and red cell cation transport in uremia: Role of membrane free fatty acids 595
Kelson K (abst) 737

Kempson SA (abst) 188, 381
Kennedy D (abst) 243
Kenoyer G (abst) 914
Kenyon M (abst) 915
Keown PA (abst) 195
Kerabellia H (abst) 1443
Kerjaschki D (abst) 159
Kern E (abst) 431
Kern EFO (abst) 435
Kern EFO *See* Baker L et al 1345
Kern P (abst) 350, 360
Kerr PG (abst) 742, 753
Keshaviah P (abst) 243, 251
Kessel M (abst) 437
Kestenbaum R (abst) 399
Kester M (abst) 179, 293
Ketchum R (abst) 491
Ketel B (abst) 520
Ketteler M (abst) 480
Key J (abst) 237, 259
Khairuddin F (abst) 744
Khamiseh G (abst) 435
Khanna R (abst) 238
Kiberd B (abst) 517
Kihara I (abst) 352, 367
Kikawa K (abst) 434
Kikeri D (abst) 408, 456
Kilingis V (abst) 1444
Killen P (abst) 366
Kim C (abst) 456
Kim H (abst) 227
Kim HK (abst) 519
Kim JK, Summer SN, Durr J, Schrier RW: Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons 799
Kim KE (abst) 318, 334
Kim KS (abst) 199, 272
Kim Y (abst) 342
Kim YS (abst) 175
Kimburis I (abst) 1443
Kimmel PL (abst) 195, 222, 233
Kimura G (abst) 264, 327, 328, 471, 471
Kimura H (abst) 431
Kincaid-Smith P (abst) . 374, 431, 435, 738, 739, 740, 741, 742, 746, 749, 752
Kincaid-Smith PS (abst) 747, 749
Kindig N (abst) 463
King A (abst) 258, 521
King AJ (abst) 314
Kingstone D (abst) 439
Kingswood JC (abst) 223, 251
Kinne RKH (abst) 496
Kinoshita S (abst) 329
Kinoshita Y (abst) 482
Kinsella JL (abst) 167
Kintziger PN (abst) 383
Kirchner KA (abst) 326, 432
Kiriaki D (abst) 1440, 1441, 1443
Kirk KA *See* Gifford JD et al 90
Kirlin L (abst) 266
Kirlin LF *See* Van Wyck DB et al 712
Kirousis J (abst) 1437
Kirschbaum B (abst) 251
Kirschenbaum MA (abst) 162, 279, 292, 293
Kiss B (abst) 210
Kissane MJ (abst) 205
Kita T (abst) 526
Kitajima W (abst) 312
Kjellstrand CM (abst) 224, 228, 232, 242, 257, 519
Kladnik S (abst) 250
Klag MJ (abst) 518
Klahr S (abst) 195, 287, 416, 429, 438, 461
Klahr S *See* Purkerson ML 1306
Klassen DK (abst) 294, 404, 430, 474
Klaus E (abst) 481
Klavdianos L (abst) 1447
Kleeman C (abst) 298
Kleeman CR (abst) 156
Klein DJ (abst) 352
Klein J (abst) 175
Klein M (abst) 239
Klein RM (abst) 311
Kleinert HD (abst) 304
Kleinman J (abst) 478
Kleinman KS (abst) 179, 229
Kleinman KS, Coburn JW: Amyloid syndromes associated with hemodialysis (Editorial Review) 567
Kleinman LI (abst) 483
Kleinzeller A (abst) 495
Kleppel M *See* Butkowski RJ et al 1195
Kleppel MM (abst) 352
Kleyman T (abst) 155
Kleyman TR (abst) 160, 465
Kliger AS (abst) 228, 267
Klimopoulos S (abst) 1445
Klinger M (abst) 389
Klinkefus J (abst) 488
Kloss K *See* Shusterman NH et al 887
Klotman P (abst) 294, 425
Klotman PE (abst) 335, 505
Klotman PE *See* Coffman TM et al 24
Kneip JM *See* Levitt MD et al 1145
Kneisley JD (abst) 194
Knepper MA (abst) 465, 489, 494, 501
Kniaz D (abst) 456
Knibloe KA (abst) 383
Knight JA (abst) 419, 517
Knight JF (abst) 742
Knight PR (abst) 183
Knowler WC *See* Kunzelman CL et al 681
Knox FG (abst) 389, 482
Knox FG *See* Gonzalez-Campoy JM et al 767
Knutson DW (abst) 367
Knuuttila KG *See* Wistrand PJ 851
Kobayashi S, Nagase M, Honda N, Adachi K, Ichinose N, Hishida A: Analysis of anionic charge of the glomerular basement membrane in aminonucleoside nephrosis (Technical Note) 1405
Kobilka BK (abst) 163
Kobrin S (abst) 229, 252, 260
Koch K (abst) 262, 338
Koch KM (abst) 249, 254, 263, 270
Koch MO *See* McDougal WS 105
Kochar M (abst) 334, 335
Kocochis S (abst) 153
Koeffler HP (abst) 186
Koene RAP (abst) 340, 353, 1429, 1431
Koene RAP: The role of adaptation in allograft acceptance (Nephrology Forum) 1073
Koenig KG (abst) 393
Koethe JD (abst) 456
Koh HI (abst) 370

Koh HI *See* Lee HS et al 880
Kohan D (abst) 353
Kohda Y (abst) 251
Kohen J (abst) 224
Kohler H (abst) 365, 370
Kohli R (abst) 525
Kohn OF (abst) 228, 457
Kohnen PW (abst) 748
Kojima S (abst) 264, 327, 328, 471, 471
Kok A (abst) 908
Kokolina E (abst) 1440
Kokot F (abst) 263
Kolare S (abst) 314
Kolner ST (abst) 252
Kon V (abst) 278, 306, 410
Kone B (abst) 321
Kone BC (abst) 320, 402, 480, 482
Konecky A (abst) 216
Kontessis PS (abst) 470
Koolen M (abst) 1430
Koomans HA (abst) 207, 281, 283, 470, 1429, 1431, 1432, 1433, 1434
Koomans HA *See* Boer WH et al 1183
Koomen GCM (abst) 470
Koomen GCM *See* Krediet RT et al 1064
Koopman MG (abst) 470
Koopman MG *See* Krediet RT et al 1064
Kopecky RT (abst) 329
Kopp JB (abst) 376, 518
Kopp UC (abst) 294
Kopple JD (abst) 195, 274, 312
Kopple JD *See* Hirschberg R et al 865
Kopple JD *See* Slomowitz LA et al 704
Korbet SM (abst) 196, 199
Kornhaus J *See* Grantham JJ et al 1379
Korzets Z (abst) 272
Koseki C (abst) 457
Koshikawa S (abst) 236, 469
Kostakis A (abst) 1436, 1440, 1441
Kostogiani-Papagalani G (abst) 1447
Kostogianni G (abst) 1443, 1443
Kotchen JM (abst) 329
Kotchen T (abst) 329
Koudstaal J (abst) 221
Koukoudis P (abst) 1437, 1446
Koulentianos I (abst) 1440, 1441
Koutoulidis K (abst) 1437
Koutsikos D (abst) 1439, 1441
Kovacs IB (abst) 518
Kovithavongs T (abst) 518
Koyle M (abst) 526
Koyle MA (abst) 524
Kraehenbuhl JP (abst) 155, 160
Kraft N (abst) 743, 745
Kramer HJ (abst) 285, 286, 287, 314, 337, 423
Kramer MS (abst) 252
Kramer P (abst) 245
Krapf R (abst) 457
Kraus AP Jr (abst) 196
Kraus LM (abst) 196
Kraut JA (abst) 175, 383, 456, 499
Krediet RT (abst) 470
Krediet RT, Koomen GCM, Koopman MG, Hoek FJ, Struijk DG, Boeschoten EW, Arisz L: The peritoneal transport of serum proteins and neutral dextran in CAPD patients 1064
Kreisberg JI (abst) 156
Kremer S (abst) 176, 176, 179
Kreutzer S (abst) 206
Kriger FL (abst) 518
Kripalani K (abst) 245
Krishna GG (abst) 196
Krishnamurthy T (abst) 322
Kristein M (abst) 281
Krol H (abst) 303
Krothapalli R (abst) 214
Krsulovic P (abst) 214
Kruger M (abst) 912, 912, 912, 913
Kubey W (abst) 273
Kubo K (abst) 264
Kubota T (abst) 368, 372, 374, 376
Kuhn R (abst) 354
Kuhn RJ (abst) 250
Kuizinga MC (abst) 226
Kujubu DA (abst) 176
Kuklinski P (abst) 286
Kumagai H (abst) 182, 227, 399
Kumano K (abst) 252
Kumar R (abst) 381
Kunau RT (abst) 470
Kunis CL (abst) 210
Kunkel S (abst) 366
Kuntziger HE (abst) 383
Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH: Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians 681
Kunzendorf U (abst) 263, 519
Kuo SM (abst) 498
Kuramochi M (abst) 264, 327, 328, 471, 471
Kurihara S (abst) 237, 252
Kurnik BRC (abst) 411
Kurnik PB (abst) 411
Kurokawa K (abst) 177, 179, 313, 392, 438
Kurtz I (abst) 153, 173, 186, 380, 398, 454, 457, 484
Kurtz I *See* Ferdows M et al 783
Kurtzman NA (abst) 312, 386, 387, 448
Kurunsaari KM (abst) 241
Kurz P (abst) 1438
Kurz RW (abst) 321, 383
Kuschnaroff LM (abst) 522
Kut J (abst) 507
Kuwahara K (abst) 251
Kuwahara M (abst) 188, 495
Kwok C (abst) 505, 507, 508
Kyle R (abst) 209
Kyriakidis S (abst) 1440, 1441
Kyrle PA (abst) 294
La Greca G (abst) 231, 246, 261, 261
La Q (abst) 487
Labigne-Roussel A *See* Meyrier A et al 696
Lacave R (abst) 180
Lacave R, Rondeau E, Ochi S, Delarue F, Schleuning WD, Sraer JD: Characterization of a plasminogen activator and its inhibitor in human mesangial cells 806
Lacoste M *See* Antignac C et al 1336
Lacour B (abst) 429
Lafferty HM (abst) 284, 290
Lafi N (abst) 1442, 1442
Lagos G (abst) 1444
Lagouranis A (abst) 1443
Lagueruela CC (abst) 205

Lai KN (abst) 370
Laidlaw SA (abst) 195
Laidlaw SA *See* Slomowitz LA et al 704
Laitman R (abst) 210
Lam K *See* Read RR et al 614
Lam KT (abst) 443
Lamas S (abst) 179, 314
Lamas S *See* Olivera A et al 1300
Lamas S *See* Rodríguez-Puyol D et al 632
Lamberts LV (abst) 244
Lambertz M (abst) 519
Laminski N (abst) 912
Laminski NA (abst) 912, 912, 913
Lamm ME (abst) 345, 347, 756, 760
Lamperi S (abst) 342
Lan S (abst) 230
Landesman SH (abst) 242
Landry D (abst) 160
Landwehr EP (abst) 417
Lanese D (abst) 400
Lanese DM (abst) 253
Lanese DM, Alfrey PS, Molitoris BA: Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers (Technical Note) 1409
Lang F (abst) 160, 180, 410
Langevin J (abst) 343, 347
Langford R (abst) 223
Langhorst P (abst) 519
Langley J (abst) 512
Languino L (abst) 341
Lapointe JY (abst) 483
Lapointe M (abst) 329, 422
Laragh JH (abst) 324
Larsson SH (abst) 314
Lasker N (abst) 248
Laskin C (abst) 344
Laskow DA (abst) 512, 517
Laszlo A (abst) 177, 407
Lau DCW, Wong KL, Hwang WS: Cyclosporine toxicity on cultured rat microvascular endothelial cells 604
Lau K (abst) 387, 387, 393, 438
Laude D *See* Hannedouche T et al 95
Laupacis A (abst) 196
Laurenzi M (abst) 754
Laver MC (abst) 253
Lawler RG (abst) 493
Lawless C (abst) 215
Lawless S (abst) 410
Lawrence PL (abst) 273
Lawrence S (abst) 745
Lawton WJ (abst) 330
Lazar AM (abst) 380
Lazaro M (abst) 429
Lazarovits AI (abst) 272
Lazarus JM (abst) 253
Lazzaro V (abst) 741
Le Carpentier JE (abst) 310, 315, 427, 440
Le Grimellec C (abst) 155, 166
Leaf A (abst) 412
Leahy AE *See* Strife CF et al 836
Leary JF (abst) 355
Leatherman JR (abst) 226
Lebel M (abst) 291
Lebon P (abst) 257
Lechene C (abst) 325, 487
Lechner K (abst) 294
Lederer ED (abst) 378
Ledingham JGG (abst) 396
Lee DBN (abst) 260, 313, 382, 396, 524
Lee DY, Cho KW, Lee JS, Honeyman TW, Park CS: Stimulation of renin secretion by non-diuretic sulfhydryl reagents 812
Lee E (abst) 752
Lee HB (abst) 199, 272
Lee HS (abst) 151, 370, 496
Lee HS, Choi Y, Lee JS, Yu BH, Koh HI: Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data 880
Lee JP (abst) 496
Lee JS *See* Lee DY et al 812
Lee JS *See* Lee HS et al 880
Lee JY (abst) 336
Lee P (abst) 436
Lee RE (abst) 275
Lee SD (abst) 519
Lee SR (abst) 519
Leehey DJ (abst) 229, 247
Lefevre A (abst) 1430
Lefkowith J (abst) 361
Lefkowith JB (abst) 362
Lefkowitz RJ (abst) 163
Lefurgey A (abst) 411
Legault L (abst) 284
Leichter HE (abst) 231
Leite M Jr (abst) 497
Lele PS (abst) 426
Lelongt B (abst) 160, 164, 166
Lemann J (abst) 216
Lemann J Jr., Gray RW, Pleuss JA: Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men 688
Lemire JM (abst) 527
Lencer WI (abst) 152, 502
Lentino JR (abst) 229
Lenz K (abst) 225, 229
Lenzner B (abst) 254
Leone CA (abst) 390
Leone D (abst) 315
Lerner JL (abst) 515
Leung WM (abst) 284
Levere RD (abst) 446, 448
Leverger G *See* Antignac C et al 1336
Levey AS (abst) 195, 197, 200
Levi J (abst) 271, 375
Levi M (abst) 150, 388, 411
Leviel F (abst) 458, 459, 460
Levillain O (abst) 449
Levin A (abst) 253
Levin NW (abst) 245, 254, 262, 265, 328, 512, 516
Levine BS (abst) 383
Levine G (abst) 229
Levine JS (abst) 272
Levine M (abst) 176
Levine S (abst) 225
Levine SD (abst) 497, 497
Levitt MD, Kneip JM, Overdahl MC: Influence of shaking on peritoneal transfer in rats 1145
Levy G (abst) 344, 505
Levy J (abst) 239

Levy M (abst) 284
Lew SQ (abst) 220, 271
Lewicki J (abst) ..... 28[illegible]
Lewis DJ (abst) 749, 751, 753
Lewis E (abst) 323, 428
Lewis EJ (abst) 165, 196, 199, 208, 369
Lewis RM (abst) 506
Lewis S (abst) 273
Lewis-Finch J (abst) 391
Lewis-Finch J *See* Brown AJ et al 19
Lewis-Finch J *See* Dusso A et al 860
Lewy JE (abst) 207
Leypoldt JK (abst) 270, 273, 274, 349
Leypoldt JK *See* Henderson LW 589
Lezotte D (abst) 205, 206
Lezotte DC *See* Gabow PA et al 675
Li L (abst) 236, 353, 376
Li N (abst) 743
Li XW (abst) 353
Li Y (abst) 416
Liamos O (abst) 1440, 1444
Liang CT (abst) 153, 176
Lianos EA (abst) 295
Lianos EA: Eicosanoids and the modulation of glomerular immune injury 985
Lieberthal W (abst) 411
Liebes L (abst) 371
Lien YH (abst) 498
Lietz S (abst) 224
Lifschitz MD (abst) 173
Light D (abst) 165, 483
Ligier S (abst) 202
Lim I (abst) 461
Limacher M (abst) 337
Limburg PC (abst) 1430
Lin SN *See* Jonas AJ et al 99
Lin SY (abst) 327
Linari F *See* Bruno M et al 1189
Linas S (abst) 410
Linas SL (abst) 185, 412
Lindberg J (abst) 383, 393
Lindenfeld J (abst) 330
Lindheimer M (abst) 479
Lindheimer MD (abst) 494
Lindholm B (abst) 274
Lindholm B, Alvestrand A, Fürst P, Bergström J: Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis 1219
Lindman B (abst) 344, 359
Linehan WM *See* Elliot S et al 1245
Ling B (abst) 526
Ling BN (abst) 483
Linke E (abst) 254
Linke RP (abst) 756
Linker A (abst) 187
Linker-Israeli M (abst) 193, 389
Linne T (abst) 197
Lins LE (abst) 194, 519
Linser PJ (abst) 465
Linsert PJ (abst) 458
Lipkowitz MS (abst) 432, 451
Lipman J (abst) 434
Lipman JJ (abst) 273
Lipner HI (abst) 412, 497
Lipson LG (abst) 427
Little JM (abst) 738
Litwack G (abst) 182
Liu FY (abst) 458
Liu PL (abst) 737
Liu Z (abst) 353
Llach F (abst) 215, 218, 254, 259, 261, 377, 379, 391, 426
Llach F *See* Felsenfeld AJ et al 1371
Lloren P (abst) 752
Lloyd CM (abst) 746
Lobaugh B (abst) 391
Lobeck H (abst) 254
Lochs H (abst) 225
Locksley RM (abst) 369
Lockwood CM *See* Pusey CD 929
Lodish HF (abst) 150, 152
Loftus D (abst) 407
Loftus J (abst) 287
Loftus JP (abst) 471
Logan A (abst) 284, 289
Logan JL (abst) 295
Loghman-Adham M (abst) 165, 384
Lohr JW (abst) 432
Lohse MJ (abst) 163
Lohstroh P (abst) 492
Lombardi A (abst) 192
Lombardi MJ (abst) 480
Lombardo V (abst) 754
Lomberg H (abst) 371
Lombet J (abst) 422
London RD (abst) 432
Lonergan M (abst) 202, 206
Long D (abst) 512
Long J (abst) 154
Longhofer SL (abst) 354
Longuet P (abst) 412
Lonnemann G (abst) 254, 270
Loo DDF (abst) 151
Loon NR (abst) 210, 211, 337
Lopes MJ (abst) 458
Lopez C (abst) 319
Lopez EL (abst) 230
Lopez G (abst) 406
López-Farré A *See* Rodríguez-Puyol D et al 632
Lopez-Hilker S (abst) 391, 393
Lopez-Hilker S *See* Brown AJ et al 19
Lopez-Hilker S *See* Dusso A et al 860
Lopez-Novoa JM (abst) 179, 314
López-Novoa JM *See* Olivera A et al 1300
López-Novoa JM *See* Rodríguez-Puyol D et al 632
Lopez-Rivas A (abst) 179
Lorenz JM (abst) 483
Lorig R (abst) 325
Lorr E (abst) 438
Lough J (abst) 201
Louis BM (abst) 412
Loutzenhiser R (abst) 282, 291, 315, 323
Lovett DH (abst) 169, 348
Low I (abst) 506
Lowe J (abst) 174, 330
Lowe MG (abst) 747
Lowenstein J (abst) 295
Lowry R (abst) 3827
Lu CY (abst) 507
Lucas E (abst) 349, 356
Lucas ME (abst) 484
Lucas PA (abst) 394
Luconi PS (abst) 522

Ludovico N (abst) 373
Ludvik G (abst) 316
Luft FC (abst) 354
Lugon JR (abst) 479, 484
Lui SF (abst) 315, 321, 525
Lujic K (abst) 490
Luke RG (abst) 453, 454, 464, 512, 516
Lumpkin MD (abst) 385, 392
Lundin AP (abst) 247
Lupus Nephritis Collaborative Study Group (abst) 230
Luscher TF (abst) 325, 330, 511
Lustig A (abst) 239
Lustig S (abst) 396
Lynch SV (abst) 738
Lynn KL (abst) 739
Lysaght M (abst) 744, 744, 753
Maack T (abst) 281, 285
Maass CN (abst) 1431
Mac Carthy EP (abst) 253
Mac-Moune Lai F (abst) 370
Macartney K (abst) 743
MacCarthy EP (abst) 358
MacDonald M (abst) 346
MacDougall IC (abst) 273
MacDougall ML (abst) 498
Macgregor K (abst) 911
MacGregor KJ (abst) 911
Machin S (abst) 251
Macica C (abst) 297
Maciejewski A (abst) 477
Mackenzie R (abst) 277
Mackie JD (abst) 506
Macleod AM *See* Al-Muzairai IA et al 1057
Macon EJ (abst) 255, 395
Madaio MP (abst) 346
Maddison W (abst) 908
Maddux M (abst) 520
Maddux S (abst) 520
Madias NE (abst) 214
Madsen KM (abst) 458, 464, 465
Maesaka JK (abst) 208, 215, 217, 484
Magana P (abst) 1437, 1442
Magdenic M (abst) 243
Maggana P (abst) 1437
Maggiore Q (abst) 246, 338
Magnusson MO (abst) 509
Magoula I (abst) 1446
Mahajan S (abst) 399
Mahajan SK (abst) 198
Mahan J (abst) 341, 354
Mahan JD (abst) 344, 351, 361
Maharaj R (abst) 913
Maher E (abst) 284
Maher JF (abst) 275, 755
Mahman NS (abst) 221
Mahony J (abst) 739, 740, 742, 752
Mahony JF (abst) 737
Mahuran D *See* Thorner P et al 843
Mai ML (abst) 384
Maiga M (abst) 253
Maini RN (abst) 241
Maita M (abst) 297
Maiz A (abst) 475
Majais SK (abst) 338
Maki R (abst) 349
Maki S *See* Yoshioka K et al 1203
Makino H (abst) 351
Makker SP (abst) 211, 351
Malachi TA (abst) 271
Malamitsi J (abst) 1437
Malavasi F *See* Roccatello D et al 622
Maldifassi P (abst) 756
Malegos J (abst) 1445
Malik N (abst) 334
Malis CD (abst) 412
Mall G (abst) 384
Mall G *See* Szabo A et al 1049
Mallamaci F (abst) 338, 755
Malluche HH (abst) 215, 220, 377
Malluche HH *See* Baker LRI et al 661
Malnic G (abst) 458
Maloney NA (abst) 258, 518
Malt RA (abst) 415
Manahan FJ (abst) 255, 260, 271
Manaligod I (abst) 1436
Manco-Johnson M *See* Gabow PA et al 675
Mandel LJ (abst) 411, 413, 416, 444
Mandel T (abst) 748
Manfrini E (abst) 754
Manfro RC (abst) 507, 522
Mangiarotti G (abst) 758
Mangino M (abst) 505
Mangoo-Karim R *See* Grantham JJ et al 1379
Manika Z (abst) 1444
Manikkam NEG (abst) 910
Mann JFE (abst) 284
Mann RA (abst) 354, 363
Mannik M (abst) 347
Manohar NL (abst) 412
Manolas J (abst) 1447
Mantyh CR (abst) 207
Mantyh PW (abst) 207
Manuli MA (abst) 161, 483
Maragou M (abst) 1437
Marangella M *See* Bruno M et al 1189
Marchini F (abst) 754
Marcondes M (abst) 376, 473
Marcus R (abst) 255
Maret J (abst) 257
Margellos B (abst) 1445, 1445, 1446
Margolis B (abst) 176
Margolius L (abst) 915
Margolius LP (abst) 909, 911
Marinides G (abst) 187
Marinides GN (abst) 348, 355
Marinos L (abst) 1442
Markarian K (abst) 483
Markell MS (abst) 246, 519
Markovic-Lipkovski J *See* Müller CA et al 116
Marks ES (abst) 316
Maroni BJ (abst) 413
Marrano P *See* Thorner P et al 843
Marrero MM (abst) 446
Marsden PA (abst) 177
Marsh DJ (abst) 468, 469
Marsh F (abst) 189, 192, 349, 356
Marsh JT (abst) 257
Marshall C (abst) 521
Marshall V (abst) 745
Marshall VC (abst) 738, 746
Martasek P (abst) 446, 448
Martella D (abst) 759

Martin B (abst) 265
Martin BM (abst) 298
Martin ER (abst) 316
Martin G (abst) 294
Martin JP (abst) 506
Martin K *See* Dusso A et al 860
Martin KJ (abst) 172, 391, 393, 394
Martin R (abst) 398
Martin V (abst) 301, 313
Martinelli R, Noblat ACB, Brito E, Rocha H: *Schistosoma mansoni*-induced mesangiocapillary glomerulonephritis: Influence of therapy 1227
Martinez A (abst) 509
Martinez AJ (abst) 219
Martinez ME (abst) 379
Martinez-Maldon M (abst) 493
Martínez-Zorzano VS, Berrocal FJR, Cabezas JA, de la Cadena MP: Comparative studies of two acid β-galactosidases from rabbit and bovine kidney 1295
Martis L (abst) 274
Martone WJ (abst) 255
Marty E (abst) 458, 460
Marumo F (abst) 217, 234, 237, 252, 288, 487
Maruyama N *See* Takeuchi E et al 638
Maruyama Y (abst) 150
Marzolla O (abst) 246
Maschio G (abst) 198, 336
Masilamani D (abst) 484
Mason AJ (abst) 253
Mason J (abst) 331, 413, 414, 510
Mason N (abst) 344
Massad TC (abst) 478
Massara C (abst) 759
Massry SG (abst) 193, 281, 389, 422, 427, 435, 755
Masters SB (abst) 178
Mastrolitti G *See* Schena FP et al 875
Matheson KL (abst) 493
Mathew TH (abst) 738
Mathews D (abst) 431, 739, 741
Mathews DC (abst) 742
Matons C (abst) 215
Matsui K (abst) 351
Matsui N (abst) 234
Matsumoto AM (abst) 193
Matsumoto K (abst) 355
Matsunaga H (abst) 177
Matsuo H (abst) 475
Matsuo N (abst) 250
Matsuo S (abst) 367
Matsuoka H (abst) 471
Matsushima M (abst) 202
Matsushima Y (abst) 457
Matsuzaki K (abst) 453, 484
Matthias S (abst) 384
Matthys E (abst) 430
Mauer SM (abst) 342, 520
Mauer SM, Steffes MW, Azar S, Brown DM: Effects of dietary protein content in streptozotocin-diabetic rats 48
Mavromati L (abst) 1444
Mavromatides K (abst) 1446
Mavromatidis K (abst) 1447
Mavros SM (abst) 505
May R (abst) 433, 446
May RC (abst) 428
Mayer G (abst) 316
Mayopoulou-Symvoulidis D (abst) 1448
Mayopoulou-Symvoulidou D (abst) 1446
Mayopoulou-Symvoulidou N (abst) 1444
Mazurchuk R (abst) 432
Mazzucco G (abst) 756
Mazzucco G *See* Roccatello D et al 622
McAfee JG (abst) 329
McAllister C (abst) 351, 361
McAndrew JD (abst) 506
McArdle S (abst) 316
McAteer J *See* Grantham JJ et al 1379
McBride DE (abst) 459, 486
McCarron D (abst) 338
McCarron DA (abst) 324, 328, 333
McCarron DA: Calcium metabolism and hypertension (Nephrology Forum) 717
McCarthy DM (abst) 297
McCarthy JT (abst) 255
McCarthy RT (abst) 279
McCauley J (abst) 507
McClellan W (abst) 256
McCluskey RT (abst) 187
McConkey C (abst) 172
McConkey CL (abst) 394
McConnell KR (abst) 498
McCulley K (abst) 438
McCulloch L (abst) 345
McDaniel HG *See* Gifford JD et al 90
McDermott RG (abst) 184
McDonald ATJ (abst) 205
McDonald F (abst) 399
McDonald FD (abst) 198, 403
McDougal WS, Koch MO: Effect of sulfate on calcium and magnesium homeostasis following urinary diversion 105
McDougall JF (abst) 510
McDougall JG (abst) 748
McFadden M (abst) 329
McGann S (abst) 520
McGarry BM (abst) 436
McGovern B (abst) 305
McGrath K (abst) 403
McGuire A (abst) 190
McInnes R *See* Thorner P et al 843
McIver M (abst) 751, 753
McKay CP (abst) 394
McKay DB (abst) 507
McKay S (abst) 195
McKenna BA (abst) 230
McLain LA (abst) 236
McLean RH (abst) 368
McLeish K (abst) 175
McLeish KR (abst) 177
McMahon LP (abst) 745
McNamara ER (abst) 501
McNamara MM (abst) 432
McNaughton D (abst) 1440
McPherson JA (abst) 226
McPherson R (abst) 222
McVicar M (abst) 223
McWeeny OJ (abst) 488
MDRD Study Group (abst) 195, 197, 201, 226
Meadows JH (abst) 191
Medeiros M (abst) 403
Medina F (abst) 240, 240

Medow MS (abst) 161, 501
Meema HE (abst)..... 1438
Mees EJD (abst)..... 1429, 1431, 1432, 1434
Mees EJD *See* Boer WH et al..... 1183
Megalokonomos K (abst)..... 1441
Meggs LG (abst)..... 313, 446
Megill D (abst)..... 197
Mehta PS (abst) 485
Mehta R (abst)..... 363
Mehta RL (abst)..... 355
Meibner M (abst)..... 281
Meijer S (abst)..... 1434, 1434
Meijer-Paape ME (abst) 520, 525, 1432, 1433
Meisinger V (abst)..... 383
Meissner NA (abst)..... 518
Mela-Riker L (abst) 405
Melaragno CS (abst) 522
Melendez A (abst) 269
Melle M (abst) 371
Melton L (abst)..... 511
Melzi ML (abst)..... 323
Membrane Transplant Research Group (abst)..... 483
Memmos D (abst) 1437
Mendelsohn D (abst)..... 912
Mendelsohn FAO (abst)..... 740
Mendelssohn DC (abst) 498
Mendez M (abst)..... 252
Mendilaharzu F (abst) 230
Mene P (abst) 171, 179, 295
Mené P (abst) 759
Mené P *See* Pugliese F et al..... 817
Mentis A (abst)..... 1444
Mento P (abst) 297
Menton D (abst) 177, 407
Mercier O (abst) 389, 459
Merke J *See* Szabo A et al 1049
Merke T (abst)..... 384
Merli C (abst)..... 353, 459
Merrill R (abst) 331
Merritt B (abst)..... 298
Merritt S (abst) 366
Messa M (abst) 758
Messa P (abst) 758
Messana JM (abst)..... 404, 408, 413
Metaxatos G (abst)..... 1442, 1445
Metz R (abst)..... 355
Meuer SC (abst)..... 370
Meuwissen SGM (abst)..... 503
Meyer S (abst) 213
Meyer TW (abst) 433, 437
Meyer Zum Busch KH (abst)..... 365, 370
Meyer-Lehnert H (abst)..... 285, 287, 314, 337, 423
Meyers AM (abst)..... 909, 911, 912, 912, 912, 913, 915, 915
Meyrier A (abst)..... 197, 199, 201
Meyrier A, Condamin MC, Fernet M, Labigne-Roussel A, Simon P, Callard P, Rainfray M, Soilleux M, Groc A: Frequency of development of early cortical scarring in acute primary pyelonephritis 696
Miariti N (abst)..... 1447
Michael AF (abst)..... 205, 352
Michael AF *See* Butkowski RJ et al..... 1195
Michael H (abst) 520
Michaels R (abst) 256
Michelis MF (abst)..... 216, 379
Michielsen P (abst)..... 1435
Middendorf D (abst)..... 221
Middleton JP (abst)..... 178, 180, 391
Miettinen A (abst) 153, 164, 356
Migdal SD (abst) 198
Mignon F (abst) 245
Miki S (abst)..... 475
Milan M (abst) 246
Milanes C (abst)..... 400
Milanes CL (abst)..... 396
Miles D (abst)..... 237
Milford EL (abst) 505, 507, 508
Milgrom F (abst) 356
Milgrom M (abst) 522
Miller J (abst)..... 289, 522
Miller JH (abst) 256, 264
Miller LA (abst) 232
Miller N (abst)..... 479, 913
Miller PL (abst) 433, 437
Miller R (abst) 251
Miller RT (abst) 178
Miller W (abst) 287, 471
Miller WL (abst) 317
Milligan MK (abst) 232
Milne FJ (abst)..... 908, 911, 915
Milne JF (abst)..... 915
Milner LS (abst)..... 909, 913, 914
Miltenburg AMM (abst) 520, 525, 1432, 1433
Mimran A (abst)..... 288
Minetti E (abst)..... 755
Minetti EE (abst)..... 759
Minetti L (abst) 755, 759
Minto AWM (abst) 360
Mintz GS (abst) 318, 334
Minuth W (abst) 480, 485
Mioli V (abst) 754
Mion C (abst)..... 238, 270
Mioni G (abst) 758
Mischel MG (abst)..... 399
Miscio F (abst)..... 405
Mishell J (abst) 239
Mishler DR (abst) 383, 499
Misler S (abst) 161
Mitch W (abst) 433, 446
Mitch WE (abst) 413, 428
Mitch WE *See* Kelly RA et al..... 595
Mitchell KD (abst) 301, 303
Mitchell PP (abst)..... 457
Mitsis J (abst)..... 1437
Mitsuhashi T (abst)..... 331
Mittman N (abst) 209, 220, 239, 269
Miyahara T (abst)..... 184, 393, 418
Miyakawa S (abst)..... 384
Miyamoto H *See* Yoshioka K et al..... 1203
Miyata M (abst) 356
Miyauchi A (abst)..... 394
Mizelle HL (abst) 285, 326, 474
Moe O (abst) 301
Mohini R (abst)..... 256
Mola R (abst)..... 456
Molitoris BA (abst) 253, 398, 410, 418
Molitoris BA *See* Lanese DM et al 1409
Moliz MA (abst)..... 319
Molony DA (abst) 485, 485
Moltaji H (abst)..... 168
Monga G (abst) 756
Monsour ME (abst)..... 514
Montagni F (abst)..... 757

Montanari A (abst) 317
Montanaro D (abst) 758
Montani D (abst) 172
Montani JP (abst) 285
Montegut M (abst) 494
Montemurro P (abst) 198
Monteon FJ *See* Slomowitz LA et al 704
Montez AJ (abst) 260
Monti JP, Gallice P, Baz M, Murisasco A, Crevat A, Elsen R: Intraerythrocytic pH variations during hemodialysis: A ^{31}P NMR study 871
Montinaro V (abst) 371, 373
Montruchio G (abst) 310
Mooppan UMM (abst) 227
Moore B (abst) 256
Moore J (abst) 378
Moore L (abst) 237, 414, 508
Moore MJ (abst) 303
Moore R (abst) 349, 356
Moorhead JF (abst) 315, 321, 433, 439, 525
Moosa AYD (abst) 914
Moosa MR (abst) 909
Morabito S (abst) 757
Moraes M (abst) 912
Morales H (abst) 475
Moran A (abst) 352, 397
Moran J (abst) 753
Moran M (abst) 487, 509, 520
Mordhorst M (abst) 169, 181
Morduchowicz G (abst) 161
Morelli E (abst) 210, 211
Morgan J (abst) 206
Morgano P (abst) 306
Morganti A (abst) 757
Morgenstern BZ (abst) 274
Morgenthaler J (abst) 237
Morgunov NS (abst) 317, 485
Morimoto C (abst) 360
Moriniere P (abst) 257, 377
Morioka T (abst) 351, 357
Moritz M (abst) 520
Moriyama T (abst) 499
Morris K (abst) 231
Morris PJ (abst) 745
Morris RC (abst) 331
Morris RC Jr (abst) 452
Morris RC Jr. (abst) 387
Morrison AR (abst) 169, 181
Morrison R (abst) 913
Morrissey J (abst) 395, 397
Morrone LF (abst) 198
Morrow W (abst) 746
Morse GD (abst) 510
Morsing P (abst) 526
Mortimore GE (abst) 449
Moscovitz A (abst) 379
Moskowitz DW (abst) 317
Mota de Freitas D (abst) 322
Motz A (abst) 423
Moullier PH (abst) 356
Mountokalakis T (abst) 1444, 1446, 1448
Mourad G (abst) 238
Mouri T (abst) 321
Mourikis D (abst) 1438
Moustakas G (abst) 1443, 1443, 1445
Moutafis S (abst) 1438
Moutzouris D (abst) 1445, 1445, 1446
Mower P (abst) 433
Moynot A (abst) 245
Mozaffari MS (abst) 357
Mozes M (abst) 520
Muallem S (abst) 156, 298, 459
Muff R (abst) 311
Mujais S (abst) 422
Mujais SK (abst) 331, 431, 442
Mukadam A (abst) 908
Mullen JL *See* Shusterman NH et al 887
Muller CA (abst) 371
Müller CA, Markovic-Lipkovski J, Risler T, Bohle A, Müller GA: Expression of HLA-DQ, -DR, and -DP antigens in normal kidney and glomerulonephritis 116
Muller GA (abst) 178, 369, 371
Müller GA *See* Müller CA et al 116
Muller J (abst) 158, 497
Muller-Schweinitzer E (abst) 331
Mulroney S (abst) 222
Mulroney SE (abst) 385, 392, 440
Munda R (abst) 515
Mundy GR (abst) 173
Munger KA (abst) 296
Munno I *See* Schena FP et al 875
Munoz E (abst) 332
Murduchowicz G (abst) 302
Murer H (abst) 178, 188, 386
Murisasco A *See* Monti JP et al 871
Murphy BF (abst) 746
Murphy R (abst) 235
Murphy WM (abst) 515
Murray BE (abst) 230
Murray BM (abst) 302, 525
Murray J (abst) 909
Murray JJ (abst) 308
Murray SA (abst) 507
Muso E (abst) 202, 357
Muso E *See* Takeuchi E et al 638
Mutchnick MG (abst) 198
Muto S (abst) 489
Mutz B (abst) 425
Myburgh JA (abst) 909, 911
Myers BD (abst) 210, 211, 424
Mzamane DVA (abst) 915
Nadler SP (abst) 499
Naftilan AJ (abst) 303
Nagai T (abst) 471, 471
Nagami GT (abst) 460, 499
Nagase M *See* Kobayashi S et al 1405
Nahman NS Jr (abst) 162
Naicker S (abst) 908, 908, 908, 913, 914
Naidoo DP (abst) 910
Naiker IP (abst) 908, 908, 908, 913, 914, 914
Nair D (abst) 315, 321
Naizot C *See* Antignac C et al 1336
Najean Y (abst) 245
Najman A (abst) 245
Nakagawa Y (abst) 382, 385
Nakahama H (abst) 406
Nakajima M (abst) 431, 739, 741
Nakamoto SS (abst) 243
Nakamura S (abst) 357, 359
Nakamura S *See* Carone FA et al 1034
Nakamura S *See* Carone FA et al 1351

Nakanishi T (abst) 499
Nakano M (abst) 194
Nakashima J (abst) 288
Nakazato Y (abst) 171, 179
Nakhoul NL (abst) 451, 460
Nakopoulou L (abst) 1436
Nalbantian-Bran C (abst) 390
Nally JV (abst) 302, 325
Nanbu M (abst) 252
Nanra RS (abst) 737, 749, 752
Nanra S (abst) 749
Naran AD (abst) 914
Naray-Fejes-Toth A (abst) 486
Nares F (abst) 406
Naret C (abst) 245
Narins RG (abst) 446
Narita I (abst) 357
Nasini MG (abst) 342
Nast C (abst) 422
Nast CC (abst) 513, 521
Nath KA (abst) 414, 434
Nathoo BC (abst) 914, 914, 914
Natke E Jr. (abst) 500
Natsche T (abst) 1437
Natshe T (abst) 1440
Navar LG (abst) 301, 303, 332, 424
Navran SS (abst) 306
Nawab ZM (abst) 237
Nayar S (abst) 354, 363
Neale TJ (abst) 740, 741
Neff J (abst) 369
Neiberger R (abst) 385
Neilson EG (abst) 308, 349, 352, 358, 363
Neilson EG: Pathogenesis and therapy of interstitial nephritis (Nephrology Forum) 1257
Nemenoff RA (abst) 292
Nesser D (abst) 512
Neugarten J (abst) 332, 441
Neumann HPH (abst) 332
Neumann P (abst) 311
Neumayer HH (abst) 414
Neusy AJ (abst) 234, 234, 371
Newell J (abst) 253
Newman LJ (abst) 161
Ng C (abst) 526
Nguyen T (abst) 162
Nhoung S (abst) 403
Nicholls K (abst) 748
Nickel JC *See* Read RR et al 614
Nicolls MR (abst) 403
Niedmann P (abst) 348
Nigam R (abst) 317
Nihei H (abst) 264
Nikolaou I (abst) 1436
Nikolopoulou N (abst) 1437, 1437, 1442, 1442, 1445, 1445, 1446
Niles JL (abst) 187
Ninin D (abst) 909, 913
Nishi S (abst) 150
Nishida A (abst) 264
Nishijima F (abst) 346, 430, 434
Nissenbaum A (abst) 412
Nissenson AR (abst) 257, 266
Nissim I (abst) 447, 447, 448, 448
Nitsch J (abst) 355
Nitschke R (abst) 444
Nitti L (abst) 371
Niwa H (abst) 368, 372, 374, 376
Njoku N (abst) 184, 342
Noblat ACB *See* Martinelli R et al 1227
Nockolds C (abst) 740
Noe L *See* Baud L et al 1111
Noel J (abst) 442, 447, 449, 450
Noguchi T (abst) 441
Nolph K (abst) 274
Nonoguchi H (abst) 288
Nooyen Y (abst) 439
Nora N (abst) 414
Nord EP (abst) 168, 175, 182, 185, 453, 456
Noree LO (abst) 519
Norkus EP (abst) 244
Norman D (abst) 521
Norman JT (abst) 167, 176, 179, 420
Noronha I (abst) 375
Norris KC (abst) 398
North American Renal Transplant Cooperative Study (abst) 521
North RA (abst) 740, 752
Northrup T (abst) 460
Nortier J (abst) 280, 305
Nortman P (abst) 909
Norwood N (abst) 264
Nossent J (abst) 1434
Novak M (abst) 267
Novak R (abst) 359
Novarini A (abst) 317
Novick AC (abst) 325, 509, 525
Ntobros N (abst) 1436
Nundel M (abst) 437
Nunley J (abst) 277, 521
Nunley R (abst) 343, 347
Nussenzveig DR (abst) 281, 285
Nutting C (abst) 243, 257
Oathes D (abst) 521
Obregon L (abst) 319
Obst G (abst) 247, 271, 274, 275
Ochi RF *See* Schulze M et al 60
Ochi S (abst) 172
Ochi S *See* Lacave R et al 806
Ochi S *See* Shin SH et al 1320
Ochs T (abst) 491
O'Connor J (abst) 738, 749
Oda T (abst) 368, 372, 374, 376
Odar-Cederlof I (abst) 201, 242
Odar-Cederlof L (abst) 257
O'Donnell MP *See* Kasiske BL et al 40
Oegema T Jr (abst) 359
Oegema TR Jr (abst) 352
Oettinger CW (abst) 255, 395
Offermann G (abst) 263, 519
Offord K (abst) 209
Offord KP (abst) 204, 303
Ofosu-Appiah A (abst) 299
Ogden DA (abst) 266
Ogden DA *See* Van Wyck DB et al 712
Ogino S (abst) 150
Oguno S (abst) 292
Oh MS (abst) 218
Ohi H (abst) 372
Ohneda M (abst) 321
Ohshima S (abst) 372
Oikonomopoulou C (abst) 1439

Oite T (abst) 351, 357
Ojeda F (abst) 268
Ojha PP (abst) 159
Okada K (abst) 307, 307, 324, 333
Okamoto SN (abst) 274
Oken D (abst) 495
Oken DE (abst) 415
Okubo M (abst) 350, 358
Okuda S (abst) 341
Okuda T (abst) 177, 179, 313
Okusa MD (abst) 486
Olbricht CJ (abst) 249, 447, 504
Oldrizzi L (abst) 198, 336
Oleggini R (abst) 760
Olgaard K (abst) 299
Olin JW (abst) 333
Oliveira DBG, Peters DK: Autoimmunity and the kidney 923
Oliver JC (abst) 255, 395
Oliver NWJ (abst) 748
Olivera A (abst) 179, 314
Olivera A, Lamas S, Rodriguez-Puyol D, López-Novoa JM: Adenosine induces mesangial cell contraction by an A_1-type receptor 1300
Olivera A *See* Rodríguez-Puyol D et al 632
Olling S (abst) 223
Olling S *See* Hannerz L et al 1133
Olsen B (abst) 360
Olsen DB (abst) 278, 289
Olsen L (abst) 752
Olshan JS *See* Baker L et al 1345
Olsson CA *See* Sawczuk IS et al 1315
Olsson P (abst) 224
Omae T (abst) 264, 327, 328, 471, 471
Onal E (abst) 224
Ondash R (abst) 342
Ondrizek T (abst) 438
Ong J (abst) 350, 360
Onishi S (abst) 258
Ono K (abst) 434
Onorato JJ (abst) 178, 180
Onoyama K (abst) 227, 250
Ooi BS (abst) 358
Ooshima A *See* Yoshioka K et al 1203
Opsahl J (abst) 243
Opsahl JA (abst) 198, 236, 301
Ordonez JD (abst) 199
Oreopoulos D (abst) 1445
Oreopoulos DG (abst) 274, 1438
Orikasa M (abst) 351
Orita Y (abst) 172, 406, 441
Orita Y *See* Shin SH et al 1320
Orlowski JM (abst) 162
Oros M (abst) 493
Ortega G *See* Rodríguez-Puyol D et al 632
Ortega J (abst) 407
Ortiz C (abst) 258, 522
Ortiz P (abst) 279
Ortola FV (abst) 285
Osborn JL (abst) 471
Osgood RW (abst) 479, 484, 506
Oshikawa Y (abst) 372, 374
Osterby R (abst) 450
Otieno LS (abst) 395
Otsuki T (abst) 385
Ott C (abst) 329
Ott SM (abst) 518
Oudinet J-P *See* Baud L et al 1111
Oudinet JP (abst) 309
Oudshoorn-Snoek M (abst) 1430
Ouellette AJ (abst) 169, 415
OvBrien D (abst) 526
OvConnor DT (abst) 332, 335
OvDonnell MP (abst) 293, 430, 434, 473
OvDonoghue DJ (abst) 372
Oveisi F (abst) 435
Overdahl MC *See* Levitt MD et al 1145
OvNeil RG (abst) 162
OvNeill KM (abst) 362
OvSullivan D (abst) 503
OvSullivan DJ (abst) 494
Owada A (abst) 234
Owen S (abst) 218
Owings B (abst) 274
Pabico RC (abst) 230
Pacheco-Silva A (abst) 522
Pacitti A (abst) 758
Packham D (abst) 435
Packham DK (abst) 739, 740, 742, 752
Padilha RM (abst) 428, 473
Pagalos M (abst) 1446
Paganin L (abst) 758
Paganini EP (abst) 240, 243
Page D (abst) 272
Pahl MV (abst) 435
Paillard F (abst) 199
Paillard M (abst) 389, 458, 459, 460
Pak CYC (abst) 383
Pal I (abst) 271
Palac D (abst) 322
Palaia TA (abst) 158, 502
Palant CE (abst) 153
Paletas K (abst) 1446
Palkovits M (abst) 278
Palla K (abst) 167
Palla R (abst) 755
Paller MS (abst) 414, 415
Pallone TL (abst) 500
Pallone TL, Hyver S, Petersen J: The simulation of continuous arteriovenous hemodialysis with a mathematical model 125
Pallotta G (abst) 198
Palmer J (abst) 523
Palmer LG (abst) 480
Palmieri P (abst) 405
Pals G (abst) 503
Pan C (abst) 372
Panchamoorthy G (abst) 374
Pandian MR (abst) 376
Panichi V (abst) 755
Pankewycz O (abst) 358
Pankewycz OG (abst) 506
Pannacci C (abst) 754
Papadakis E (abst) 1436, 1436
Papadakis G (abst) .. 1436, 1436, 1436, 1439, 1439, 1442, 1445, 1446
Papadakis J (abst) 1437, 1447
Papadimitriou M (abst) 1436, 1437, 1439, 1440, 1440, 1446
Papadodimas N (abst) 1436, 1439
Papadodimas NH (abst) 1439
Papadopoulos K (abst) 1447
Papadoyannakis N (abst) 1437, 1438

Papagalanis ND (abst) 1443, 1443, 1443, 1447
Papaioakim P (abst) 1444
Papakyriazi E (abst) 1439
Papanicolaou M (abst) 1439, 1441
Papasteriades C (abst) 1437
Papendick R (abst) 415
Paradellis T (abst) 1444
Parag KB (abst) 908, 914, 914, 914, 914
Paraskevakou H (abst) 1447
Parbtani A (abst) 368
Pardo V (abst) 415
Pardo V *See* Gouvea WL et al 1041
Parekh N *See* Steinhausen M et al 1151
Parent L (abst) 479
Parfrey PS (abst) 206, 258
Park CS *See* Lee DY et al 812
Park MS (abst) 199, 272
Park YH (abst) 519
Parker CJ (abst) 242, 258
Parker CJ *See* Cheung AK et al 576
Parker M (abst) 427
Parker M *See* Dworkin LD et al 790
Parlongo S (abst) 338, 755
Parr GVS (abst) 249
Parrini M (abst) 755
Partridge NA, Regnier FE, White JL, Hem SL: Influence of dietary constituents on intestinal absorption of aluminum (Technical Note) 1413
Pasadakis P (abst) 1444, 1444
Pascoe MD (abst) 911, 911
Pascoe V (abst) 744
Pasque C (abst) 211
Pastan I (abst) 158
Pastore A (abst) 373
Pastoriza E (abst) 180
Patchin D (abst) 329
Patel S (abst) 390, 395, 396
Paties C (abst) 757
Patrikarea A (abst) 1437, 1447
Patrikios V (abst) 738
Patrissi GA (abst) 274
Patrono C (abst) 296
Patterson T (abst) 517
Patton M (abst) 913
Paul RV (abst) 286
Paul W (abst) 396, 524
Paulais M (abst) 461
Paulmichl M (abst) 180, 410
Pauly MV (abst) 254, 516
Paz-Martinez V (abst) 396, 400
Pazderka F (abst) 518
Peach MJ (abst) 280, 299, 300
Pecker MS (abst) 324
Pederson J (abst) 254
Pederson JA (abst) 259
Pederson L (abst) 391
Pedram A (abst) 162, 279
Pei Y (abst) 378
Peitrzak I (abst) 275
Pelayo JC (abst) 468, 500
Pellegrino N *See* Schena FP et al 875
Pelton KA (abst) 281
Pena JC (abst) 268, 406
Pennell JP (abst) 408
Penniston JT (abst) 381
Peppler R (abst) 366
Perakis K (abst) 1438
Peraldi M-N *See* Baud L et al 1111
Peraldi MN (abst) 180, 181, 185, 309
Perdue ST (abst) 229
Perego A (abst) 755
Perez G (abst) 258, 522
Perez J (abst) 318
Perez-Gonzalez M (abst) 396
Perez-Grovas H (abst) 189
Perfetto M (abst) 307
Perfumo F (abst) 760
Pergolizzi R (abst) 436
Perico N (abst) 286, 508
Perkin GD (abst) 241
Perkinson DT *See* Schulze M et al 60
Perl SI (abst) 743
Perlmutter J (abst) 435
Perna AF (abst) 435
Pernalete N (abst) 396, 400
Pernis A (abst) 211
Perrino ML (abst) 755
Perrone RD (abst) 201, 459, 486
Persan L (abst) 508
Persaud J (abst) 439
Persson AEG (abst) 525, 526
Persson H (abst) 228
Perticucci E (abst) 460
Pesce AJ (abst) 515
Pesigan M (abst) 438
Pestana JOA (abst) 522
Peters A (abst) 225
Peters DK *See* Oliveira DBG 923
Peters DK *See* Rees AJ et al 921
Petersen J (abst) 259
Petersen J *See* Pallone TL et al 125
Petersen M (abst) 277
Peterson DR (abst) 388, 503
Peterson E (abst) 245
Peterson J (abst) 249
Peterson LN (abst) 416
Peterson OW (abst) 402, 406, 467
Peterson OW *See* Bird JE et al 1282
Petitclerc T (abst) 267
Petrie JJB (abst) 738, 749
Pettifor JM (abst) 908
Pettitt DJ *See* Kunzelman CL et al 681
Pfaller W (abst) 445
Phan S (abst) 366
Phan SH (abst) 436
Philippen KH (abst) 263
Phillips F *See* Kasiske BL et al 40
Phillips T (abst) 195
Phillips V (abst) 189
Piccione JM (abst) 484
Piccoli G *See* Roccatello D et al 622
Pichon M (abst) 275, 276
Pickard LL (abst) 508
Picken M (abst) 373
Pickering LK (abst) 230
Pieper RK (abst) 517
Piering WF (abst) 191
Pierucci A (abst) 757
Pierucci L (abst) 296
Pietromonaco SF (abst) 163
Pimentel C (abst) 368
Pinori E (abst) 758

Pinto JR (abst) 470
Pion I (abst) 440
Pipkin FB (abst) 750
Piraino BM (abst) 275
Pirani CL (abst) 211
Pires MC (abst) 428, 473
Pisani M (abst) 757
Pitts TO (abst) 193, 389
Pivor M (abst) 302
Planch A (abst) 276
Planelles G (abst) 461
Platsakis C (abst) 1443
Platsakis K (abst) 1436, 1443, 1445
Platt JL (abst) 344, 352, 359
Platt O (abst) 187
Pleasants JR (abst) 343
Pleszcynski KJ (abst) 745
Pleuss JA *See* Lemann J Jr. et al 688
Pluviano F (abst) 759
Pober JS *See* Cotran RS 969
Podjarny E (abst) 286, 287, 296
Poelstra K (abst) 359, 1433
Pohanka E (abst) 507, 522
Pohl M (abst) 230, 369
Poisett PG (abst) 757
Poisetti PG (abst) 757, 757
Polinsky M (abst) 410, 523
Politi K (abst) 1447
Pollak R (abst) 520
Pollak VE (abst) 235, 253, 259
Pollock AS (abst) 154
Pollock C (abst) 739, 740, 742, 744, 744, 750, 752
Polymenidis Z (abst) 1439
Pomerantz A (abst) 272, 286, 287, 296
Pomrantz A (abst) 213
Ponce de Leon S (abst) 268
Ponikvar R (abst) 250
Popatia AS (abst) 333
Popovtzer MM (abst) 379, 397, 418, 446
Popovzer MM (abst) 514
Port FK (abst) 194, 200, 522
Portale AA (abst) 387
Porter BA (abst) 518
Porter JP (abst) 476
Portilla D (abst) 181
Portman R (abst) 527
Posner M (abst) 521
Postorino M (abst) 246, 338
Potamitis K (abst) 1437
Potgieter CD (abst) 915
Potjan B (abst) 346
Poulopoulos A (abst) 1442, 1445, 1445
Powell D (abst) 436
Powell P (abst) 237
Prado EBA (abst) 428, 442
Prado MJBA (abst) 428, 442
Prager S (abst) 385
Prasad A (abst) 399
Pratt RE (abst) 303
Precht P (abst) 153
Predel HG (abst) 286, 287
Prehn J (abst) 350, 360
Preisig PA (abst) 450, 461
Preisig R (abst) 514
Prentis J (abst) 247, 271, 274, 275
Price P (abst) 417
Prigent A (abst) 459
Prior JE (abst) 318, 334
Pritzl P *See* Stahl RAK et al 1161
Pronk JC (abst) 503
Provenzano R (abst) 262
Pruchno C (abst) 350, 362
Pruchno CJ (abst) 359
Prutis K (abst) 420
Psimenos G (abst) 1439
Ptachcinski R (abst) 507
Puddey IB (abst) 748
Pugliese F (abst) 296, 318
Pugliese F, Mené P, Anania MC, Cinotti GA: Neutralization of the anionic sites of cultured rat mesangial cells by poly-L-lysine 817
Pugsley DJ (abst) 738
Pulazzini E (abst) 757
Punyarit P (abst) 357, 359
Punyarit P *See* Carone FA et al 1034
Punyarit P *See* Carone FA et al 1351
Purcell HE (abst) 461
Purkerson ML (abst) 287, 416, 429
Purkerson ML, Klahr S: Prior inhibition of vasoconstrictors normalizes GFR in postobstructed kidneys 1306
Puschett JB (abst) 390
Pusey CD, Lockwood CM: Autoimmunity in rapidly progressive glomerulonephritis 929
Pussell BA (abst) 743
Pybus J (abst) 739
Pyrpasopoulos M (abst) 1436
Pytela R (abst) 159
Quamme G (abst) 178, 386, 388
Quarles LD (abst) 391, 517
Queirolo C (abst) 760
Querfeld U (abst) 350, 360
Quesamberry C (abst) 199
Quigg RJ (abst) 170, 360
Quigg RJ *See* Salant DJ et al 976
Quinn JM (abst) 738
Quinn P (abst) 259
Quinn R (abst) 247
Quintanilla A (abst) 338
Quintanilla AP (abst) 337
Quorso P (abst) 757
Rababa M (abst) 1445
Rabb H *See* Hirschberg R et al 865
Rabelink AJ (abst) 281, 283, 436, 1431, 1433, 1434
Rabelink AJ *See* Boer WH et al 1183
Rabito CA (abst) 163
Rabkin R (abst) 443, 447, 449
Raccosta G (abst) 754
Rachael KM (abst) 198
Racusen LC (abst) 416
Radda GK *See* Endre ZH et al 1249
Rademaker P (abst) 1434
Rader B (abst) 246
Radl J *See* van den Wall Bake AWL et al 1400
Radnik RA (abst) 156
Radtke HW (abst) 326
Raghunath M (abst) 355
Ragni A (abst) 756
Ragni G (abst) 317
Ragosta A (abst) 343, 347
Rahman M (abst) 320
Raij L (abst) 183, 326, 419

Raine AEG (abst) 396
Rainfray M (abst) 199
Rainfray M *See* Meyrier A et al 696
Raja R (abst) 247
Raja RM (abst) 229, 252, 260
Rajaraman S (abst) 333
Rajiv R (abst) 259
Rajpoot D (abst) 213
Ramanujam L (abst) 247
Ramanujan L (abst) 255, 260
Ramasamy R (abst) 322
Ramasubramanian N (abst) 244
Rambausek M (abst) 375
Ramee MP (abst) 191
Ramos OL (abst) 522
Ramsammy L (abst) 159, 163, 279, 401
Ramsaroop R (abst) 908, 908, 914, 914
Rao KV (abst) 517, 523
Rao RM (abst) 333
Rao TKS (abst) 242
Rapoport J (abst) 216
Rapp N (abst) 393
Rascher W (abst) 307, 311
Rasenas LL (abst) 216, 379
Rashad A (abst) 203
Rashad MN (abst) 214
Rasmussen H (abst) 300
Ratcliffe PJ *See* Endre ZH et al 1249
Rathaus M (abst) 286, 287, 296
Rauber K (abst) 326
Rauterberg EW (abst) 355
Ray C (abst) 750
Raymond JR (abst) 163
Raza M (abst) 268
Razi M (abst) 202, 206
Razynska A (abst) 400
Read RR, Eberwein P, Dasgupta MK, Grant SK, Lam K, Nickel JC, Costerton JW: Peritonitis in peritoneal dialysis: Bacterial colonization by biofilm spread along the catheter surface 614
Reams G (abst) 303
Rech G (abst) 219
Reckelhoff J (abst) 472
Rector F (abst) 481
Reddy S (abst) 318, 747, 751
Redfield M (abst) 317, 471
Redfield MM (abst) 287, 420
Redha R (abst) 319
Redhead C (abst) 160
Rees AJ, Andres GA, Peters DK: Introduction 921
Regnier FE *See* Partridge NA et al 1413
Reichlin S (abst) 502
Reid JM (abst) 162
Reilly KM (abst) 415
Reilly RF (abst) 156, 164
Reisch C (abst) 284
Reithmeier RAF (abst) 164
Remick D (abst) 366
Remuzzi A (abst) 424, 436, 472
Remuzzi G (abst) 286, 472, 508
Rennke HG (abst) 422, 433, 437
Repine JE (abst) 412
Resch K (abst) 297
Reschke V (abst) 504
Restifo AC (abst) 738
Revie DR (abst) 362
Reynolds J (abst) 526
Reynolds JC (abst) 269
Rhew HY (abst) 519
Ribadeniera M (abst) 500
Ribot S (abst) 260
Ribstein J (abst) 288
Ricanati S (abst) 345
Rich A (abst) 461
Rich S (abst) 205
Richards GK (abst) 247, 271, 274, 275
Richards N (abst) 349, 356
Richards RI (abst) 746
Richards S (abst) 151
Richeson J (abst) 230
Richter WS (abst) 519
Rick R (abst) 501
Rickenbacher U (abst) 413
Riedel E (abst) 429, 437
Rifai A (abst) 371
Rifici V *See* Wasserman J et al 1168
Rifkin J (abst) 267
Rigby RJ (abst) 738, 749
Riggio R (abst) 191
Riggio RR (abst) 523
Riley M *See* Bergstein JM 14
Riley SL (abst) 422
Rinner S (abst) 219
Rios TB (abst) 192
Rippe B, Stelin G: Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism 1234
Risler T (abst) 178, 371
Risler T *See* Müller CA et al 116
Risuis B (abst) 333
Ritchie S (abst) 208, 524
Rits M (abst) 365
Ritter C (abst) 389, 392, 397
Ritz E (abst) 284, 355, 375, 384
Ritz E *See* Szabo A et al 1049
Rizell L (abst) 440
Robbs JV (abst) 913
Roberts M (abst) 260, 396
Robertson JA (abst) 398
Robillard JE (abst) 474, 488
Robinette JB (abst) 289, 404, 472
Robson AM (abst) 205
Roccatello D, Mazzucco G, Coppo R, Piccoli G, Rollino C, Scalzo B, Guerra MG, Cavalli G, Giachino O, Amore A, Malavasi F, Sena LM: Functional changes of monocytes due to dialysis membranes 622
Rocha A (abst) 403, 421
Rocha H *See* Martinelli R et al 1227
Rocher L (abst) 526
Rocher LI (abst) 522
Rodby RA (abst) 196, 199
Rodemann P (abst) 178
Rodrigues P (abst) 387
Rodriguez M (abst) 211, 254, 261, 377, 379, 391, 426
Rodriguez M *See* Felsenfeld AJ et al 1371
Rodriguez-Puyol D (abst) 179, 314, 319
Rodríguez-Puyol D, Lamas S, Olivera A, López-Farré A, Ortega G, Hernando L, López-Novoa JM: Actions of cyclosporin A on cultured rat mesangial cells 632
Rodriguez-Puyol D *See* Olivera A et al 1300

Roe CJ (abst) 220, 747, 749
Roe CJ *See* Baker LRI et al 661
Rogal GJ (abst) 230
Rogers SA (abst) 181
Rohde R (abst) 369
Rohmeiss P (abst) 354
Roinel N (abst) 444, 476
Rolando P (abst) 759
Rolles K (abst) 1440, 1440
Rollino C *See* Roccatello D et al 622
Rombola G (abst) 323, 462
Rome L (abst) 487, 495
Romero JC (abst) 482
Romero JC *See* Gonzalez-Campoy JM et al 767
Romero L (abst) 336
Ronco C (abst) 231, 246, 261, 261
Ronco P (abst) 160, 164, 166, 340
Rondeau E (abst) 180, 181, 185, 309, 405
Rondeau E *See* Lacave R et al 806
Rondeau R *See* Baud L et al 1111
Rondon I (abst) 288
Roots I (abst) 346
Rosansky SJ (abst) 200
Roscoe J (abst) 208
Roscoe JM (abst) 202
Rosen S (abst) 402
Rosenbaum J (abst) 190
Rosenberg AR (abst) 749
Rosenberg ME (abst) 200
Rosenblum N (abst) 360
Rosenthal T (abst) 513
Roskopf M (abst) 329
Ross D *See* Felsenfeld AJ et al 1371
Ross EA (abst) 275, 276
Rossetti RG (abst) 425
Rossi N (abst) 472
Rossier B (abst) 155, 160, 465
Rossier BC (abst) 154
Rossini M (abst) 508
Roth D (abst) 522
Roth E (abst) 225
Roth KS (abst) 501
Roth P (abst) 1438
Rothman DL (abst) 492
Rothrock J (abst) 151, 386, 426
Rothstein D (abst) 360, 505, 508
Rovera L *See* Bruno M et al 1189
Rovin B (abst) 361
Rovin BH (abst) 362
Row PG (abst) 738, 749
Rowe JC (abst) 380
Roy S III (abst) 212
Rubeglio E (abst) 230
Rubin A (abst) 191, 523
Rubin J (abst) 276
Rubinger D (abst) 379, 397
Rubinger DI (abst) 446, 514
Rudy D (abst) 261
Ruedin P (abst) 181
Ruegg CE (abst) 416
Rugiu C (abst) 198, 336
Ruiz J (abst) 266
Ruiz J *See* Van Wyck DB et al 712
Ruiz O (abst) 224
Ruiz OS (abst) 455, 462, 464
Ruiz P (abst) 425, 505
Ruiz P *See* Coffman TM et al 24
Ruiz-Palacios GM (abst) 268
Rumbelow B (abst) 745
Rumbelow BD (abst) 753
Runyan NS (abst) 386
Ruoslahti E (abst) 341
Ruschhaupt WF (abst) 333
Russ GP (abst) 742
Russ GR (abst) 738, 739
Russell J (abst) 427
Russi JB (abst) 403
Rutsky EA *See* Gifford JD et al 90
Saavedra M (abst) 260
Sabatini S (abst) 312, 386, 387, 448
Sabbaga E (abst) 376
Sabbatini M (abst) 754
Sablay L (abst) 210, 425
Sabnis S (abst) 408, 424
Sabo A (abst) 275, 276
Sabonadière P (abst) 741
Saccomani G (abst) 303
Sack E (abst) 319, 464
Sackin H (abst) 480, 487
Sacks P (abst) 387
Sacktor B (abst) 153, 167, 176, 182, 184, 399
Sadick MD (abst) 369
Sadika K (abst) 422
Sadjadi SA (abst) 218, 262
Sadler JH (abst) 518
Sadovnic MJ (abst) 361
Safirstein R (abst) 417
Safirstein R *See* Winston JA et al 1175
Sagalowsky A (abst) 511
Sagel I (abst) 368
Sagripanti A (abst) 758
Sahai A (abst) 181
Sahdev I (abst) 223
Sahlgren B (abst) 325
Said R (abst) 212
Saito T (abst) 150, 321
Sakai T (abst) 228, 252
Sakamoto H (abst) 182, 399
Sakamoto N (abst) 367
Sakellariou G (abst) 1436, 1437, 1439, 1440, 1446
Sakhuja V (abst) 334
Sakurai N (abst) 417
Sala C (abst) 757
Salant DJ (abst) 170, 360
Salant DJ, Quigg RJ, Cybulsky AV: Heymann nephritis: Mechanisms of renal injury 976
Saldivar S (abst) 268
Saleh A (abst) 323
Salido EC (abst) 319
Salit M (abst) 249, 342
Salmon J (abst) 343
Salmon RF (abst) 462
Salnitro F (abst) 755
Salomon DR (abst) 508
Salomone M (abst) 758
Salomonsson M (abst) 525
Salort D (abst) 244
Salusky IB (abst) 276, 398, 399
Salvati P (abst) 296
Salvatierra O Jr. (abst) 522
Salvidio G (abst) 760
Salzbrunn B (abst) 311

Samsell L (abst) 472
Samudra K (abst) 361
Sanai T (abst) ..... 264, 327, 47[illegible]
Sandberg AM (abst) 195
Sanders PW (abst) 361
Sandroni S (abst) 262
Sands JM (abst) 465, 501, 748
Sanfelice NFT (abst) 428, 473
Sanfilippo F *See* Coffman TM et al 24
Sanson S (abst) 487
Sant GR (abst) 194
Santa Ana C (abst) 384
Santacroce S (abst) 267
Santiago A (abst) 225, 320, 362, 439
Santiago A *See* Wasserman J et al 1168
Santiago Y (abst) 406
Santos MM (abst) 428, 442
Sapir DG (abst) 300
Sarantakis P (abst) 1439
Sargent J (abst) 237
Sargent JA (abst) 262
Saruta T (abst) 312
Sarvan I (abst) 908
Sasaki AW (abst) 328
Sasaki S (abst) 217, 487
Satlin LM (abst) 462
Sato T (abst) 251
Sato TT (abst) 488
Satriano JA (abst) 182
Saunders C (abst) 272
Sauter D (abst) 320
Sauve R (abst) 479
Savdie E (abst) 745
Savidis N (abst) 1445
Savige JA (abst) 738, 743, 746
Savin V (abst) 487
Savory J (abst) 261
Sawanishi K (abst) 202
Sawaya B (abst) 262
Sawczuk IS, Hoke G, Olsson CA, Connor J, Buttyan R: Gene expression in response to acute unilateral ureteral obstruction 1315
Sayegh M (abst) 507
Sayegh MH (abst) 505, 508
Scalzo B *See* Roccatello D et al 622
Scanferla F (abst) 239, 334
Scarborough R (abst) 285
Scarpioni L (abst) 757, 757
Scavini M (abst) 292, 296
Schabel T (abst) 476
Schaefer K (abst) 263, 346, 388
Schaefer RM (abst) 263, 281
Schaeffer J (abst) 381
Schafer JA (abst) 504
Schafferhans K (abst) 278, 392, 408, 417
Schalekamp M (abst) 1429
Schalekamp MADH (abst) 1435
Schambelan M (abst) 216
Scharschmidt L *See* Wasserman J et al 1168
Scheinman JI (abst) 212
Schena FP (abst) 198, 373, 756, 760
Schena FP, Mastrolitti G, Jirillo E, Munno I, Pellegrino N, Fracasso AR, Aventaggiato L: Increased production of interleukin-2 and IL-2 receptor in primary IgA nephropathy 875
Schena P (abst) 371
Schepers T (abst) 175
Scherberich JE (abst) 304
Scheuermann EH (abst) 348
Schifferli JA, Taylor RP: Physiological and pathological aspects of circulating immune complexes 993
Schild L (abst) 488
Schindhelm K (abst) 744
Schindler R (abst) 254
Schlatter E (abst) 525
Schlaut J (abst) 518
Schlebusch I (abst) 910
Schleifer CR (abst) 323
Schleuning WD *See* Lacave R et al 806
Schlondorff D (abst) 157, 182, 225, 320, 362, 439, 441, 508
Schlondorff D *See* Wasserman J et al 1168
Schlosser J (abst) 182
Schlossman SF (abst) 360
Schmer G (abst) 363
Schmissas M (abst) 414
Schmitz PG (abst) 434, 473
Schnabel E (abst) 164, 356
Schnaper HW (abst) 373
Schneider JA *See* Jonas AJ et al 99
Schnell T (abst) 247
Schnellmann RG (abst) 413
Schnermann J (abst) 473
Schnitzler C (abst) 908
Schoeppe W (abst) 304, 320, 326, 348, 364, 506
Schoeppe W *See* Thaiss F et al 76
Scholey JW (abst) 437
Schollmeyer P (abst) 266, 291
Schomig A (abst) 307
Schonbaum G (abst) 409
Schoolwerth A (abst) 261
Schoolwerth AC (abst) 445
Schratt W (abst) 501
Schreiner G (abst) 361, 392
Schreiner GF (abst) 362, 364
Schreuder IMT (abst) 1431
Schrier R (abst) 203, 205, 206
Schrier RW (abst) 305, 307, 307, 324, 333, 403, 511, 737
Schrier RW *See* Conger JD et al 1126
Schrier RW *See* Gabow PA et al 675
Schrier RW *See* Kim JK et al 799
Schroeder TJ (abst) 514, 515
Schrohenloher RE (abst) 365
Schuetz E (abst) 189
Schuetz J (abst) 189
Schulman G (abst) 169, 182, 256
Schulman I (abst) 193
Schulman S (abst) 410, 523
Schultz H (abst) 394
Schultz KT (abst) 354
Schulz JT (abst) 157
Schulz W (abst) 481
Schulze M (abst) 350, 359, 362
Schulze M, Baker PJ, Perkinson DT, Johnson RJ, Ochi RF, Stahl RAK, Couser WG: Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat 60
Schumacher B (abst) 357
Schumacher BS *See* Carone FA et al 1351
Schunk J (abst) 225
Schuster V (abst) 453, 463
Schuster VL (abst) 484
Schuyler S (abst) 334

Schwab SJ (abst) 231, 232, 391
Schwab TR (abst) 420
Schwartz AB (abst) 318, 334
Schwartz GJ (abst) 451, 462
Schwartz JH (abst) 335, 443, 451, 463, 464, 501
Schwartz M (abst) 323, 428
Schwartzberg M (abst) 291, 308
Schwartzman ML (abst) 446, 448
Schwarz A (abst) 263
Schwarz L (abst) 421
Schwarz SM (abst) 161, 501
Schweitzer S (abst) 257, 266
Schweitzer SU (abst) 229
Schwertschlag US (abst) 183
Schwiebert E (abst) 483
Scigalla P (abst) 245, 429, 437
Sciolla JP (abst) 238
Scoggins BA (abst) 510, 748, 750
Scott D (abst) 753
Scott JW (abst) 300
Scoumi D (abst) 1439
Sealey JE (abst) 324
Sealfont M (abst) 219
Sebastian A (abst) 387, 452
Sedmak DD (abst) 373
Sedor JR (abst) 179, 184, 342, 347
See H (abst) 164
Seedat YK (abst) ... 908, 908, 908, 913, 913, 914, 914, 914, 914
Segal R (abst) 183
Segasothy M (abst) 374
Segel DP (abst) 207
Seggie J (abst) 909, 911, 911, 911, 915
Segoloni GP (abst) 758
Segre GV (abst) 378
Seguro A (abst) 421
Seidel CL (abst) 306
Seidler AJ (abst) 518
Seikaly MG (abst) 473
Seki M (abst) 372
Sekkarie MA (abst) 200
Sella M (abst) 397
Sellers EM (abst) 493
Sellers M (abst) 491
Semana G (abst) 204
Semeraro N (abst) 198
Sena LM *See* Roccatello D et al 622
Senecal J (abst) 449
Senesky D (abst) 435
Seney FD Jr. (abst) 212
Seno A (abst) 374
Sens DA (abst) 178, 391
Sens DA *See* Hazen-Martin DJ et al 31
Sens MA *See* Hazen-Martin DJ et al 31
Seow F (abst) 740
Serhan CN (abst) 152, 291
Seri I (abst) 285, 320
Serkes EK (abst) 274
Serre A (abst) 238
Serventi M (abst) 317
Servilla K (abst) 509, 517
Seta N (abst) 412
Sethi D (abst) 241
Seveso M (abst) 755
Sexton PM (abst) 740
Sfheropoulos G (abst) 1438
Shah BV (abst) 200
Shah GM (abst) 275, 276
Shah RM (abst) 218, 262
Shah SV: Effect of thrombin on cyclic AMP content in glomeruli isolated from rat kidney 824
Shah SV: Role of reactive oxygen metabolites in experimental glomerular disease (Editorial Review) 1093
Shaldon S (abst) 254, 263, 270
Shanley PF (abst) 409, 417, 418
Shannon B (abst) 351, 361
Shapiro JI (abst) 239, 330, 463, 498, 511
Shapiro JI, Cosby RL, Chan L: P-31 nuclear magnetic resonance spectral changes in obstructed or dehydrated kidney 830
Shapiro LJ (abst) 319
Shapiro RJ (abst) 437
Sharkins K (abst) 454
Sharma A (abst) 401
Sharma R (abst) 518
Shauger KL (abst) 375
Shaw A (abst) 320
Shaw S (abst) 281
Shaw SG (abst) 311
Shaw W (abst) 338
Shayman JA (abst) 155, 168, 183
Shearman JD (abst) 751
Sheikh MS (abst) 384
Sheikh-Hamad D (abst) 396
Sheikhamad D (abst) 161
Shelat H (abst) 306
Shen S (abst) 404
Shen SY (abst) 362, 474
Shen V (abst) 407
Shen X (abst) 354
Shenkman L (abst) 286, 287
Shenolikar S (abst) 166
Sherman BM (abst) 269
Sherrard DJ (abst) 258, 376, 378, 518
Sherry LM (abst) 751
Sherwood L (abst) 427
Sherzer P (abst) 397, 418
Sheth A (abst) 335
Sheth KJ (abst) 231
Shewring L (abst) 344
Shey J (abst) 174
Shi LB (abst) 502
Shibasaki T (abst) 418
Shibata K (abst) 417
Shiells EA (abst) 494
Shilo L (abst) 286, 287
Shimada T (abst) 357
Shimada T *See* Takeuchi E et al 638
Shimamura T (abst) 427
Shimizu F (abst) 351, 357
Shimizu T (abst) 492
Shin S (abst) 172
Shin SH, Fujiwara Y, Takama T, Ochi S, Wada A, Fukunaga M, Orita Y, Kamada T, Tagawa K: Analysis of inositol tris- and tetrakisphosphate in mesangial cells by HPLC 1320
Shina A (abst) 402
Shinaberger JH (abst) 256, 264
Shinowara NL (abst) 158, 502
Shiozawa DK (abst) 289
Shiraga H (abst) 363
Shirasawa H (abst) 417
Shoemaker MO (abst) 273

Shoker A (abst) 523
Shollmeyer P (abst) 248
Shopp G (abst) 506
Shostak A (abst) 276
Shu M (abst) 404
Shulman RG (abst) 418, 449, 492
Shultz P (abst) 183, 326
Shusterman N (abst) 249
Shusterman NH, Kloss K, Mullen JL: Successful use of double-lumen, silicone rubber catheters for permanent hemodialysis access (Technical Note) 887
Siakotos M (abst) 1436, 1436, 1437, 1440, 1441, 1442, 1442, 1445, 1445, 1446
Siamopoulos K (abst) 1436, 1438
Siamopoulos KC (abst) 1444
Sibley RK (abst) 424, 520
Sica D (abst) 245, 261, 277
Sica DA (abst) 521
Sicuso C (abst) 246
Sideras G (abst) 1443
Siegal FP (abst) 208, 215, 217, 434
Siegel NJ (abst) 407, 418, 449, 492
Siegler RL (abst) 232
Sigler MH (abst) 323
Silva FG (abst) 212
Silva P (abst) 282, 290, 448, 502
Silver J (abst) 514
Silverman M (abst) 202, 340, 493, 498, 502
Silverman S (abst) 433, 440
Simenhoff ML (abst) 426
Simkins R (abst) 262
Simmons DA (abst) 435
Simon B (abst) 452
Simon E (abst) 353
Simon EE (abst) 459, 463
Simon F (abst) 171
Simon P (abst) 191, 201, 204, 241
Simon P *See* Meyrier A et al 696
Simonetti BM (abst) 757
Simons K (abst) 186, 188
Simonsen R (abst) 405
Simonson MS (abst) 184
Simpson A (abst) 396
Singer S (abst) 279
Singh AB (abst) 354, 363
Singh AK (abst) 159, 165, 208
Singh H (abst) 403
Singh M (abst) 206
Singhal P (abst) 225, 305, 320
Sinico RA (abst) 756
Sinico RA *See* D'Amico G et al 1004
Sinkey CA (abst) 330
Sioudas A (abst) 1446
Sirajedine K (abst) 468
Sirota R (abst) 213
Siskind MS (abst) 335
Skandalis N (abst) 1444
Sklar AH (abst) 217
Sklivagou N (abst) 1437
Skopicki HA (abst) 388, 503
Skorecki K (abst) 176, 179, 284, 289, 505
Skorecki KL (abst) 176
Skott O (abst) 299
Skroder R (abst) 232
Slatopolsky E (abst) 264, 389, 391, 392, 393, 397
Slatopolsky E *See* Blair HC et al 1119
Slatopolsky E *See* Brown AJ et al 19
Slatopolsky E *See* Dusso A et al 860
Slayman CW (abst) 156, 158, 164
Slingeneyer A (abst) 270
Sloan RS (abst) 220
Sloand J (abst) 363
Slomowitz L (abst) 524
Slomowitz LA, Monteon FJ, Grosvenor M, Laidlaw SA, Kopple JD: Effect of energy intake on nutritional status in maintenance hemodialysis patients 704
Slotki IN (abst) 463
Slotkj IN (abst) 464
Sluiter H (abst) 1434
Smart A (abst) 299
Smead W (abst) 341
Smeby L (abst) 263
Smeenk R (abst) 1434
Smeenk RJT (abst) 341
Smetana O (abst) 272
Smit JA (abst) 909, 911
Smit S (abst) 914
Smith A (abst) 506
Smith C (abst) 233
Smith CD (abst) 474
Smith FG (abst) 474, 488
Smith J (abst) 343
Smith KL (abst) 241
Smith LA (abst) 294
Smith LH (abst) 255
Smith MC (abst) 242
Smith PD (abst) 751
Smith S (abst) 197
Smith SM (abst) 374
Smith-Powell L (abst) 336
Smogorzewski M (abst) 435
Smolens P (abst) 173, 331
Smoyer WE (abst) 474
Snyder J (abst) 372
Sodden S (abst) 239
Soejima M (abst) 250
Sofianou L (abst) 915
Sohen S (abst) 360
Soilleux M *See* Meyrier A et al 696
Solangi K (abst) 446, 448
Solanki J (abst) 387
Sold M (abst) 282
Soleimani M (abst) 464
Solez K (abst) 209, 416, 524
Solhaug MJ (abst) 300, 488
Soliman AR (abst) 422, 427
Solomon J (abst) 297
Solomon SL (abst) 255
Sombolos K (abst) 1438, 1445, 1445
Somerstein M (abst) 268
Sompolos K (abst) 1446
Sone M (abst) 321
Soni A (abst) 213
Sonnekus MI (abst) 912, 912, 913
Sonnenberg H (abst) 216, 288
Sonnenfeld G (abst) 175
Soong S (abst) 516
Sorenson GB (abst) 165
Sorger K (abst) 365
Sorkin MI (abst) 275

Sorokin G (abst) 335
Soto LE (abst) 268
Sotsiou F (abst) 1437, 1437, 1442
Southwood TR (abst) 737
Souvignet C (abst) 468
Spagnuolo G (abst) 192
Spaia S (abst) 1447
Spanos P (abst) 1436
Spark J (abst) 214
Speck RF (abst) 514
Speight P (abst) 502
Spence CD (abst) 750
Spiegel DM (abst) 418
Spielman WS (abst) 310
Spiliadis C (abst) 1444
Spital A (abst) 524
Spitzer A (abst) 380, 385, 437
Spitzer RE (abst) 363
Spokes K (abst) 402
Sporer P (abst) 245
Sprague SM (abst) 379
Spring KR (abst) 155
Spurney RF (abst) 232
Sraer JD (abst) 180, 181, 185
Sraer JD *See* Lacave R et al 806
Sridhara S (abst) 176
Srinivasa NS (abst) 524
Srivastava LM (abst) 374
Stahl RAK (abst) 304, 320, 326, 348, 364
Stahl RAK, Adler S, Baker PJ, Johnson RJ, Chen Y-P, Pritzl P, Couser WG: Cyclosporin A inhibits prostaglandin E_2 formation by rat mesangial cells in culture 1161
Stahl RAK *See* Schulze M et al 60
Stahl RAK *See* Thaiss F et al 76
Stamatiadis D (abst) 1436, 1443
Stanley CA *See* Baker L et al 1345
Stanton B (abst) 165, 483
Stanton RC (abst) 184
Stapleton FB (abst) 232, 368
Staprans I (abst) 425
Starmann B (abst) 526
Starosta R (abst) 396, 400
States B (abst) 448
Stathakis C (abst) 1443
Stathoulopoulou F (abst) 1443, 1443
Stathoulopoulou P (abst) 1443
Statius van Eps LW (abst) 234
Staub O (abst) 155
Staugianoudakis G (abst) 1442
Stavraka-Kakavaki A (abst) 1441
Stavropoulos C (abst) 1439, 1441
Stavropoulou A (abst) 1441
Stavrou C (abst) 915
Stead WW *See* Brazy PC et al 670
Steed DB *See* Georgaki-Angelaki HN et al 84
Steele A (abst) 381
Steffes MW *See* Mauer SM et al 48
Stein H (abst) 213
Stein J (abst) 407
Stein JH (abst) 479, 484
Stein-Oakley A (abst) 743
Steinberg W (abst) 233
Steinhart CM (abst) 217
Steinhauer HB (abst) 291
Steinhausen M, Blum M, Fleming JT, Holz FG, Parekh N, Wiegman DL, Dussel R: Visualization of renal autoregulation in the split hydronephrotic kidney of rats 1151
Steinman TI (abst) 201
Steinman TI *See* Kelly RA et al 595
Steinmetz PR (abst) 457
Steinmuller DR (abst) 525
Stelin G *See* Rippe B 1234
Stelkens H (abst) 314
Stelzer E (abst) 188
Stenberg A (abst) 526
Stenzel K (abst) 191, 523
Stephens MK (abst) 227
Stephens VM (abst) 260
Stephenson RL (abst) 456
Sterling W (abst) 506
Sterns RH (abst) 218
Sterns RH, Thomas DJ, Herndon RM: Brain dehydration and neurologic deterioration after rapid correction of hyponatremia 69
Sterzel R (abst) 307
Sterzel RB (abst) 172, 342, 343, 348, 350, 354, 1431
Stewart JH (abst) 738, 745
Stewart KN *See* Al-Muzairai IA et al 1057
Stewart-Phillips JL (abst) 201
Stinson MW (abst) 356
Stirati G (abst) 757
Stitzel AE (abst) 363
Stivelman J (abst) 266
Stivelman JC *See* Van Wyck DB et al 712
Stockenhuber F (abst) 294, 321, 383, 509
Stoff J (abst) 315
Stoff JS (abst) 297, 425
Stokes J (abst) 453
Stokes JB (abst) 481, 484
Stokes T (abst) 407
Stokes TJ (abst) 287, 438
Stom MC (abst) 411
Stone DK (abst) 167, 467
Stone W (abst) 248
Stote RM (abst) 249
Stow JL (abst) 165
Stowe NT (abst) 302, 325, 509
Strandhoy JW (abst) 488
Strange K (abst) 489
Strasheim A (abst) 168, 297
Strasheim A *See* Teitelbaum I et al 647
Stratta P (abst) 759
Straub SG (abst) 466
Strauss J (abst) 219, 265, 267, 385
Strazzullo P (abst) 189, 468
Streat S (abst) 752
Streem SB (abst) 325, 525
Street P (abst) 223
Strife CF (abst) 372
Strife CF, Leahy AE, West CD: Antibody to a cryptic, solid phase C1Q antigen in membranoproliferative nephritis 836
Striker G (abst) 171
Striker GE *See* Elliot S et al 1245
Striker L (abst) 171
Striker LJ *See* Elliot S et al 1245
Strober S (abst) 424
Strohmeier J (abst) 417
Strom T (abst) 358

Strom TB (abst) 506, 510, 511
Strom TB, Kelley VE: Toward more selective therapies to block undesired immune responses 1026
Stromski M (abst) 418
Stromski ME (abst) 402, 496
Strong RW (abst) 738
Struck M (abst) 485
Struijk DG *See* Krediet RT et al 1064
Stubenbord W (abst) 523
Stull RW (abst) 316
Sturgill BC (abst) 233
Sturk A (abst) 234
Subayti Y (abst) 220
Subayti Y *See* Baker LRI et al 661
Sudhakar T (abst) 268
Sugar AM (abst) 272
Sugihara H (abst) 417
Sugimoto K (abst) 417
Sugimoto T (abst) 397
Sugino N (abst) 264
Suh J-I *See* D'Agati V et al 1358
Sujansky E (abst) 206
Sukhatme VP (abst) 169, 415
Suki WN (abst) 443, 497
Sullivan D (abst) 474
Sullivan J (abst) 191
Sullivan JM (abst) 515
Sullivan KA (abst) 178
Sullivan L (abst) 503
Sullivan LP (abst) 495
Sullivan P (abst) 335
Sullivan S (abst) 169
Sulser D (abst) 273
Sumikura T (abst) 475
Sumithran E (abst) 750
Summer SN *See* Kim JK et al 799
Sun AM (abst) 489
Sun C (abst) 526
Sun CH (abst) 524
Sun MJ (abst) 358
Sunder-Plassman G (abst) 294, 321, 383, 509
Susani M (abst) 159
Susin M (abst) 223
Suthanthiran M (abst) 213, 509, 523
Sutton RLA (abst) 282
Suzuki M (abst) 184, 393
Svalander C (abst) 327
Svetkey LP (abst) 335
Swaak A (abst) 1434
Swainson CP (abst) 233
Swanepoel CR (abst) 909
Swann S (abst) 243
Swanson V (abst) 243
Swartz B (abst) 526
Swedenborg J (abst) 232
Sweeney WE (abst) 423
Sweet J (abst) 344
Sweny P (abst) 315, 321, 433, 439, 525
Swift C (abst) 525
Sylven M (abst) 232
Symonds EM (abst) 750
Symvoulidis A (abst) 1448
Szabo A (abst) 384
Szabo A, Merke J, Beier E, Mall G, Ritz E: 1,25(OH)$_2$ vitamin D$_3$ inhibits parathyroid cell proliferation in experimental uremia 1049
Szabo P (abst) 205
Szerlip H (abst) 438
Tabei K (abst) 489
Tagawa K *See* Shin SH et al 1320
Takahashi K (abst) 296, 298, 308, 312, 321, 364
Takahashi N (abst) 264
Takama T (abst) 172, 406
Takama T *See* Shin SH et al 1320
Takamitsu Y (abst) 475
Takasugi M (abst) 526
Takeda S (abst) 306
Takemura T *See* Yoshioka K et al 1203
Takeuchi A (abst) 368, 372, 374, 376
Takeuchi E (abst) 357
Takeuchi E, Doi T, Shimada T, Muso E, Maruyama N, Yoshida H: Retroviral gp70 antigen in spontaneous mesangial glomerulonephritis of ddY mice 638
Takiyyuddin MA (abst) 335
Talley TE (abst) 265
Talor Z (abst) 319, 455, 462, 464
Tamura T (abst) 184
Tan S (abst) 387, 438
Tanaka T (abst) 441
Taniguchi J (abst) 166
Tannen RL (abst) 181
Tanner MK (abst) 266
Tanuma Y (abst) 372
Tapia E (abst) 336
Tapia L (abst) 191, 523
Tarawneh M (abst) 212
Tarkowski A (abst) 235, 327
Tatsumo J (abst) 452
Tatsuno J (abst) 387
Tayeb J (abst) 265
Taylor AJ (abst) 191
Taylor CEP (abst) 1439
Taylor P (abst) 329
Taylor R (abst) 258
Taylor RP *See* Schifferli JA 993
Teatin U (abst) 755
Teehan BP (abst) 323
Tegzess AM (abst) 233, 516, 1432
Teitelbaum I (abst) 168, 297
Teitelbaum I, Strasheim A, Berl T: Adrenergic control of cAMP generation in rat inner medullary collecting tubule cells 647
Teitelbaum SL *See* Blair HC et al 1119
Tejani A (abst) 213
Tejedor A (abst) 301, 447, 449, 450
Telles T (abst) 336
Ten Cate JW (abst) 234
Ten Kate RW (abst) 503
Ter Borg EJ (abst) 213
ter Borg EJ (abst) 1434
Ter Wee PM (abst) 233
Terada Y (abst) 288, 489, 501
Termaat R (abst) 1434
Termaat RM (abst) 341
Terranova R (abst) 500
Terrell CH (abst) 364
Terrell R (abst) 346
Terreros DA (abst) 419
Tersigni R (abst) 757
Tervaert JWC (abst) 1430
Terzian A (abst) 318

Teschan P (abst) 434
Teschan PE (abst) 273
Tetens E (abst) 438
Tetta C (abst) 310
Textor SC (abst) 336
Thaiss F (abst) 304, 320, 348, 364
Thaiss F, Germann PJ, Kahf S, Schoeppe W, Helmchen U, Stahl RAK: Effect of thromboxane synthesis inhibition in a model of membranous nephropathy 76
Thea A (abst) 758
Theodorides T (abst) 1437
Theodoridou-Fragouli E (abst) 1440
Theodoropoulos P (abst) 1442
Theodorsson E (abst) 257
Theothoropoulos P (abst) 1442, 1442
Thibodeau SN (abst) 203
Thiery J (abst) 348
Thies HL (abst) 208, 215, 217
Thiru S (abst) 1440
Thodis H (abst) 1444, 1444
Thomas A (abst) 738, 746
Thomas CE (abst) 265
Thomas D (abst) 218
Thomas DJ *See* Sterns RH et al 69
Thomas FD (abst) 329
Thomas G (abst) 344
Thomas MAB (abst) 746, 746
Thomas T (abst) 240
Thompson B (abst) 423
Thompson CS (abst) 193
Thompson HR (abst) 328
Thompson J (abst) 304, 304, 511
Thompson NM (abst) 744
Thomson NM (abst) 743, 745, 753
Thomson PD (abst) 908, 909, 909, 911, 913, 914
Thorner P, Baumal R, Valli VEO, Mahuran D, McInnes R, Marrano P: Abnormalities in the NCI domain of collagen type IV in GBM in canine hereditary nephritis 843
Thornhill BA (abst) 280
Thornton M (abst) 419
Thulin G (abst) 407, 418, 449
Tidgren B (abst) 194, 232, 257, 475
Tipan L (abst) 189
Tipping PG (abst) 741, 743, 747
Tipping PG *See* Boyce NW et al 778
Tisher CC (abst) 445, 458, 464, 465
Tiwari SC (abst) 374
Tjonou A (abst) 1447
Tobash J (abst) 381
Tobian L (abst) 336
Toffoletto P (abst) 221
Tohda M *See* Yoshioka K et al 1203
Tolchard S (abst) 273
Tolins J (abst) 326
Tolins JP (abst) 414, 419
Tolis G (abst) 1446
Tomita K (abst) 217, 234, 288
Tomlanovich S (abst) 507
Tomlinson K (abst) 191
Topley N (abst) 297
Torok J (abst) 338
Toronto Glomerulonephritis Study Group (abst) 208
Torres M (abst) 362
Torres VE (abst) 203, 204, 303
Toto R (abst) 511
Totsume K (abst) 321
Tourkantonis A (abst) 1436, 1445
Townes-Anderson E (abst) 281
Trachtman H (abst) 381, 490
Tran J (abst) 490
Tran M (abst) 279
Traneus A (abst) 519
Trautmann M (abst) 291
Trescony P (abst) 359
Treser G (abst) 213, 368
Tresham J (abst) 510
Tresham JJ (abst) 748
Trevino G (abst) 512
Trevisan R (abst) 470
Triantaphyllou G (abst) 1442, 1442, 1442
Trifillis AL (abst) 419
Triggiani R (abst) 198
Trinh MM (abst) 449
Trivelli G (abst) 754
Trost C (abst) 256
Trott M (abst) 260
Troy JL (abst) 284
Troyer DA (abst) 185
Trudel M (abst) 364
Truong L (abst) 407
Tsagarakis N (abst) 1443
Tsai P (abst) 307, 307, 324, 333
Tsakiris D (abst) 1441, 1441, 1441
Tsao T (abst) 443, 447, 449
Tsapas G (abst) 1446
Tsau YK (abst) 420
Tsianas N (abst) 1442, 1442, 1445
Tsianos EB (abst) 1444
Tsinakis A (abst) 1439
Tsobanelis T (abst) 1438
Tsoufakis G (abst) 1443, 1443
Tsouroulas M (abst) 1445
Tsoutakis G (abst) 1443
Tsukamoto Y (abst) 397
Tsunoda K (abst) 740
Tuck ML (abst) 324
Tucker A (abst) 482
Tucker B (abst) 518
Tucker BJ (abst) 467, 475
Turco M (abst) 230
Turk E (abst) 496
Turner RJ (abst) 499
Turner ST (abst) 490
Turolo L (abst) 757
Turrini F (abst) 452
Tuttle E (abst) 256
Twardowski ZJ (abst) 238
Tzamou E (abst) 1440, 1446
Tzanakis I (abst) 1443
Tzetzis V (abst) 1446
Ubeda M (abst) 303
Uccello F (abst) 754
Uchic M *See* Grantham JJ et al 1379
Uchica S (abst) 313
Uchida S (abst) 177, 438
Uehlinger DE (abst) 311
Ueno M (abst) 288
Ujiie K (abst) 234
Ullian M *See* Dworkin LD et al 790
Ullian ME (abst) 185

Umen A (abst) 242
Umetani N (abst) 358
Unger T (abst) 354
Unwin R (abst) 307, 452, 490
Urbaitis B (abst) 404
Urbaitis BK (abst) 400, 430
Urena P (abst) 267
Uriu K (abst) 250
Urivetsky M (abst) 381
Uzuni A (abst) 1447
V. Steenberge EPM (abst) 1431
Vaamonde CA (abst) 415
Vaamonde CA *See* Gouvea WL et al 1041
Vadgama J (abst) 406, 504
Vafiadis S (abst) 1437, 1447
Valderrabano F (abst) 265
Valdivieso A (abst) 475
Valencia SH (abst) 337
Valentich J (abst) 487
Valentin JP (abst) 288
Valeri AM (abst) 234, 234, 371
Valis D (abst) 1447
Valli VEO *See* Thorner P et al 843
Vallisa D (abst) 317
Valtin H (abst) 494, 503
Valvo E (abst) 336
Van Adelsberg J (abst) 465
van Bakel C (abst) 753
Van Bockel JH (abst) 224
Van Damme B (abst) 1435
van den Berg R (abst) 744
van den Wall Bake AWL, Daha MR, Haaijman JJ, Radl J, van der Ark A, van Es LA: Elevated production of polymeric and monomeric IgAl by the bone marrow in IgA nephropathy 1400
van der Ark A *See* van den Wall Bake AWL et al 1400
van der Giessen M (abst) 1430
van der Groen G (abst) 1430
van der Heide JJH (abst) 1432
Van Der Hem GK (abst) 208, 227, 280, 283, 327
van der Hem GK (abst) 1430, 1432
Van Der Woude FJ (abst) 520, 525
van der Woude FJ (abst) 1432, 1433
Van Deventer SJH (abst) 234
van Elven EH (abst) 1430
Van Es BLA (abst) 520, 525
Van Es LA (abst) 365
van Es LA (abst) 1430, 1432, 1433
van Es LA *See* van den Wall Bake AWL et al 1400
van Ittersum FJ (abst) 1435
Van Leer EHG (abst) 341
Van Liew J (abst) 760
van Loon AM (abst) 1429
Van Luijk WHJ (abst) 221
van Luijk WHJ (abst) 1429
Van Norman MA (abst) 490
Van Putten V (abst) 305
van Renen MJ (abst) 737
Van Stone J (abst) 238
Van Waarde A (abst) 407, 418, 449
Van Wyck DB (abst) 266
Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia 712
Vander Molen M (abst) 185
Vandewalle A (abst) 160, 164, 166
Vandongen R (abst) 748
Vangelista A (abst) 759
Varadarajan GS (abst) 412
Varet B (abst) 245
Vargemezis V (abst) 1444, 1444
Varghese Z (abst) 315, 321, 433, 439, 525
Vari RC (abst) 207, 337
Varla M (abst) 1439, 1441
Vaughn DA (abst) 477
Vayonas G (abst) 1447
Vaziri ND (abst) 435
Vazquez M (abst) 230
Veerkamp J (abst) 1434
Velazquez H (abst) 479, 486
Velez R (abst) 512
Velosa J (abst) 209
Vendrell JP (abst) 238
Venien C (abst) 166
Venkatachalam M (abst) 407
Venning M (abst) 349, 356
Venuto RC (abst) 290, 525
Vera G (abst) 450
Verbalis JG (abst) 219
Verberckmoes R (abst) 1435
Verburg KM (abst) 304
Vercellone A (abst) 758, 759
Vergne P (abst) 512
Vergoulas G (abst) 1436
Verhagen R (abst) 1430
Verkman AS (abst) 152, 154, 188, 491, 495, 502
Verlander JW (abst) 458, 464, 465
Vernier RL (abst) 344
Verpooten GA (abst) 244
Verroust P (abst) 160, 164, 166, 340
Verroust PJ: Kinetics of immune deposits in membranous nephropathy (Nephrology Forum) 1418
Versluis DJ (abst) 1435
Veryemezis V (abst) 1436
Vial S (abst) 475
Viar MJ (abst) 515
Viberti GC (abst) 470
Villamediana LM (abst) 180, 181, 185
Villarreal D (abst) 303
Vinay P (abst) 442, 447, 449, 450
Vincent HH (abst) 1435, 1435
Vinge E (abst) 201
Vining R (abst) 737
Viron B (abst) 245
Virvidakis K (abst) 1443
Visvardis G (abst) 1446
Vita L (abst) 1438
Vlachojannis J (abst) 1438
Vlassis T (abst) 1441
Vlonjou E (abst) 1441
Vocino V (abst) 405
Voelker JR (abst) 432
Voelkl H (abst) 160
Vogt A (abst) 365
Volpe M (abst) 324
Von Albertini B (abst) 241
Von Herrath D (abst) 263, 346, 388
Vooys GP (abst) 1431
Vosburgh E (abst) 235
Vosnides G (abst) 1436, 1437, 1439, 1442, 1443
Vu ST (abst) 162
Wada A *See* Shin SH et al 1320

Wade AL (abst) 373
Wadgymar A (abst) 524
Wadhwa NK (abst) 235
Wagener O (abst) 337
Wagner K (abst) 414
Wagner L (abst) 509
Wald H (abst) 397, 418, 446
Waldherr R (abst) 375
Waldo FB (abst) 365, 368
Walker J (abst) 388
Walker JR (abst) 1439
Walker JT (abst) 501
Walker RG (abst) 747, 749
Walker RJ (abst) 741
Walker WG (abst) 197, 220, 225, 226, 235
Wall B (abst) 219
Wall BM (abst) 300
Wall DR (abst) 738
Wall SM (abst) 465
Wallace D (abst) 503
Wallace MR (abst) 488
Walli A (abst) 348
Walls K (abst) 738, 746
Walser M (abst) 439
Walsh J (abst) 256
Walsh JM (abst) 748
Walshe JJ (abst) 510
Walz G (abst) 263, 510, 511
Wang H (abst) 399
Wang W (abst) 491
Wang X (abst) 243
Wang XM (abst) 369
Wangemann P (abst) 444
Wann S (abst) 171
Wanner C (abst) 266
Wanning C (abst) 314, 337
Ward H (abst) 504
Ward HJ (abst) 524, 526
Ward L (abst) 439
Ward RA (abst) 266
Warden R (abst) 742
Warner L (abst) 284, 289
Warnock D (abst) 455
Warnock DG (abst) 154, 465
Warns G (abst) 237
Warshaw BL (abst) 375, 516
Wasserman J (abst) 439
Wasserman J, Santiago A, Rifici V, Holthofer H, Scharschmidt L, Epstein M, Schlondorff D: Interactions of low density lipoprotein with rat mesangial cells 1168
Wasserstein AG (abst) 308
Watanabe M (abst) 322
Watanabe S (abst) 372
Watanabe Y (abst) 367
Watlington C (abst) 189
Watson J (abst) 271
Watson MA (abst) 1441
Watzinger U (abst) 316
Waugh D (abst) 742
Weaver M (abst) 248
Weber M (abst) 365
Weber PC (abst) 412
Webster SK (abst) 277
Weening J (abst) 345
Weening JJ (abst) 439, 520, 1433
Weening JJ *See* Hoedemaeker PJ 1015
Weerts C (abst) 244, 264
Wehrle R (abst) 307
Weidmann P (abst) 281, 311
Weimar W (abst) 1431, 1435
Weinberg JM (abst) 170, 420
Weinberg R (abst) 527
Weiner ID (abst) 466
Weinman EJ (abst) 166, 193, 467
Weinstein MJ (abst) 235
Weinstein RS (abst) 241
Weinstein T (abst) 271, 375
Weir MR (abst) 353, 366, 474
Weisberg LS (abst) 411
Weisinger JR (abst) 400
Weiss MA (abst) 210, 423
Weiss R (abst) 368
Weissgarten J (abst) 526
Welbourne TC (abst) 466
Welford A (abst) 374
Welin L (abst) 298
Wellhausen SR (abst) 266
Welling DJ (abst) 491
Welling LW (abst) 491, 498
Welsh KI (abst) 746
Welsh KL (abst) 742
Wendel G (abst) 429
Wenting GJ (abst) 1431, 1435
Werner E (abst) 1438
Wesselschmidt RL (abst) 373
Wesson DE (abst) 466
West CD (abst) 372
West CD *See* Strife CF et al 836
Westberg G (abst) 235, 327
Westenend PJ (abst) 439
Westenfelder C (abst) 278, 289, 289
Weyer P (abst) 152, 503
Whalen M (abst) 463
Whaley BP (abst) 248
Whang P (abst) 349
Wharram B (abst) 366
Wheeler DC (abst) 433, 439
Whelchel JD (abst) 526
Whelton PK (abst) 518
White D (abst) 1440
White DJG (abst) 1439
White JL *See* Partridge NA et al 1413
White JV (abst) 167
White SJ (abst) 491
Whitehead R (abst) 747
Whiteside C (abst) 304, 304, 420
Whittenburg D (abst) 412
Whitworth JA (abst) 435, 510, 739, 740, 742, 748, 750, 752
Widdicombe JH (abst) 491
Widener L (abst) 405
Wiedemann E (abst) 327
Wieder K (abst) 511
Wieder KH (abst) 510
Wiegman DL *See* Steinhausen M et al 1151
Wiegmann TB (abst) 498
Wieland H (abst) 266
Wiesinger D (abst) 510
Wieslander J *See* Butkowski RJ et al 1195
Wigfall DR (abst) 375
Wiggins R (abst) 366, 366, 436
Wikstad I (abst) 223

Wikstad I *See* Hannerz L et al 1133
Wikstrand J (abst) 298
Wilcox CS (abst) 337, 354
Wilcox L (abst) 242
Wilcox LA (abst) 258
Wilder L (abst) 402, 409
Wilke L (abst) 482
Wilkes B (abst) 297, 433, 440
Wilkinson A (abst) 513, 524
Wilkinson RH (abst) 212
Willekes N (abst) 470
Willekes-Koolschijn N (abst) 1432
Williams C (abst) 254, 259
Williams DG (abst) 742, 746
Williams G (abst) 210
Williams GW (abst) 195
Williams HH (abst) 300
Williams JC *See* Jonas AJ et al 99
Williams JC Jr (abst) 504
Williams JD (abst) 273, 277
Williams PK (abst) 393
Williams S (abst) 265
Williamson S (abst) 403
Wilson CB (abst) 356
Wilson CB: Study of the immunopathogenesis of tubulointerstitial nephritis using model systems 938
Wilson DM (abst) 255
Wilson DR (abst) 288
Wilson P (abst) 150, 388, 411
Wilson PD (abst) 167, 310, 408
Wilson R (abst) 521
Wilson T (abst) 508
Winberg J (abst) 194
Winchester J (abst) 222
Winchester JF (abst) 440
Winchester MD (abst) 206
Windsor I (abst) 908
Windus D (abst) 244, 264
Wingo CS (abst) 466
Winston JA, Feingold R, Safirstein R: Glomerular hemodynamics in cyclosporine nephrotoxicity following uninephrectomy 1175
Winter S (abst) 1440
Wistrand PJ, Knuuttila KG: Renal membrane-bound carbonic anhydrase. Purification and properties 851
Wittner M (abst) 444
Wolcott DL (abst) 257, 266
Wolf G (abst) 304
Wolfe RA (abst) 194, 200, 512, 522
Woll E (abst) 180
Woloj M (abst) 230
Wong C (abst) 153
Wong EFC (abst) 282, 441
Wong KL *See* Lau DCW et al 604
Wong NLM (abst) 282, 441
Wong P (abst) 505
Wong PY (abst) 292
Woo DD (abst) 186
Wood CJ (abst) 744
Woodhead JS (abst) 396
Woodroffe A (abst) 741
Woodroffe AJ (abst) 751
Woodruff PWH (abst) 738
Woods LL (abst) 338
Work J (abst) 454
Wreghitt TG (abst) 1439
Wright EM (abst) 151, 496
Wright FS (abst) 486
Wu D (abst) 183
Wurst EA (abst) 438
Wuthrich R (abst) 367
Wuthrich RP (abst) 366
Wyatt RJ (abst) 368
Wyss JM (abst) 357
Xantjikonstantinou B (abst) 1446
Xie XS (abst) 167, 467
Xiong W, Chao L, Chao J: Renal kallikrein mRNA localization by in situ hybridization 1324
Yacoub J (abst) 214
Yagil Y (abst) 476, 500
Yamada A (abst) 372
Yamada Y (abst) 294
Yamaguchi D (abst) 298
Yamaguchi DT (abst) 156
Yamaji Y (abst) 312
Yamamoto S (abst) 441
Yamamoto T (abst) 352, 367
Yamanaka K (abst) 367
Yamato K (abst) 186
Yamauchi A (abst) 406, 441
Yan T (abst) 388
Yanagawa N (abst) 152, 161, 302, 313, 324
Yang Z (abst) 325, 330, 511
Yaoita E (abst) 352, 367
Yared A (abst) 298
Yarger WE (abst) 505
Yashiro M (abst) 202
Yasmineh D (abst) 420
Yates J (abst) 429
Ye R (abst) 502
Yeh I (abst) 259
Yen PH (abst) 319
Yeni P (abst) 409, 412
Yeung SP (abst) 743
Yonemura K (abst) 167
Yoneshima H (abst) 237, 252
Yong LCJ (abst) 749
Yoo J (abst) 441
Yoshida F (abst) 367
Yoshida H (abst) 202, 357
Yoshida H *See* Takeuchi E et al 638
Yoshida K (abst) 252, 327, 328, 357, 471
Yoshida V (abst) 403, 421
Yoshida Y (abst) 430
Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis 654
Yoshimi H (abst) 327, 328, 471
Yoshimoto M (abst) 441
Yoshimura A (abst) 236, 469
Yoshimura NN (abst) 396
Yoshinaga K (abst) 321
Yoshinaga K *See* Ito S et al 1138
Yoshioka K, Takemura T, Tohda M, Akano N, Miyamoto H, Ooshima A, Maki S: Glomerular localization of type III collagen in human kidney disease 1203
Yoshioka T (abst) 410, 421, 469
Yoshitomi K (abst) 457, 481, 492
Yoshiyama N (abst) 234
Yoshizawa N (abst) 368, 372, 374, 376

Young E (abst) 338
Young EW (abst) 333
Young G (abst) 274
Young JR (abst) 333
Yu BH *See* **Lee HS et al** 880
Yu VYH (abst) 751
Yu Y (abst) 236
Yuan BH (abst) 289, 472
Yuan BH *See* **Conger JD et al** 1126
Yuasa S (abst) 475
Yudis M (abst) 213
Yudkoff M (abst) 447, 448
Yui M (abst) 358, 367
Yulo T (abst) 160
Yura T (abst) 475
Yusufi A (abst) 389
Yusufi ANK (abst) 168
Zabetakis PM (abst) 216, 379
Zachary J (abst) 220, 226
Zager P (abst) 292, 296
Zager RA (abst) 419, 421
Zahid M (abst) 338
Zahir SA (abst) 271
Zakolski WJ (abst) 912
Zambianchi A (abst) 757
Zamboni M (abst) 336
Zambraski E (abst) 421
Zanker B (abst) 510, 511
Zasuwa G (abst) 245, 256, 265
Zatz R (abst) 428, 442, 473
Zavos G (abst) 1440
Zavros M (abst) 1445
Zeidel ML (abst) 282, 321, 456
Zeier M (abst) 355
Zelikovic I (abst) 492
Zerefos N (abst) 236, 1437
Zerva C (abst) 1440
Zerva T (abst) 1443
Zerwekh JE (abst) 393
Zhang C (abst) 476
Zhang J (abst) 376
Zhong HP (abst) 369
Zhou FQ (abst) 271
Zhou GY (abst) 751
Zhou HZ (abst) 511
Zhous SF (abst) 369
Ziegler A (abst) 392
Ziegler L (abst) 207
Ziegler MG (abst) 267
Zikos D (abst) 388, 503
Zilleruelo G (abst) 219, 267, 385
Zimmer R (abst) 306
Zimmerman E (abst) 184
Zimmerman MB (abst) 290
Zincke H (abst) 204
Zingraff J (abst) 267
Zins B (abst) 245, 267
Zipp TM (abst) 219
Ziroghiannis P (abst) 1436, 1436
Ziroyannis P (abst) 1444, 1445
Ziroyiannis P (abst) 1443, 1443
Ziyadeh F (abst) 428
Ziyadeh FN (abst) 322, 495
Zocali C (abst) 338, 755
Zoubos N (abst) 1442, 1442
Zucchelli P (abst) 756
Zuo FR (abst) 467
Zuo HL (abst) 292
Zuo WM (abst) 303

Subject Index For Volume 35

2′,5′-Dideoxyadenosine (abst) 172
2K1C Hypertension (abst) 286, 302, 330, 332
^{3}H thymidine incorporation, cell line UMR 106-01 1119
5′-Nucleotidase (abst) 407
5-Hydroxyindoleacetic, RPF 95
6-Hydroxydopamine (abst) 401
87-Rubidium MMR, cation flux 1249

A6 cell RNA encoding (abst) 155
ACE inhibitors (abst) 245, 277, 332, 437
ADPKD
  cell proliferation and fluid secretion in cysts 1384
  cyst-derived cells in vitro 1356
  DNA probe in diagnosis of (abst) 738
  renal concentrating capacity 675
ADPase (abst) 359
ADR nephrosis (abst) 472
AIDS nephropathy (abst) 213, 215, 222, 234, 368
ATPases
  analysis (abst) 448, 462, 502
  antagonists and inhibitors (abst) .. 157, 320, 337, 431, 459, 466, 467
  drug effects on (abst) 299, 314
  isolation and purification (abst) 154
  pathophysiology (abst) 167, 418, 489
  pharmacokinetics (abst) 423
  pharmacologic actions (abst) 483
  physiology (abst) 157, 431, 452
  regulation (abst) 161, 311, 321, 323, 337, 430, 478
  transport (abst) 461, 463
Abdominal aorta, arteritis (abst) 913
Abscesses, renal and peri-renal (abst) 910
Acetates (abst) 243, 257
Acid B-galactosidases compared 1295
Acid-base
  balance, Ca and $KHCO_3$ 688
  disorder, Cl^-/base exchange in mesangial cells 783
  net acid excretion, "new" bicarbonate 1277
Acid-base equilibrium
  drug effects on (abst) 237
  drug therapy (abst) 241
  pathology (abst) 458
  pathophysiology (abst) 453, 454
  physiology (abst) 388
  regulation (abst) 172, 173, 180, 215
  transport (abst) 455, 461
Acid-base imbalance (abst) 202, 214, 457, 464, 503
Acidification
  carbonic anhydrase 851
  Cl^-/base exchange 783
Acidosis
  amino acid dialysis solution in CAPD 1189
  sulfate effect after urinary diversion 105
  voltage-dependent, induced by amiloride 1107
Acquired immunodeficiency syndrome
  complications (abst) 212, 213, 217, 234, 339, 388
  diagnosis (abst) 268
  immunology (abst) 242
  mortality (abst) 208, 248, 260
  occurrence (abst) 258
  pathology of HIV-associated nephropathy 1363
  pathophysiology (abst) 484
Active transport (abst) 186, 299, 462
Acute hypersensitivity nephritis (abst) 210, 227
Acute nephritis (abst) 345
Acute poststreptococcal glomerulonephritis (abst) . 212, 216, 356, 376
Acute primary pyelonephritis, early cortical scarring 696
Acute renal failure
  ANP and dopamine in ischemia 1126
  CsA nephrotoxicity, uninephrectomy 1175
  atraumatic rhabdomyolysis, hyperpyrexia (abst) 752
  complications (abst) 404
  diagnosis (abst) 393
  drug effects on (abst) 315
  drug therapy (abst) 282, 400, 403, 415, 477
  etiology (abst) 204, 225, 227, 228, 525
  interstitial nephritis 1257
  metabolism (abst) 418
  mortality (abst) 234, 410
  occurrence (abst) 222, 224
  outcome (abst) 234
  pathophysiology (abst) .. 400, 407, 408, 410, 411, 413, 414, 421
  prevention and control (abst) . 296, 406, 408, 414, 508, 525
  rehabilitation (abst) 232
  renal function in children after 84
  snake-bite induced in India 891
  therapy (abst) 223, 251, 292
Acute tubular necrosis
  diagnosis (abst) 416
  pathophysiology (abst) 403, 407, 416, 418
  prevention and control (abst) 402, 415, 512
Acyl transferases (abst) 169
Adenosine
  analogs and derivatives (abst) 470
  antagonists and inhibitors (abst) 310, 415
  biosynthesis (abst) 430
  mesangial cell contraction 1300
  metabolism (abst) 182, 407
  pharmacologic actions (abst) . 179, 257, 309, 314, 316, 435, 471, 472
  physiology (abst) 403, 474
  transport (abst) 400
Adenosine triphosphate (abst) 398, 400, 442, 444, 449
Adenylate cyclase (abst) 173, 175, 298, 446, 476
Afferent arterioles
  effect of prostanoids on renin release 1138
Affinity chromatography (abst) 363
Age factors (abst) 270, 280, 513, 519
Aged (abst) 262, 334
Aggregates (abst) 502
Aggrephores (abst) 187, 305
Aging (abst) 161, 176, 346
Alanine (abst) 407

Albumin
biosynthesis (abst) 431, 441
blood (abst) 406, 432
pharmacologic actions (abst) 473
therapeutic use (abst) 236
urine (abst) 230
Albuminuria (abst) 209
Alcohol
abuse (abst) 374
renal water transport (abst) 750
Aldose reductase (abst) 292, 425, 433, 499, 501
Aldosterone
(abst) 169, 291
adverse effects (abst) 216
metabolism (abst) 299
pharmacologic actions (abst) 162, 299, 486
physiology (abst) 454, 480, 485, 486
regulation (abst) 459
secretion (abst) 279, 300, 300, 329
Alkalies (abst) 218
Allograft
rejection, thromboxane inhibition prevents 24
Alloisoleucine (abst) 195
Allopurinol
(abst) 219
superoxide dismutase (abst) 746
Alport's syndrome (abst) 203, 205
Aluminum
absorption and excretion by intestine (abst) 745
adverse effects (abst) ... 189, 192, 265, 267, 377, 378, 378, 379
desferrioxamine therapy in HD 1376
exposure due to contaminated concentrate (abst) 753
intestinal absorption, diet 1306
micromolar levels reduce ^{3}H-thymidine, UMR 106-01 1119
pathophysiology (abst) 380
pharmacologic actions (abst) 252, 261, 399
physiology (abst) 379
toxicity (abst) 377, 397, 398
transport (abst) 399
Aluminum hydroxide (abst) 221, 427
Amiloride
analogs and derivatives (abst) 156, 465
induced, voltage-dependent tubular acidosis 1107
pharmacologic actions (abst) 160, 288, 443, 455, 458
Amino acids
blood (abst) 192
dialysis solution in CAPD 1189
gluconeogenic, alanine and BCAA on hemodynamics (abst) 756
metabolism (abst) 196, 437
pharmacologic actions (abst) 308
physiology (abst) 475
plasma and muscle free, CAPD 1219
supplements, none in CRF diet (abst) 737
therapeutic use (abst) 396
transport (abst) 413
Aminoglycosides (abst) 229, 406, 511
Aminonucleoside nephrosis
anionic charge in GBM 1410
Aminonucleosides (abst) 209, 420
Ammonia
biosynthesis (abst) 445, 447, 463
kinetics (abst) 398
secretion (abst) 442, 460
transport (abst) 452, 459
Ammonium chloride (abst) 173, 447
Amphotericin (abst) 409, 412, 419
Amylase (abst) 190
Amyloid
syndromes in hemodialysis 567
Amyloidosis
(abst) 212, 224
β_2-m related in chronic HD (abst) 744
clinical presentation (abst) 910
Analbuminemia (abst) 428, 442
Analgesic nephropathy (abst) 192
Analgesic syndrome
RPN, CIN and NSAIDS (abst) 752
Analgesics (abst) 192
Ancrod (abst) 344
Anemia
CRF, effects of recombinant erythropoietin 134
adverse effects (abst) 246
drug therapy (abst) . 193, 227, 229, 240, 245, 257, 265, 266, 273, 321, 334
i.p. deferoxamine therapy for iron overload in children 1335
iron status, erythropoietin 712
therapy (abst) 196
Angiocardiography (abst) 414
Angioplasty in stenosis of AVF in HD (abst) 754
Angiotensin II
concentration of inositol phosphates 1325
pregnancy, effects on BP and Na excretion (abst) 750
vasoconstrictors normalize GFR in postobstruction .. 1311
Angiotensin converting enzyme
(abst) 234, 298, 482
treatment in hypertension (abst) 750
Angiotensinases (abst) 304
Angiotensins
administration and dosage (abst) 298, 301
antagonists and inhibitors (abst) ... 207, 300, 302, 303, 416
biosynthesis (abst) 325, 333
metabolism (abst) 303, 304, 443
pathophysiology (abst) 405, 474
pharmacologic actions (abst) . 158, 172, 183, 196, 279, 300, 301, 302, 304, 320, 445, 460
physiology (abst) 288, 302, 423, 440, 458, 472, 473
regulation (abst) 302, 303, 354
secretion (abst) 338
Angiotension II
receptors in IgAN (abst) 741
Anions (abst) 164, 179, 493, 495
Anisotropy microscopy, cell imaging (abst) 154
Ankylosing spondylitis (abst) 213
Antacids (abst) 261
Antagonists and inhibitors (abst) 287, 288
Anti-inflammatory agents
non-steroidal (abst) 206, 420
Antibiotics (abst) 247, 253, 511
Antibodies
adverse effects (abst) 339, 349, 351
against neutrophil cytoplasmic antigen (abst) 743
circulating immune complexes 993
collagen in the basement membrane 1195
cross reactivity of anti-DNA (abst) 746
definition of intercalated cell subtypes (abst) 150
immunopathogenesis of TIN 938

interaction with renal cell surface antigens 954
isolation and purification (abst) 347
occurrence (abst) 255, 268
pathophysiology (abst) 373, 524
pharmacokinetics (abst) 351
physiology (abst) 352
therapeutic use (abst) 506
to ClQ antigen in MPGN 836
type III collagen localized 1203
Antibody
formation (abst) 363, 514, 520
lack of xenoantibody response, transplantation (abst) . 746
transplantation, CsA and transfusion 1057
Antidiuresis, obstructed or dehydrated kidney, P-31 NMR 830
Antigen-antibody reactions (abst) 347, 360
Antigens
adverse effects (abst) 344, 358, 365
definition of discrete glomerular (abst) 740
expression in normal and glomerulonephritic kidney .. 116
HLA in rejection episodes (abst) 742
immunology (abst) 508
isolation and purification (abst) 340
physiology (abst) 344, 352
regulation (abst) 509
retroviral gp70, mesangial glomerulonephritis 638
Antilipemic agents (abst) 429, 436
Antioxidant therapy
ischemic renal failure 1282
Antioxidants (abst) 421
Antiviral activity (abst) 272
Anuria (abst) 232
Aorta (abst) 278
Arachidonic acids
analogs and derivatives (abst) 312
metabolism (abst) 290, 290, 293, 295, 296, 298
pharmacologic actions (abst) 296
regulation (abst) 315, 482
Arginine (abst) 474
Arginine vasopressin
reflex non-osmotic control of (abst) 755
Aromatic amino acid decarboxylases (abst) 312
Arteriolar C3 disease (abst) 750
Arteriolar nephrosclerosis (abst) 334
Arteriovenous shunt, surgical (abst) 259
Arteritis
primary, of the aorta (abst) 913
surgical management (abst) 913
Artificial membranes
adverse effects (abst) 240, 242, 248, 256, 258, 266
instrumentation (abst) 251, 260, 262
methods (abst) 239, 261, 263
physiology (abst) 249, 254, 259
Ascending pyelonephritis, kidney growth 1133
Ascites (abst) 231
Ascorbate (abst) 426
Aspirin (abst) 359
Atenolol (abst) 322
Atherosclerosis (abst) 201, 239, 333, 437
Atraumatic rhabdomyolysis, ARF (abst) 752
Atrial natriuretic factor
administration and dosage (abst) 283, 286
analogs and derivatives (abst) 278, 281, 282, 283, 289
analysis (abst) 207, 278, 279
and intrarenal hormone systems, mineralocorticoids .. 767
blood (abst) 281, 283, 287, 289, 290, 405
drug effects on (abst) 229
enzymatic and binding effects 799
isolation and purification (abst) 278, 289
kinetics (abst) 279
metabolism (abst) 285, 479
pharmacologic actions (abst) . 158, 279, 280, 280, 282, 283, 284, 284, 285, 285, 286, 287, 287, 288, 288, 300, 483
physiology (abst) 277, 279, 281, 284, 286, 289 408, 423
regulation (abst) 471
secretion (abst) 227, 264, 280, 282, 286, 441
split hydronephrotic kidney, autoregulation 1151
therapeutic use (abst) 282, 411, 417, 420, 506, 509, 511
Atrial natriuretic factor binding proteins (abst) 278
Atrial natriuretic peptide
binding, chronic heart failure (abst) 740
dopamine in ischemic ARF 1126
effect on transport (abst) 751
natriuresis inhibited by CEI (abst) 751
volume homeostasis in NS (abst) 759
Autoantibodies
adverse effects (abst) 341, 346
biosynthesis (abst) 346, 363
immunology (abst) 208, 226, 341
isolation and purification (abst) 347
pathophysiology (abst) 211, 369, 370
Autoantigens 923
(abst) 372
Autoimmune injury (abst) . 339, 341, 342, 343, 344, 345, 347, 348, 349, 354, 355, 356, 359, 360, 362, 364, 367
Autoimmunity and the kidney 923
Autonomic nervous system
growth and development (abst) 474
pathophysiology (abst) 471, 519
physiology (abst) 278, 328, 335, 354, 392
Autoregulation (abst) 468
Azathioprine
(abst) 506
prednisolone therapy in transplantation (abst) 745
Azotemia (abst) 190, 435

B cell lymphoma (abst) 510
B cells (abst) 347, 407, 526
Band 3 proteins (abst) 150, 152, 159, 463
Bartter's syndrome (abst) 207, 216
Basement membrane
analysis (abst) 163
antibodies to (abst) 341
collagen 1195
immunology (abst) 352
injuries (abst) 359
pathology (abst) 373
physiology (abst) 150
ultrastructure (abst) 165
Basolateral membranes
cytochalasin B binding 1290
Benzoates (abst) 398
Beta adrenergic blockers (abst) 238
Beta-$_2$-microglobulin
(abst) 238, 259, 263, 265
adverse effects (abst) 241
kinetics (abst) 252
metabolism (abst) 258

occurrence (abst) 254
Betaine (abst) 499
Bicarbonates
adverse effects (abst) 463
drug effects on (abst) 452
"new" in net acid excretion 1277
regulation (abst) 156, 444
secretion (abst) 456, 457, 461, 462
therapeutic use (abst) 241, 249, 263, 271
transport (abst) 306, 384, 451, 452, 453, 454, 455, 456, 458, 459, 460, 460, 464, 465
Bile acids and salts (abst) 382
Binding sites
analysis (abst) 316, 319
isolation and purification (abst) 156
physiology (abst) 150
regulation (abst) 319
Bioavailability (abst) 383
Biofilms (abst) 247, 271, 275
Bioimpedance (abst) 239
Biological membranes, polycations and MCN (abst) 760
Biopsy
(abst) 513, 521, 526
improved technique (abst) 745
terminal complement components (abst) 746
Bladder
metabolism (abst) 312
physiology (abst) 497
ultrastructure (abst) 453, 456, 461
Bleeding time (abst) 235
Blood
coagulation abnormalities in Blacks with NS (abst) 914
DDAVP to correct skin bleeding time (abst) 751
hemostasis activation in NS (abst) 758
pretransplant transfusion, CsA (abst) 739
Blood coagulation disorders (abst) 257, 294, 518, 525
Blood coagulation factors (abst) 198, 202, 510
Blood flow
measurement (abst) 243
thromboxane inhibition during allograft rejection 24
Blood gas analysis (abst) 214, 259
Blood groups (abst) 371, 522
Blood pressure
(abst) 324, 326, 330, 337
Na-retaining effects of mineralocorticoids 767
antihypertensive therapy 790
calcium metabolism and hypertension 717
drug effects on (abst) 240, 259, 283, 288, 301, 304, 309, 311, 313, 329, 334
physiology (abst) 236, 264, 336
progression of renal insufficiency 670
relates to urinary stone disease (abst) 754
serum ionized calcium (abst) 748
split hydronephrotic kidney 1151
Blood proteins, transport (abst) 275
Blood transfusion
(abst) 250, 518, 522, 522
adverse effects (abst) 519
complications (abst) 241, 246
therapeutic use (abst) 504
Blood urea nitrogen (abst) 247, 255, 260
Body fat, CAPD (abst) 752
Body fluid compartments (abst) 237, 252, 264, 274, 494
Bombesin (abst) 318, 502
Bone
(abst) 376, 378, 378, 399
and joint disease in primary hyperoxaluria (abst) 908
development (abst) 377
disease, Al-related, desferrioxamine 1376
IgA1 elevated by marrow in IGAN 1405
marrow transplantation, mesangiolysis, renal failure 1341
vitamin D in moderate renal failure 661
Bone diseases
drug therapy (abst) 220
etiology (abst) 258, 267
pathophysiology (abst) 261, 378, 379
prevention and control of (abst) 377
Bone marrow
(abst) 245
transplantation (abst) 223, 419
Bradykinin (abst) 168, 169, 171
Brain
analysis (abst) 278, 498
dehydration after rapid correction of hyponatremia 69
edema (abst) 217, 239
injuries (abst) 490
metabolism (abst) 496
pathology (abst) 214
pathophysiology (abst) 519
physiology (abst) 273
Bromides (abst) 219
Brush border
analysis (abst) 153, 159, 388
anatomy and histology (abst) 159, 164
drug effects on (abst) 411
physiology (abst) 150, 164, 166, 168, 382
transport (abst) 161, 302, 385, 451, 452, 492
ultrastructure (abst) 166, 501
Brush border membrane
glucose metabolism (abst) 152
light chain binding sites (abst) 150
phosphate depletion alters phospholipid (abst) 153
Bumetanide (abst) 337, 452
Burst forming unit erythroid (abst) 755
Butyrate (abst) 500

C3 disease, arteriolar (abst) 750
C3 nephritic factor (abst) 372
CAPD
amino acid dialysis solution 1189
analysis (abst) 274
body fat status (abst) 752
complications (abst) 267, 268, 268, 269, 271, 272, 275, 342
drug therapy (abst) 273
induction of IL-1 during 1212
loss of peritoneal membrane function (abst) 908
methods (abst) 268
pathophysiology (abst) 270, 271, 378
peritonal morphology (abst) 740
peritonitis (abst) 744
peritonitis spread by biofilm along catheter surface 614
persistent peritonitis, treatment 908
PTFE wheel catheter (abst) 908
pharmacokinetics (abst) 277
physiology (abst) 271
plasma and muscle free amino acids 1219
rational treatment of peritonitis (abst) 913
relevance of urea kinetic modeling (abst) 744
therapeutic use (abst) 199

total body nitrogen (abst) ... 742
transport of serum proteins and dextran ... 1064
two-pore formalism in solute transport ... 1234
ultrafiltration (abst) ... 752
CAVH, simulation with a math model ... 125
Cadaveric transplantation
complications (abst) ... 526
drug therapy (abst) ... 512, 518
immunology (abst) ... 518
outcome (abst) ... 523
utilization (abst) ... 522
Cadmium (abst) ... 410
Calcitonin
gene related peptide (abst) ... 311
pharmacologic actions (abst) ... 311, 315, 321, 391
physiology (abst) ... 391
therapeutic use (abst) ... 525
Calcitriol
biosynthesis (abst) ... 392
metabolism (abst) ... 390, 395, 396
physiology (abst) ... 391
therapeutic use (abst) ... 391
uremia ... 860
Calcium
adverse effects (abst) ... 404
analogs and derivatives (abst) ... 221, 292
and Mg homeostasis following urinary diversion ... 105
anionic sites of mesangial cells, poly-L-lysine ... 817
balance, $KHCO_3$ improves in healthy men ... 688
intracellular (abst) ... 156, 168, 171, 171, 175, 177, 180, 182, 279, 293, 301, 309, 314, 324, 331, 332, 337, 387, 393, 398, 438, 463, 505
metabolism (abst) ... 254, 338, 426
metabolism and hypertension ... 717
metabolism disorders (abst) ... 271, 395
oral load (abst) ... 758
pathophysiology (abst) ... 409
pharmacologic actions (abst) ... 166, 292, 474
physiology (abst) ... 394, 435
regulation (abst) ... 243, 333, 335, 386, 399, 486
secretion (abst) ... 378, 379
serum ionized and BP (abst) ... 748
stones disease, metabolic abnormalities (abst) ... 749
therapeutic use (abst) ... 377
toxicity (abst) ... 170
transport (abst) ... 169, 177, 179, 183, 183, 184, 279, 380, 381, 382, 384, 386, 387, 397, 493
urine (abst) ... 194
Calcium carbonate (abst) ... 255, 264
Calcium channel blockers (abst) ... 281, 282, 291
Calcium citrate (abst) ... 399
Calcium ketovalin (abst) ... 388
Calculi
(abst) ... 383
hyperoxaluria (abst) ... 913
Calorie restriction (abst) ... 327
adrenergic control of generation in IMCD ... 647
dopamine stimulation of (abst) ... 153
membrane fluidity in epithelial cells (abst) ... 155
thrombin effect ... 824
Campylobacter jejuni gastroenteritis (abst) ... 749
Canine hereditary nephritis
NC1 domain of collagen type IV in GBM ... 843
Captopril
diagnostic use (abst) ... 302, 331, 335
pharmacologic actions (abst) ... 211, 287, 326, 327, 334
therapeutic use (abst) ... 197, 199, 336, 422
Carbicarb (abst) ... 463
Carbohydrates (abst) ... 248, 498
Carbon dioxide (abst) ... 453, 454, 466
Carbonic acid (abst) ... 461
Carbonic anhydrase
(abst) ... 453, 456, 461, 465
inhibitors (abst) ... 429
renal membrane-bound ... 851
Cardiac
output (abst) ... 331, 463
pacing, artificial (abst) ... 283
Carnitine (abst) ... 266, 267
Carrier proteins
analogs and derivatives (abst) ... 164
isolation and purification (abst) ... 158, 160, 164, 167, 464
transport (abst) ... 443
Cartilage (abst) ... 436
Catecholamines
(abst) ... 214, 257, 267, 482
drug effects on (abst) ... 332
in IMCD, adrenergic control of cAMP ... 647
physiology (abst) ... 307, 474, 488
secretion (abst) ... 335
Cathepsins (abst) ... 173
Catheter
(abst) ... 262
ageing of silicone rubber peritoneal (abst) ... 757
complications (abst) ... 253, 275
double-lumen, silicone rubber and permanent access ... 887
loss of peritoneal membrane function ... 908
methods (abst) ... 237, 262
peritonitis in dialysis by biofilm ... 614
PTFE wheel, CAPD (abst) ... 908
surgery (abst) ... 269
tissue adhesive use in implantation (abst) ... 757
Cation flux, 87-rubidium NMR ... 1249
Cationic drugs (abst) ... 493
cDNA (abst) ... 298
Cell
adhesion (abst) ... 156, 186, 352, 361
communication (abst) ... 173, 473, 508
contraction, A1-type receptor, adenosine ... 1300
culture techniques (abst) ... 167, 419
cultured (abst) ... 160, 343, 348, 355, 360, 362, 507
death (abst) ... 408
differentiation (abst) ... 170, 174, 186, 314
division (abst) ... 451
growth, hepatoma G2 conditioned medium ... 1245
imaging of membrane fluidity (abst) ... 154
line UMR 106-01, Al levels ... 1119
line, transformed (abst) ... 164, 166
lysis (abst) ... 525
mediated immunity in GN (abst) ... 741
procoagulant activity (abst) ... 743
proliferation and fluid secretion in cysts ... 1384
proliferation, gene expression in ureteral obstruction ... 1320
red, cation transport in uremia, hemodialysis ... 595
surface antigens react to antibodies ... 954
Cell membrane
antibodies to (abst) ... 360
pathology (abst) ... 153
permeability (abst) ... 187, 188, 361
physiology (abst) ... 461

transport (abst) 491
ultrastructure (abst) 160, 162, 188
Cell proliferation
(abst) 173, 176, 179, 179, 184, 184, 306, 339, 357, 384, 401, 408
antagonists and inhibitors (abst) 157, 187, 277, 507
drug effects on (abst) 447
pathophysiology (abst) 178, 340
physiology (abst) 428
regulation (abst) ... 179, 183, 318, 320, 345, 348, 358, 367, 436, 438
Cell volume
pathology (abst) 461
pathophysiology (abst) 330, 487
regulation (abst) ... 155, 160, 184, 478, 479, 483, 487, 488, 489, 491, 500, 503
Central pontine myelinolysis (abst) 218
Cerebrovascular disorders (abst) 324
Chelating agents (abst) 265
Chemoreceptors (abst) 294
Chemotactic factors (abst) 254, 342, 361, 369
Chemotaxis (abst) 361
Children
ascending pyelonephritis and kidney growth 1133
Fanconi syndrome, urine glyceraldehyde excretion 99
FSGS in South Africa (abst) 914
hepatitis B nephrotic syndrome (abst) 909
i.p. deferoxamine therapy for iron overload, CAPD .. 1335
low PO_4, low protein diet, CRF (abst) 737
malnourished, urinary tract infection (abst) 910
post-ARF renal function in 84
renal vein thrombosis (abst) 751
transplantation and dialysis (abst) 753
Chloride
deficiency (abst) 452, 455, 464, 466
intracellular (abst) 485
physiology (abst) 454
regulation (abst) 156, 167, 478, 481, 481, 485, 486
transport (abst) 160, 176, 306, 432, 453, 454, 455, 456, 457, 476, 480, 484, 487, 491, 502
Cholesterol
(abst) 150, 239, 437, 473
embolism (abst) 228
modulates BBM fluidity and Pi transport 150
Chondroitin (abst) 352
Chromatography (abst) 168, 183, 357, 510, 514
Chromium release T cell cross match (abst) 909
Chromogranin A (abst) 332, 335
Chronic glomerulonephritis (abst) 374
Chronic heart failure
ANP binding (abst) 740
Chronic renal disease
amyloid syndromes in hemodialysis 567
hemodynamic changes vs. hypertrophy 654
Chronic renal failure
analysis (abst) 201, 228
anemia, recombinant erythropoietin 134
complications (abst) 192, 199, 235, 238, 252, 271, 396, 422, 435
diagnosis (abst) 233, 439
diet therapy (abst) 226, 424
drug therapy (abst) .. 220, 220, 229, 318, 379, 384, 427, 440
etiology (abst) 223, 228, 229
immunology (abst) 198, 371, 375
intestinal absorption of Al 1306
lipid metabolism 40
metabolism (abst) 195, 390, 395, 446
mortality (abst) 523
occurrence (abst) 222, 234
outcome (abst) 190, 194, 198
pathophysiology (abst) .. 197, 221, 276, 284, 285, 294, 346, 392, 394
phosphate restriction, PGE_2 excretion (abst) 737
plasma and muscle free amino acids, CAPD 1219
protein restriction (abst) 909
Schistosoma mansoni, mesangiocapillary GN 1227
therapy (abst) 223
vitamin D receptors decreased in parathyroid glands ... 19
Chylomicrons (abst) 425
Ciprofloxacin (abst) 227
Circadian rhythm (abst) 470
Circulatory failure (abst) 214
Cisapride (abst) 272
Cisplatin
(abst) 218, 383, 402, 409
nephrotoxicity (abst) 740
nephrotoxicity, PTX (abst) 755
Citrate synthase (abst) 485
Citrates (abst) 337, 378, 398, 443
Cl^-/base exchange in mesangial cells, pH regulation 783
ClQ antigen antibody in MPGN 836
Clearance
lithium in humans 1183
nephrectomy and glomerular solute transport 589
two-pore formalism, solute transport in CAPD 1234
Clindamycin (abst) 244
Cloning, molecular (abst) 155, 163, 358
Co-transport
analysis (abst) 151, 496
pathology (abst) 485, 490
pathophysiology (abst) 411, 450
physiology (abst) 451, 498, 502
regulation (abst) ... 154, 168, 178, 178, 303, 324, 454, 457, 462
Cobra venom (abst) 355
Cocaine (abst) 225
Coeliac disease, IgAN (abst) 756
Colchicine (abst) 187
Collagen
analysis (abst) 205
basement membrane in the kidney 1195
biosynthesis (abst) 322, 348, 349, 360, 429, 436
glomerular localization 1203
isolation and purification (abst) 352
metabolism (abst) 366
regulation (abst) 322
Collecting tubules
embryology (abst) 305
pathophysiology (abst) 216, 383
physiology (abst) 165, 431, 448, 497
transport 450, 451, 482, 484, 489, 501
ultrastructure (abst) 150, 400, 419, 453, 464, 465, 503
Colon neoplasms (abst) 247
Colony stimulating factors (abst) 342, 355, 367
Complement
activation (abst) 258, 308, 365, 372
adverse effects (abst) 353, 355, 363
antagonists and inhibitors (abst) 373
C3 fragments, hemodialysis membranes 576
deficiency (abst) 210, 372

diagnostic use (abst) ... 369
induction of IL-1 during dialysis ... 1212
kinetics (abst) ... 250
pathophysiology (abst) ... 368
physiology (abst) ... 242, 248, 256, 266, 268, 341, 362
secretion (abst) ... 240
Computers (abst) ... 226, 259, 467
Concanavalins (abst) ... 164, 354, 360
Concentrating ability (abst) ... 493
Concentrating capacity in PKD ... 675
Confocal microscopy (abst) ... 186, 188
Congestive heart failure (abst) ... 230, 258, 283, 287
Connecting tubules (abst) ... 393
Contrast media (abst) ... 231, 412
Contrast nephropathy ... 231, 411, 413, 414, 417
Corticosterone
(abst) ... 312
6-beta-hydroxylase (abst) ... 189
Cotransporter
currents associated from Na/glucose (abst) ... 151
Coulter counter (abst) ... 222
Creatinine
(abst) ... 200, 231, 526
clearance (abst) ... 197, 222
Crescentic glomerulonephritis in Natal (abst) ... 914
Crescents
formation in IgAN (abst) ... 743
formation in RPGN, autoimmunity ... 929
Cross infection (abst) ... 242, 253
Cryoglobulinemia ... 1004
Crystal growth inhibitor (abst) ... 363
Cyanate (abst) ... 196
Cyclic AMP
antagonists and inhibitors (abst) ... 176
biosynthesis (abst) ... 318
intracellular (abst) ... 155, 293, 295
metabolism (abst) ... 162, 178
pharmacologic actions (abst) ... 172, 180
physiology (abst) ... 310, 381, 432
regulation (abst) ... 153, 458
transport (abst) ... 454
Cyclic GMP
blood (abst) ... 405
metabolism (abst) ... 288
pharmacologic actions (abst) ... 169, 483
physiology (abst) ... 285
urine (abst) ... 284
Cyclophosphamide
(abst) ... 207, 210, 211, 346
interstitial nephritis ... 1257
Cyclosporin A
actions on cultured mesangial cells ... 632
limits PGE_2 formation ... 1161
steroid-insensitive nephrotic syndrome ... 909
transplantation and antibody development after transfusion ... 1057
Cyclosporine
administration and dosage (abst) ... 213
adverse effects (abst) ... 181, 331, 336, 407, 504, 506, 508, 510, 511, 519, 525
analogs and derivatives (abst) ... 505
dopamine reverses toxicity (abst) ... 754
drug therapy (abst) ... 342
hemodynamics in CsA nephrotoxicity, uninephrectomy ... 1175
induced hypertension (abst) ... 748
nephropathy (abst) ... 407
pharmacokinetics (abst) ... 510, 513, 514, 516, 517
pharmacologic actions (abst) ... 402, 476, 507
physiology (abst) ... 508
therapeutic use (abst) ... 348, 366, 512, 518, 520
toxicity (abst) ... 197, 357, 401, 404, 405, 409, 413, 447, 504, 505, 507, 508, 509, 516, 519, 521, 524, 741
toxicity in microvascular endothelial cells ... 604
Cystic renal disorders
diagnosis (abst) ... 191
pathophysiology (abst) ... 167, 303, 310 311, 357, 359, 364, 434
Cystine (abst) ... 444
Cystine stone formation, MGN ... 1418
Cystinosis (abst) ... 462
Cystinuria, dietary sodium reduction (abst) ... 912
Cysts
cell proliferation, fluid secretion ... 1384
derived cells, no accelerated growth or features in vitro ... 1356
formation, tubular basement membrane change ... 1034
methylprednisolone induced (abst) ... 747
Cytochalasian B
binding to basolateral membranes ... 1290
Cytochrome P450 (abst) ... 290, 295, 312, 426
Cytokine
TNF production, bacterial lipopolysaccharide ... 1111
vascular indothelium, injury ... 969
Cytological techniques (abst) ... 419
Cytomegalovirus infection in transplantation (abst) ... 908
Cytoprotection (abst) ... 413
Cytoskeleton
(abst) ... 188
proteins (abst) ... 166, 187, 188, 356
Cytotoxicity, immunologic (abst) ... 518, 520
Cytotoxins (abst) ... 230

D-glucose transporter, cytochalasin B binding ... 1290
D-penicillamine, cystine stone formation ... 1418
DNA
(abst) ... 203, 318, 375, 406
markers (abst) ... 202
polymerases (abst) ... 405
probe in ADPKD diagnosis (abst) ... 738
DOPA (abst) ... 316
Decay accelerating factor (abst) ... 373
Deferoxamine
(abst) ... 244
therapy in children for iron overload ... 1335
Dehydration
(abst) ... 490
P-31NMR ... 830
Denervation (abst) ... 408
Deoxycorticosterone acetate, sodium ... 767
Deoxyspergualin (abst) ... 358
Desferrioxamine
Al-associated bone disease ... 1376
Dexamethasone (abst) ... 160, 405, 481
Dextran
clearance after nephrectomy ... 589
hemodialysis (abst) ... 757
transport, serum protein in CAPD ... 1064
Diabetes
maturity onset (abst) ... 911

streptozotocin, dietary protein content 48
Diabetes mellitus
(abst) 294, 297, 425, 426, 440, 496
complications (abst) . 190, 217, 220, 226, 235, 313, 437, 450
diet therapy (abst) 423, 425
drug therapy (abst) 422, 429
gentamicin nephrotoxicity, glycosuria 1041
glycosylation prevented by islet transplantation (abst) 748
pathology (abst) 159, 163
pathophysiology (abst) ... 170, 298, 433, 435, 467, 471, 472
prevention and control (abst) 335
therapy (abst) 214, 335
type 2, proteinuria, Pima Indians 681
Diabetic glomerular injury (abst) 210, 211
Diabetic nephropathy
complications (abst) 226
drug effects on (abst) 469
drug therapy (abst) 336
pathophysiology (abst) .. 193, 200, 272, 292, 304, 313, 432, 438, 440, 440
Diacylglycerol (abst) 169, 175, 466
Dialysate
(abst) 247, 249, 251, 255, 255, 264, 267
amino acid in CAPD 1189
benefit from cool (abst) 753
influence of shaking 1145
Dialysis
(abst) 191, 200, 200, 370
amyloid syndromes in 567
B_2-m levels (abst) 745
changes of monocytes due to membranes 622
complications (abst) 239
elective total parathyroidectomy 1395
in South Africa (abst) 911
intestinal absorption of Al, diet 1306
intraerythrocytic pH variations during 871
iron status, erythropoietin, anemia 712
machines (abst) 237, 244, 250, 260
malignant hypertension and RF (abst) 915
mortality (abst) 248
peritoneal morphology (abst) 740
peritonitis spread by biofilm 614
physiology (abst) 378
plasma and muscle free amino acids during 1219
post-ARF in children 84
problems in aboriginal population (abst) 738
progression of renal insufficiency, role of BP 670
utilization (abst) 226
Dialyzer
changes of monocytes due to dialysis membranes 622
clearance of vancomycin with polysulfone 1414
induction of IL-1 during dialysis 1212
complement C3 fragments 576
Diet
(abst) 195, 197, 217, 221, 235, 256, 281, 313, 337, 348, 364, 385, 452, 480
CRF without amino acid supplements (abst) 737
energy intake effect on nutrition status, HD patients .. 704
in recurrent stone formers (abst) 912
intestinal absorption of Al 1306
low PO_4, low protein in CRF children (abst) 737
protein content in diabetic rats 48
Dietary fats (abst) 256, 423
Dietary protein
adverse effects (abst) 364
Dietary proteins
deficiency (abst) 428
metabolism (abst) 191, 521
pharmacologic action (abst) 310, 470
physiology (abst) 189, 192, 301, 302, 493
therapeutic use (abst) 193, 221
Dietary proteins (abst) 195, 196, 424, 425, 427, 431, 439
Digitalis (abst) 201
Digoxin-like factors in RF (abst) 909
Digoxin-like substances (abst) 287
Dilitiazem (abst) 513
Dipenylamine-2-carboxylate binding protein (abst) 478
Disease models, animal (abst) 354
Distal tubules (abst) 166, 458, 461, 479, 492, 500
Distension (abst) 166, 463
Diuresis
(abst) 285, 432, 481
lithium clearance in humans 1183
Diuretic
(abst) 161, 331
natriuretic effect of ANF 799
stimulation of renin secretion, sulfhydryl reagents 812
Dobutamine (abst) 215
Dopamine
analysis (abst) 329
ANP in ischemic ARF 1126
antagonists and inhibitors (abst) 172, 285, 477
cAMP production (abst) 153
pharmacologic actions (abst) 153, 321, 328
physiology (abst) 308
regulation (abst) 320
therapeutic use (abst) 230, 420
urine (abst) 316
Dose-response relationships (abst) 280
Doxorubicin (abst) 401, 420, 433, 472
Drug
administration routes (abst) ... 241, 269, 272, 276, 279, 286
metabolism (abst) 446, 448, 514
transport (abst) 158
Drug-induced nephropathies
diagnosis (abst) 401
drug therapy (abst) 404
etiology (abst) 412, 505
metabolism (abst) 418
occurrence (abst) 224, 229
pathophysiology (abst) .. 401, 406, 409, 415, 416, 419, 420, 437
prevention and control (abst) 404, 405, 408

Echocardiography (abst) 240
Eicosanoids, immune injury 985
Eicosapentaenoic acid (abst) 235
Electric charge (abst) 208, 273, 349
Electron microscopy (abst) 374
Electrophoresis (abst) 357
Enalapril
(abst) 211, 440
administration and dosage (abst) 301
adverse effects (abst) 434, 525
analogs and derivatives (abst) 338
diagnostic use (abst) 327, 329
pharmacologic actions (abst) 200, 207, 281, 304, 326
therapeutic use (abst) 197, 301, 427

Encephalitazoon cuniculi (abst) 749
End-stage renal disease
amyloid syndromes in hemodialysis 567
analysis (abst) 234
control of K in fasting 90
cyst formation, TBM change 1034
drug therapy (abst) 390
elective total parathyroidectomy 1395
in South Africa (abst) 911
metabolism (abst) 438
mixed mode therapy (abst) 753
occurrence (abst) 191, 197, 199, 200, 226
outcome (abst) 200
permanent access catheters 887
Pima Indians, type 2 diabetes 681
progression of renal insufficiency 670
therapy (abst) 194, 199
End-stage renal failure
renal concentrating capacity in PKD 675
Endocytosis (abst) 187, 188, 188, 320, 443
Endopeptidases (abst) 313
Endorphins (abst) 328
Endosomes
(abst) 152, 454, 502
localization (abst) 152
Endothelial cells
cyclosporine toxicity 604
growth and development (abst) 170
hepatoma G2 conditioned medium 1245
immunology 369, 520
metabolism (abst) 293
pathology (abst) 153
physiology (abst) 173, 177, 366
secretion (abst) 157
Endothelin
blood (abst) 321
pathophysiology (abst) 410
pharmacologic actions (abst) 171, 177, 184, 308, 309, 313, 314, 315, 317, 321, 330
physiology (abst) 325, 331
Endothelium
(abst) 326, 504
effects of cytokines on vascular 969
Endothelium derived relaxing factors (abst) 306, 325, 330
Endotoxins (abst) 234, 249, 408
Energy metabolism (abst) 447
Enkephalinases (abst) 290
Enterotoxins (abst) 353
Enzyme
carbonic anhydrase 851
reactive oxygen metabolites in glomerular disease 1093
Epidemiologic methods (abst) 200, 212, 334
Epidermal growth factor
(abst) 167, 290
adverse effects (abst) 339
analysis (abst) 309
biosynthesis (abst) 311, 317
pharmacologic actions (abst) 312, 314, 319, 420
physiology (abst) 168, 319, 349
regulation (abst) 442
urine (abst) 417
Epinephrine (abst) 475
Epithelial cells
anatomy and histology (abst) 150
antibodies to (abst) 359
cAMP and membrane fluidity (abst) 155
classification (abst) 157
growth and development (abst) 428
injuries (abst) 339, 403, 433, 504, 525
membrane heterogeneity (abst) 150
metabolism (abst) 152
pathophysiology (abst) 445
phyisology (abst) 154, 156, 169, 179, 315, 357, 453, 499
protein A-gold (abst) 741
transport (abst) 309
ultrastructure (abst) 188, 374, 431
urine (abst) 416
Epithelium
(abst) 167, 310
volume regulation by gallbladder (abst) 155
Epoprostenol (abst) 242
Erythrocytes
(abst) 253, 397
analysis (abst) 209, 220
immunology (abst) 374
metabolism (abst) 271
physiology (abst) 208, 429, 432
urine (abst) 374
Erythropoiesis
(abst) 245, 252, 318, 321
Erythropoietin
adverse effects (abst) 190, 198, 237, 240, 253, 256, 264, 265, 313
anemia of CRF 134
biosynthesis (abst) 288
iron status in anemia 712
pharmacokinetics (abst) 273
pharmacologic actions (abst) 263, 318
secretion (abst) 326
therapeutic use (abst) 190, 193, 195, 196, 227, 229, 236, 237, 240, 243, 245, 246, 247, 250, 252, 253, 257, 259, 266, 316, 321, 334, 429, 437
Essential mixed cryoglobulinemia 1004
Estradiol, cyclophosphamide in IgAN (abst) 756
Ethnic groups (abst) 190, 220, 222, 236
Ethylene glycol (abst) 228
Excretion
Ca balance, $KHCO_3$ improves 688
by intestine of Al (abst) 745
"new" bicarbonate formed in net acid 1277
of C5b-9, passive Heymann nephritis 60
oral Ca load (abst) 758
protein, antihypertensive therapy 790
renal concentrating capacity in PKD 675
water, cAMP generation control in IMCD 647
Exertion (abst) 440, 515
Exocytosis (abst) 188, 335
Extracellular matrix
biosynthesis (abst) 294, 343, 350, 432
growth and development (abst) 441
immunology (abst) 507
physiology (abst) 162, 170
secretion (abst) 341
Extracellular space (abst) 259, 467
Eye (abst) 352

Fabry's disease (abst) 202
Familial Mediterranean fever (abst) 212

Fanconi syndrome
urine glyceraldehyde excretion elevated 99
Fasting
control of K in ESRD 90
Fatty acids
(abst) 174, 185, 362, 435, 443, 516
membrane free, hemodialysis, cation transport 595
Ferritin (abst) 347, 524
Fetus (abst) 488
Fever (abst) 221
Fibrillar nephropathy, immunohistochemical study
(abst) 756
Fibrin
(abst) 198, 431
plasminogen activator and inhibitor 806
thrombin effect on cAMP content in glomeruli 824
tissue plasminogen activator therapy, Shwartzman reaction 14
Fibrinolysis (abst) 235
Fibroblasts (abst) 178, 179, 186, 308
Fibronectins (abst) 156, 159, 162, 344, 351
Fibrosis
encephalitazoon cuniculi (abst) 749
Filtration
math model of CAVH 125
Fish (abst) 289
Fish oil (abst) 293, 328, 368, 412, 414, 423
Flow cytometry
kinetics of in mesangial cells (abst) 747
Fluconazole (abst) 272
Fluid electrolyte disorders (abst) 212, 234
Fluid replacement (abst) 214, 216
Fluorescence 154, 380, 485, 491
(abst) .....
microscopy (abst) 495
probes (abst) 170, 460, 484, 485, 491
Fluoroquinolones in PKD (abst) 738
Focal glomerulonephritis
plasma cationic proteins (abst) 743
Focal glomerulosclerosis
South African children (abst) 914
Focal segmental glomerulosclerosis
pathology of HIV associated 1363
Focal segmental sclerosis
drug therapy (abst) 194, 197, 349, 440
etiology (abst) 322, 340
occurrence (abst) 422
pathology (abst) 374, 435
pathophysiology (abst) 339, 344, 350, 423, 424, 425, 428, 429, 430, 433, 434, 436, 439, 442
therapy (abst) 523
Follow-up studies (abst) 516, 521, 523
Foot processes (abst) 356
Formic acid (abst) 461
Free radicals (abst) 271, 319, 403, 407, 412, 414, 421
Furosemide
(abst) 304, 380, 432, 452, 481

G protein
(abst) 154, 176, 178, 181, 184, 297 302, 396, 496
isolation and purification (abst) 182
pharmacologic actions (abst) 165
phyisology (abst) 161, 168
Galactose (abst) 296, 425
Gene
(abst) 178, 183, 356, 415
expression regulation (abst) 155, 169, 176, 185, 300, 302, 333, 342, 511
Genetics
biochemical (abst) 152, 364, 496
linkage (abst) 203, 205, 206
Gentamicin
adverse effects (abst) 406, 503
nephrotoxicity, glycosuria 1041
toxicity (abst) 401, 405, 406, 411, 415, 418
Glomerular basement membrane
aminonucleoside nephrosis 1410
change and cyst formation 1034
collagen IV 1195
NC1 domain abnormalities 843
type III collagen localized 1203
Glomerular blood flow
split hydronephrotic kidney 1151
Glomerular filtration rate
CsA inhibits PGE_2 formation in mesangial cells 1161
actions of CsA on mesangial cells 632
adenosine induces contraction of A1 receptor 1300
antioxidant therapy in ischemic renal failure 1282
delayed effect of growth hormone 865
drug effects on (abst) 278, 286, 309, 312, 322, 356, 435, 470, 474, 474, 475, 475
glycogen storage disease, type I 1350
growth and development (abst) 488
hemodynamics in CsA nephrotoxicity, uninephrectomy 1175
methods (abst) 201, 210
pathophysiology (abst) 213, 225, 232, 233, 326, 336, 364, 424
physiology (abst) 301, 470, 472
regulation (abst) 298, 313
rejection episodes, thromboxane inhibition 24
thromboxane synthesis in MN 76
vasoconstrictors in postobstructed kidneys 1311
Glomerular thrombi
Shwartzman reaction 14
Glomerulonephritis
acute obstructive urinary schistosomiasis mimics (abst) 909
acute post-streptococcal (abst) 915
anti-DNA antibodies cross reactivity (abst) 746
campylobacter jejuni gastroenteritis (abst) 749
cell mediated immunity (abst) 741
classification (abst) 213
eicosanoids and immune injury 985
essential mixed cryoglobulinemia 1004
etiology (abst) 343
expression of antigens 116
immunology (abst) 359, 371, 373, 375, 376
macrophages produce IL-1 (abst) 747
macrophages produce reactive oxygen species 778
occurrence (abst) 191
pathophysiology (abst) 341, 343, 344, 354, 360, 364, 367, 438, 439, 441
pregnancy outcome (abst) 739
prevention and control (abst) 354
procoagulant activity (abst) 743
profile of crescentic in Natal (abst) 914
reactive oxygen metabolites 1093
retroviral gp70 antigen 638

therapy (abst) ... 344
thrombin effect on cAMP ... 824
Glomerulosclerosis
antihypertensive therapy in uninephrectomized ... 790
hemodynamic changes vs. hypertrophy ... 654
low density lipoprotein, mesangial cells ... 1168
type III collagen ... 1203
Glomerulus
anatomy and histology (abst) ... 150, 422, 436
drug effects on (abst) ... 308
growth and development (abst) ... 164, 450
injuries (abst) ... 340, 424, 424, 427
metabolism (abst) ... 296, 472
pathology (abst) ... 346, 350, 352, 355, 372, 376, 425
pathophysiology (abst) ... 424
physiology (abst) ... 159, 278, 297, 316, 319, 437, 467, 468, 469, 473
secretion (abst) ... 159, 351, 361
transport (abst) ... 349
ultrastructure (abst) ... 370
Glucagon (abst) ... 444, 459, 469
Glucocorticoids
diagnostic use (abst) ... 251
metabolism (abst) ... 189
pharmacologic actions (abst) ... 168, 477
physiology (abst) ... 446, 481
therapeutic use (abst) ... 511
urine (abst) ... 439
Glucose
antagonists and inhibitors (abst) ... 437
biochemical actions (abst) ... 322
drug effects on (abst) ... 445
elevated, alters paracellular transport ... 31
metabolism (abst) ... 152, 184, 244
physiology (abst) ... 397, 438
transport (abst) ... 151, 181, 447, 450, 502
Glutamine (abst) ... 398, 442, 463, 466
Glutathione (abst) ... 402, 413
Glyceraldehyde excretion in Fanconi syndrome
patients ... 99
Glycerol (abst) ... 418
Glycine (abst) ... 406, 413, 420, 495
Glycocalyx, epithelial cell (abst) ... 150
Glycogen storage disease (abst) ... 212, 469
Glycogen storage disease, type I ... 1350
Glycolysis (abst) ... 444
Glycoproteins
(abst) ... 157, 373
analysis (abst) ... 382
antagonists and inhibitors (abst) ... 385
antibodies to (abst) ... 339, 341
pathophysiology (abst) ... 351
physiology (abst) ... 340
secretion (abst) ... 156
Glycosaminoglycans (abst) ... 352, 357
Glycosuria, phlorizin-induced ... 1041
Golgi
apparatus (abst) ... 186
cisternae (abst) ... 162
Goodpasture's syndrome
(abst) ... 365
autoimmunity in RPGN ... 929
Graft rejection
diagnosis (abst) ... 513, 516, 520, 523, 526
etiology (abst) ... 509
immunology (abst) ... 515, 524
mortality (abst) ... 523
occurrence (abst) ... 518
prevention and control (abst) ... 504, 507, 512, 512, 520, 522
Graft success ... 1073
Graft vs. host disease (abst) ... 353, 354
Growth
glyceraldehyde excretion, Fanconi syndrome ... 99
Growth factor
insulin-like, insulin receptors (abst) ... 151
Growth hormone
(abst) ... 194, 269, 315, 385
delayed effect on renal function in humans ... 865
Growth releasing hormone (abst) ... 385
Growth substances (abst) ... 295, 310
Guanine triphosphate (abst) ... 395
Guanylate cyclase (abst) ... 288

HLA-class II antigens in GN and normal kidneys ... 116
Haplotypes (abst) ... 205
Health Maintenance Organizations (abst) ... 199
Health services administration (abst) ... 245
Heart
(abst) ... 243, 282, 515
artificial (abst) ... 278, 289
diseases (abst) ... 422, 521, 523
surgery (abst) ... 249, 525
Hematocrit (abst) ... 241, 243, 250, 265, 271
Hematuria (abst) ... 209, 220, 222
Heme oxygenase (abst) ... 446, 448
Hemodialysis
adverse effects (abst) ... 193, 214, 240, 242, 244, 246, 251, 253, 258
ageing of cathetar (abst) ... 757
aluminum hydroxide alternative (abst) ... 739
amyloid syndromes ... 567
anemia of CRF, erythropoietin ... 134
beta $_2$ microglobulin amyloidosis (abst) ... 744
complications (abst) ... 192, 238, 239, 242, 243, 244, 246, 247, 252, 252, 253, 254, 257, 258, 261, 263, 264, 267, 267, 321, 346
cool dialysate (abst) ... 753
cyst formation, tubular basement membrane change ... 1034
desferrioxamine therapy in Al-associated bone disease ... 1376
dextran (abst) ... 757
double-lumen, silicone rubber catheters, permanent access ... 887
energy intake effect on nutritional status ... 704
immunology (abst) ... 255, 256, 371
induction of interleukin-1 ... 1212
intraerythrocytic pH variations during ... 871
math model simulates CAVH ... 125
membranes, complement C3 fragments ... 576
metabolism (abst) ... 266
methods (abst) ... 237, 238, 239, 241, 242, 243, 256, 257, 259, 259, 260, 261, 262, 262, 263, 263, 265, 267
mortality (abst) ... 245, 254, 256, 260
outcome (abst) ... 251
pharmacologic actions (abst) ... 245, 252
physiology (abst) ... 236, 239, 240, 243, 248, 251, 252, 255, 257, 264, 264, 266
PTA in stenosis of AVF (abst) ... 754
red cell cation transport in uremia ... 595
rehabilitation (abst) ... 383

shaking 1145
standards (abst) 243, 255, 262
therapeutic use (abst) 249, 517
two-pore formalism, solute transport 1234
utilization (abst) 237
vancomycin clearance, polysulfone dialyzers 1414
vs. dialysis in ESRD (abst) 753
Hemodynamics
amino acids, alanine and BCAA (abst) 756
autoregulation of split hydronephrotic kidney 1151
CsA nephrotoxicity following uninephrectomy 1175
drug effects on (abst) 227, 230, 237, 238
eicosanoids modulate immune injury 985
ischemic renal failure, antioxidant therapy 1282
pathophysiology (abst) 267
PGE_2 inhibited by CsA 1161
physiology (abst) 250
regulation (abst) 475
vs. hypertrophy in GS 654
Hemofiltration
analysis (abst) 250
drug therapy (abst) 244
methods (abst) 231, 249, 256, 260, 261, 263
outcome (abst) 251
physiology (abst) 241
therapeutic use (abst) 223
Hemoglobin (abst) 400, 421
Hemolytic uremic syndrome
(abst) 223, 230, 231, 232
tissue plasminogen activator therapy 14
Hemostasis (abst) 235, 518
Henoch Schönlein disease
(abst) 759
purpura (abst) 368, 372
ultrastructural changes in IgAN 880
Heparan sulfate (abst) 163, 165, 187
Heparin
adverse effects (abst) 359
analogs and derivatives (abst) 438, 446
isolation and purification (abst) 159
pharmacologic actions (abst) 287
therapeutic use (abst) 239, 242
Hepatitis B
nephrotic syndrome in children (abst) 909
vaccine (abst) 370
viruses (abst) 376, 514
Hepatoma G2 conditioned medium 1245
Hepatorenal syndrome (abst) 229
Herbal medicines (abst) 417
Herbs (abst) 353
Hereditary nephritis
NC1 domain abnormalities in collagen type IV in GBM 843
Heymann nephritis
(abst) 313, 351
etiology (abst) 340, 365
pathophysiology (abst) 165, 211
platelet activating factor (abst) 760
renal injury mechanisms 976
urinary C5b-9 60
Histidine (abst) 175
Histocompatibility antigens
(abst) 175, 205, 356, 366, 371, 375, 504
adverse effects (abst) 231
analysis (abst) 204
antagonists and inhibitors (abst) 349
antibodies to (abst) 522
pathophysiology (abst) 368
physiology (abst) 343
Histological techniques (abst) 370
Home hemodialysis (abst) 265
Hormones
ANF interaction with 799
enzymatic and binding effects of ANF 799
Human immunodeficiency virus
(abst) 255, 258, 268
pathology of associated nephropathy 1363
Hyaline droplets (abst) 432
Hybridization
(abst) 319, 342
kallikrein mRNA localization 1329
Hydrogen
secretion induced by amiloride 1107
Hydrogen ion
antagonists and inhibitors (abst) 467
intracellular (abst) 167
physiology (abst) 300, 307
regulation (abst) 488, 490, 492
secretion (abst) 458, 459, 465, 466
transport (abst) 156, 158, 173, 174, 186, 186, 217, 306, 323, 330, 451, 451, 452, 454, 455, 455, 457, 458, 460, 464, 464, 478
urine (abst) 199
Hydrolases (abst) 345
Hydronephrosis (abst) 207, 228, 476
Hydrostatic pressure (abst) 274, 488
Hyperaldosteronism (abst) 331, 471
Hypercalcemia
(abst) 250, 378, 388
Ca metabolism and hypertension 717
elective total parathyroidectomy 1395
vitamin D in moderate renal failure 661
Hypercalciuria (abst) 400
Hypercapnia (abst) 455, 464
Hyperchloremia
(abst) 219
urinary diversion 105
Hypercholesterolemia (abst) 429
Hyperfiltration
(abst) 442
adverse effects (abst) 189
depends on prostacyclin (abst) 757
diet therapy (abst) 221
glycogen storage disease, type I 1350
occurrence (abst) 203
pathophysiology (abst) 212, 229, 425, 450
regulation (abst) 429
Hyperkalemia
control during fasting in ESRD 90
control of serum K during fasting 90
drug therapy (abst) 238
pathophysiology (abst) 216, 452
prevention and control (abst) 249
voltage-dependent acidosis, amiloride 1107
Hyperlipidemia
(abst) 246, 422, 425, 426, 436, 519
low density lipoprotein, mesangial cells 1168
reduced renal mass on tissue lipids 40
Hypernatremia (abst) 214, 496, 498

Hyperoxaluria
(abst) ... 204
bone and joint disease (abst) ... 908
recurrent renal calculi (abst) ... 913
Hyperparathyroidism
(abst) ... 391, 395, 396, 396, 426
vitamin D_3 in uremia ... 1049
Hyperphosphatemia (abst) ... 383, 426
Hypertension
1K1C (abst) ... 286, 302
ACTH induced (abst) ... 750
CsA induced (abst) ... 748
calcium metabolism ... 717
chronic ACE inhibitor treatment (abst) ... 750
complications (abst) ... 205, 220, 235, 326, 338, 523
cyclosporine toxicity in endothelial cells ... 604
diet therapy (abst) ... 323, 328, 330, 337
drug effects on (abst) ... 198
drug therapy (abst) ... 199, 200, 328, 334, 337, 338
etiology (abst) ... 190, 194, 224, 257, 313, 322, 324, 325, 336, 338
familial and genetic (abst) ... 281
fibrillar nephropathy (abst) ... 756
interstitial nephritis ... 1257
malignant, RF requiring dialysis (abst) ... 915
metabolism (abst) ... 291
occurrence (abst) ... 204, 206, 233
pathophysiology (abst) ... 201, 316, 323, 327, 328, 329, 329, 332, 336, 338, 364, 396, 422, 428, 471, 510
prevention and control (abst) ... 335
renal vascular effects of therapy (abst) ... 790
surgery (abst) ... 232
therapy (abst) ... 193
Hypertrophy
gene expression, ureteral obstruction ... 1320
hemodynamic changes, GS ... 654
Hypocalcemia, (abst) ... 215, 218, 381
Hypochloremia (abst) ... 219
Hypogammaglobulinemia, transplantation (abst) ... 739
Hypokalemia
(abst) ... 215, 216, 481, 490
mineralocorticoids, Na-retaining effects ... 767
Hyponatremia
brain dehydration after rapid correction for ... 69
complications (abst) ... 218, 219
occurrence (abst) ... 215, 218
pathophysiology (abst) ... 216, 217, 307, 333
Hypoparathyroidism (abst) ... 218
Hypophosphatemia (abst) ... 338, 386
Hypophysectomy (abst) ... 283
Hypothalamic factor (abst) ... 157
Hypoxanthine (abst) ... 418
Hypoxia (abst) ... 403, 409, 412, 482

Iatrogenic disease (abst) ... 224
Idiopathic interstitial nephritis (abst) ... 349
IgA nephropathy
angiotension II receptors (abst) ... 741
Blacks and Indians of Natal (abst) ... 914
coeliac disease (abst) ... 756
complications (abst) ... 202
crescent formation, lymphocyte activation (abst) ... 743
drug therapy (abst) ... 345
estradiol and cyclophosphamide (abst) ... 756
etiology (abst) ... 357
immunology (abst) ... 349, 356, 370, 373
induced by oral immunization (abst) ... 760
interleukin-2 and IL-2 receptors in ... 875
occurrence (abst) ... 191
pathology (abst) ... 209, 370
pathophysiology (abst) ... 198, 347, 353, 371, 372, 372
polymeric and monomeric IgA1 by bone marrow ... 1405
retroviral gp70 antigen in GN ... 638
ultrastructural changes, histologic and clinical data ... 880
IgG nephritis
solubilization of IgG, IgA, C3 (abst) ... 755
Immune complex
antibody to ClQ antigen in MPGN ... 836
interaction of antibodies with cell surface antigens ... 954
Immune complexes
adverse effects (abst) ... 351, 356, 363
analysis (abst) ... 209
antagonists and inhibitors (abst) ... 345
antibodies to (abst) ... 373
aspects of circulating ... 993
biosynthesis (abst) ... 347
metabolism (abst) ... 165, 347
pathophysiology (abst) ... 362
physiology (abst) ... 341, 362, 366
urine (abst) ... 359
Immune deposit formation in MGN ... 1418
Immune response
expression of antigens in normal and GN kidneys ... 116
therapies to block undesired ... 1026
Immunity, cellular (abst) ... 174, 362, 363, 366, 509
Immunoglobulins
adverse effects (abst) ... 357, 361, 365
analysis (abst) ... 202
antagonists and inhibitors (abst) ... 375
biosynthesis (abst) ... 526
immunology (abst) ... 362
metabolism (abst) ... 355
pathophysiology (abst) ... 349
pharmacokinetics (abst) ... 371
physiology (abst) ... 346
secretion (abst) ... 193
therapeutic use (abst) ... 517, 520
transport (abst) ... 269, 431
urine (abst) ... 150
Immunohistologic techniques (abst) ... 369, 374
Immunologic cytotoxicity (abst) ... 354
Immunologic factors (abst) ... 308
Immunologic techniques (abst) ... 186, 369, 393
Immunosuppression
(abst) ... 198, 210, 353, 505, 510, 512, 515
pathogenesis and therapy of interstitial nephritis ... 1257
Immunosuppressive agents (abst) ... 230, 519
Immunotherapy (abst) ... 512, 517, 521
India, snake-bite-induced ARF ... 891
Indomethacin (abst) ... 440
Infection
(abst) ... 230, 242, 244, 249, 263
early cortical scarring in acute primary pyelonephritis ... 696
pyelonephritis and kidney growth ... 1133
Inflammation
(abst) ... 356
TxA_2 in mesangial cells (abst) ... 759

Injury
effect of cytokines on vascular endothelium 969
glomerular immune, eicosanoids 985
Heymann nephritis 976
macrophages, reactive oxygen species, GN 778
models for human nephropathology 1015
oxygen metabolites 1093
tissue lipids and reduced renal mass 40
tubular necrosis factor, bacterial lipopolysaccharide .. 1111
ultrastructural changes in IgAN 880
Inner medullary collecting duct
adrenergic control of cAMP generation 647
Inner stripe (abst) 458
Inner zone (abst) 451, 456, 465, 489, 496
Inositol
(abst) 428, 431
deficiency (abst) 322
metabolism (abst) 428
phosphate (abst) 445
physiology (abst) 296, 316
regulation (abst) 151
triphosphate (abst) .. 168, 172, 174, 175, 179, 181, 183, 185
Inositol phospholipid 1325
Insulin
antagonists and inhibitors (abst) 151
growth factor, insulin receptors (abst) 151
metabolism (abst) 443
pathophysiology (abst) 326
pharmacologic actions (abst) 326, 447, 475
physiology (abst) 397, 413
secretion (abst) 214, 427
Insulin-like growth factors
(abst) 151, 171, 179, 376
antagonists and inhibitors (abst) 436
biosynthesis (abst) 308
delayed effect in humans 865
drug effects on (abst) 310
pharmacologic actions (abst) 185, 312
physiology (abst) 181, 315
Insulitis, therapies to block undesired immune responses 1026
Integrin (abst) 159
Intercalated cell subtypes in CCD defined (abst) 150
Intercalated cells
(abst) 462, 466
classification (abst) 150, 453
isolation and purification (abst) 458
secretion (abst) 465
transport (abst) 463
ultrastructure (abst) 464
Intercellular junctions (abst) 151, 163
Interferons (abst) 175
Interleukin
and IL-2 receptor increased in IgAN 875
macrophages produce, in GN (abst) 747
pathophysiology (abst) 169
pharmacologic actions (abst.) 297, 353
physiology (abst) 358
regulation (abst) 320
therapeutic use (abst) 370
Interleukin-1
induction during hemodialysis 1212
Interleukins
(abst) 195, 263, 355, 360, 366, 370, 373, 375, 526
adverse effects (abst) 356
antagonists and inhibitors 369
biosynthesis (abst) 511
blood (abst) 375
genetics (abst) 342
immunology (abst) 342
Interstitial fibrosis (abst) 178
Interstitial nephritis
pathogenesis and therapy 1257
Intestinal absorption (abst) 218, 381, 388, 435
Intracellular fluid (abst) 411
Intracellular pH
(abst) 167, 172, 335, 387, 450, 454, 455, 458, 477
pathology (abst) 459, 491
pharmacologic actions (abst) 156
physiology (abst) 171
regulation (abst) ... 323, 329, 445, 450, 451, 453, 456, 456, 457, 460, 460, 462, 463, 464, 466
Intracellular signal transduction (abst) ... 170, 170, 171, 171, 172, 174, 175, 175, 177, 177, 178, 178, 180, 180, 181, 182, 182, 183, 184, 316, 494, 496, 505, 509
Intravenous pyelography (abst) 302
Inulin clearance (abst) 338
Iodine radioisotopes (abst) 218
Ion channels
analysis (abst) 170, 177, 491
antagonists and inhibitors (abst) 155
antibodies to (abst) 160
isolation and purification (abst) 160, 478
pathology (abst) 479, 487
physiology (abst) 155, 162, 169, 476
regulation (abst) ... 153, 154, 165, 166, 167, 176, 180, 279, 480, 483, 487
transport (abst) 467, 491
Ion exchange
antagonists and inhibitors (abst) 156, 459
drug effects on (abst) 303
pathology (abst) 456
physiology (abst) ... 159, 164, 171, 181, 271, 306, 411, 451, 457, 466, 493
regulation (abst) 166, 178, 306, 495
Ionic currents induced by stretch, mesangial cells
(abst) 153
Iron
(abst) 241, 246, 253, 266
overload in children, deferoxamine therapy 1335
status, erythropoietin, anemia 712
Ischemia
(abst) . 293, 400, 402, 404, 410, 412, 415, 418, 420, 506, 511
ANP and dopamine in ARF model 1126
adenosine induces contraction 1300
adenosine triphosphate and magnesium in transplants . 738
effects of antioxidant therapy 1282
Islet cells (abst) 161

Joint diseases (abst) 241
Juxtaglomerular apparatus (abst) 453
Juxtamedullary nephrons (abst) 430

Kallikrein
mRNA localization by hybridization 1329
Ketoacids (abst) 195, 217
Kidney
anatomy and histology (abst) 430, 432, 434

autoregulation in split hydronephrotic 1151
function tests (abst) 228, 235, 241, 260, 524
growth and development (abst) ... 223, 352, 380, 392, 427, 434, 440, 474
growth, ascending pyelonephritis 1133
hypoplasia (abst) 224
metabolism (abst) 299, 445, 448
remnant (abst) 194
Killer cells (abst) 509

LY146032 (abst) 220
Lactates (abst) 237, 449
Lactation (abst) 322
Laminin (abst) 156, 294, 352
Lanthanum (abst) 169
Lead (abst) 410
Lectins (abst) 157, 367
Lesions
ascending pyelonephritis and kidney growth 1133
autoimmunity in RPGN 929
early cortical scarring in acute primary pyelonephritis 696
essential mixed cryoglobulinemia 1004
innumoelectronmicroscopy (abst) 739
interstitial nephritis 1257
low density lipoprotein, mesangial cells 1168
models for human nephropathology 1015
treatment of minimal change glomerular (abst) 915
ultrastructural changes in IgAN 880
Leucine (abst) 449
Leucocytes
(abst) 273, 368, 372, 376
activation assays (abst) 743
reactive oxygen metabolites in glomerular disease ... 1093
Leukotrienes
analogs and derivatives (abst) 292
antagonists and inhibitors (abst) 291, 506
biosynthesis (abst) 295, 339
immunology (abst) 177
pharmacologic actions (abst) 288, 289
secretion (abst) 291
Light chain
binding sites in BBM (abst) 150
deposits (abst) 373
disease 209
Lipases (abst) 190, 350, 360
Lipids
antibodies interact with cell surface antigens 954
composition, BBM, glucose metabolism (abst) 152
effects of reduced renal mass on 40
metabolism (abst) 201, 401, 422, 430
pathophysiology (abst) 348
peroxides (abst) 493, 517
pharmacologic actions (abst) 468
Lipopolysaccharides
adverse effects (abst) 343
pharmacologic actions (abst) 309
tumor necrosis factor 1111
Lipoprotein
(abst) 269, 433, 439, 441, 519
low density, interactions with mesangial cells 1168
Liposomes (abst) 412
Lipoxins (abst) 291, 342
Lisinopril (abst) 227
Listrotic syndrome
diet therapy (abst) 472
Lithium
(abst) 305, 317, 322, 479
clearance (abst) 207
clearance in humans 1183
Lithotripsy (abst) 325
Liver
(abst) 154, 299, 514
identification of isoform, Na, K-ATPase (abst) 154
neoplasms (abst) 441
Liver diseases
(abst) 289
complications (abst) 405, 421
etiology (abst) 244
pathophysiology (abst) 284, 284, 307, 475
prevention and control (abst) 241
Loop of Henle
drug effects on (abst) 468, 476
injuries (abst) 409
physiology (abst) 166, 310, 311, 448, 473
transport (abst) 449, 452, 457, 481, 489
ultrastructure (abst) 417
utilization (abst) 449
Lupus erythematosus
changes of monocytes due to dialysis membranes 622
Lupus erythematosus, systemic
complications (abst) 191, 235
drug therapy (abst) 221, 235
immunology (abst) 368, 369, 375
pathophysiology (abst) 327
therapy (abst) 236
Lupus nephritis
diet therapy (abst) 368
drug effects on (abst) 358
drug therapy (abst) 210, 211
etiology (abst) 367
immunology (abst) 346
outcome (abst) 424
pathophysiology (abst) 189, 213, 341, 351, 366
therapy (abst) 230
Lymphocytes
(abst) 323, 346, 375, 462, 525
Lysosomal hydrolases (abst) 202
Lysosomes (abst) 411
Lysozyme (abst) 209

MDCK cells
organic osmolyte accumulation (abst) 152
MDCK cyst
cell proliferation and fluid secretion 1384
Macrocytosis (abst) 253
Macrophages
(abst) 295, 343, 350, 360, 367, 426, 507
reactive oxygen species in GN 778
Macula densa (abst) 299, 500
Magnesium
(abst) 377, 380, 383
and Ca homeostasis following urinary diversion 105
Magnetic resonance imaging (abst) 330, 432, 492
Magnetic resonance spectroscopy (abst) 322, 385
Malaria (abst) 223
Maleic acid (abst) 381
Manganese (abst) 284
Mannitol (abst) 323, 411

Mannose-6-phosphate (abst) 181
Mass screening (abst) 247
Maternal-fetal interactions (abst) 430
Mathematical model of CAVH 125
Maturity onset diabetes (abst) 911
Mechanoreceptors (abst) 294
Melanocyte stimulating hormone (abst) 327
Melphalan (abst) 209
Membrane attack complex
  Heymann nephritis, renal injury 976
Membrane fluidity (abst) 150, 157, 164, 166, 187, 373
Membrane nephropathy
  kinetics of immune deposits 1418
Membrane potentials (abst) 151, 477
Membrane proteins (abst) 153, 157, 164, 166, 187, 373
Membranes (abst) 159, 163, 276, 309
Membranoproliferative nephritis
  antibody to ClQ antigen 836
Membranous glomerulonephritis
  drug therapy (abst) 207, 208
  etiology (abst) 211, 295
  immunology (abst) 349
  injuries (abst) 362
  pathophysiology (abst) 340, 353, 363
Membranous nephropathy
  autoimmunity and the kidney 923
  prednisolone, cyclophosphamide- warfarin-di-
    pyridamole (abst) 751
  thromboxane synthesis inhibition 76
  urinary excretion of C5b-9 60
Mercury (abst) 410, 417, 497
Mesangial cells
  actions of CsA 632
  analysis (abst) 182
  Cl^-/base exchange, pH regulation 783
  drug effects on (abst) 308, 509
  growth and development (abst) ... 169, 179, 183, 187, 358, 436, 438, 441
  immunology (abst) 169, 362
  injuries (abst) 345, 355, 433
  inositol phospholipids 1325
  ionic currents induced by stretch (abst) 153
  isolation and purification (abst) 361
  kinetics of proliferation (abst) 747
  low density lipoprotein 1168
  metabolism (abst) 181, 185, 185, 402, 429
  neutralization of anionic sites, poly-L-lysine 817
  pathophysiology (abst) 174, 340, 342, 367
  physiology (abst) ... 153, 173, 177, 277, 292, 307, 319, 320, 432, 439, 505
  plasminogen activator 806
  regulation (abst) 162, 314, 318, 320, 343, 348
  secretion (abst) 180, 308, 309, 342, 344, 348, 349, 350, 357, 360
  transport (abst) 158, 438
  ultrastructure (abst) 156, 431
Mesangial matrix protein (abst) 345
Mesangial proliferative glomerulonephritis
  (abst) 197, 312, 350, 368, 372
  pregnancy (abst) 752
Mesangiocapillary glomerulonephritis
  Schistosoma mansoni 1227
  type II (abst) 368, 374
Mesangiolysis
  bone marrow transplantation, delayed renal failure .. 1341
Mesangium (abst) 425
Messenger kNA (abst) 176, 185, 302, 303, 319, 350
Metabolic acidosis
  drug therapy (abst) 463
  pathophysiology (abst) .. 217, 382, 389, 390, 452, 454, 459, 460, 462, 466
  therapy (abst) 214
Metabolic alkalosis (abst) 216, 454, 455, 456, 464, 466
Metabolic bone disease
  children, Fanconi syndrome 99
Metabolic clearance rate
  calcitriol in uremia 860
Metabolites
  oxygen, in glomerular disease 1093
  prostanoids effect on renin release 1138
Metals (abst) 410
Methylprednisolone induced cysts (abst) 747
Microalbuminuria
  (abst) 225, 235, 440
  hyperfiltration, glycogen storage disease 1350
Microbiologic techniques (abst) 234, 272, 275
Microcirculation
  analysis (abst) 279
  anatomy and histology (abst) 515
  antibodies to (abst) 372
  drug effects on (abst) ... 272, 282, 289, 291, 301, 308, 315, 472, 476
  injuries (abst) 323, 424
  pathophysiology (abst) 294
  physiology (abst) 433, 476
Microelectrodes (abst) 480
Microfilaments (abst) 410
Microfluorimetry (abst) 457, 463
Micropuncture (abst) 484
Microscopic polyarteritis (abst) 915
Microtubules (abst) 187, 188
Mineralocorticoids
  sodium retaining effects 767
Minimal change disease
  African nephrotic child (abst) 914
  drug therapy (abst) 197, 201, 236
  pathophysiology (abst) 208, 221
Misoprostol (abst) 520
Mitochondria (abst) 402, 403, 404, 405, 417, 421
Model
  PKD in guinea pigs (abst) 749
  relevance in human nephropathology 1015
  immunopathogenesis 938
Monoclonal antibodies
  basement membrane collagen in the kidney 1195
  CD45R, CD45 in leukocyte activation assays (abst) ... 743
  circulating immune complexes 993
  define discrete glomerular antigens (abst) 740
  expression of antigens in GN 116
  measure inactive renin (abst) 757
  membrane proteins (abst) 153
  OKT3 therapy in transplantation (abst) 742
  type III collagen localized 1203
Monoclonal antibodies .....
  (abst) 153, 361, 369, 507
  anti-Ia, transplantation (abst) 745
Monocytes (abst) 277, 353, 357, 362, 362, 365, 366
Monomeric IgA1 in bone marrow 1405
Mononuclear cells, IL-2 and IL-2 receptors in IgAN 875
Morphogenesis (abst) 344, 352

mRNA
alternative 5' exon splicing (abst) 152
gene expression in ureteral obstruction 1320j
Mucopolysaccharides (abst) 341
Multiple myeloma (abst) 199, 373
Muscles (abst) 267, 413, 433, 438
Mutagenesis (abst) 386
Myasthenia gravis (abst) 219
Mycobacteria in takayasus arteritis (abst) 913
Myeloma cast nephropathy (abst) 373
Myo-inositol influx/efflux and Na (abst) 151
Myocardial function (abst) 515
Myocytes (abst) 324

N-methyl imipramine (abst) 168
Na+K-ATPase, volume and osmolality (abst) 741
Na,K-ATPase
identification of liver isoform (abst) 154
Na,K-pump regulation in skeletal muscle 1
Nadolol (abst) 322
Natriuresis
(abst) 283, 284, 284, 285, 286, 353, 475
ANP inhibited by CEI without BP changes (abst) 751
autoregulation in split hydronephrotic kidney 1151
diuretic effect of ANF 799
Na and glomerulo-tubular balance (abst) 747
Navajo Indians (abst) 197
Neoplasms (abst) 250
Neopterins (abst) 526
Nephrectomy
(abst) 233, 439
glomerular solute transport 589
outcome (abst) 194, 233, 317, 467
pathophysiology (abst) 424
physiology (abst) 299
Nephrocalcin (abst) 385
Nephrogenic diabetes insipidus (abst) 203, 206, 494
Nephrolithiasis
chemical composition of urine (abst) 912
idiopathic calcium-oxalate 754
Nephrons (abst) 312, 359, 364, 455, 462, 468
Nephropathology, experimental models 1015
Nephroptosis (abst) 334
Nephrostomy (abst) 228
Nephrotic syndrome
ANP in volume homeostasis (abst) 759
classification (abst) 233
coagulation abnormalities in Blacks (abst) 914
diagnosis (abst) 219
drug therapy (abst) 201, 211, 213, 236, 432
familial and genetic (abst) 205
hemostasis activation (abst) 758
immunology (abst) 373
minimal change disease in African child (abst) 914
pathology (abst) 375
pathophysiology (abst) 286, 401, 429, 436
repeated steroids and proteinuria (abst) 910
steroid insensitive, CsA (abst) 909
test for amyloidosis (abst) 910
therapy (abst) 236
treatment of minimal change lesions (abst) 915
Nephrotoxicity
CsA in microvascular endothelial cells 604
cadavaric transplantation (abst) 911
cisplatin (abst) 740
cisplatin, parathyroidectomy (abst) 755
dopamine reverses acute CsA (abst) 754
gentamicin, glycosuria 1041
gentamicin, poly aspartic acid (abst) 748
Nervous system
diseases (abst) 252
physiology (abst) 327
Neurofibromatosis (abst) 204
Neurologic manifestations (abst) 257, 262, 266
Neuropeptides (abst) 283, 307
Neurotransmitters (abst) 257
Neutrophils
(abst) 370
antibodies to (abst) 226, 346
immunology (abst) 248
metabolism (abst) 248, 266, 271
pathophysiology (abst) 515
physiology (abst) 361
Nicardipine (abst) 317, 328, 404
Nickel (abst) 419
Nickel nephropathy (abst) 419
Nifedipine (abst) 404, 427, 440, 512, 513
Nitrendipine (abst) 337
Nitrogen
(abst) 191, 398
CAPD (abst) 742
Nitroprusside (abst) 224, 279, 326
Non-amyloidotic fibrillary glomerulopathy (abst) 233
Norepinephrine (abst) 292, 422, 428, 472
Norfloxacin (abst) 203
Nuclear magnetic resonance
87-rubidium, cation flux measurements 1249
Nucleosides (abst) 449
Nutrition
(abst) 225, 226, 238, 274
energy intake effect on, in HD patients 704

Obesity (abst) 224, 229
Ocular hypertension (abst) 239
OKT3 immunotherapy (abst) 512, 513, 514
OKY-046 in transplantation 24
Oliguria (abst) 224, 231, 232, 418
Omeprazole (abst) 462, 466, 467
Oncogenes (abst) 364
Oncotic pressure (abst) 498
Oral immunization induces IgAN (abst) 760
Organ
preservation (abst) 505, 509
procurement (abst) 233, 524
Ornithine decarboxylase (abst) 401
Osmolarity (abst) 158, 188, 487, 494, 499
Osmolytes (abst) 152, 492, 496, 498, 499
Osmotic
demyelination syndrome 69
fragility (abst) 429
gradients (abst) 500
pressure (abst) 470
Osteitis (abst) 379
Osteoblasts (abst) 379
Osteocalcin (abst) 380
Osteomalacia
(abst) 265, 376
cell line UMR 106-01, Al levels, ^{3}H-thymidine 1119
Osteonecrosis (abst) 518
Osteopenia (abst) 517

Osteoporosis (abst) ... 379
Ouabain (abst) ... 332, 484
Oxalate nephropathy (abst) ... 204, 434
Oxalates (abst) ... 255, 275, 498
Oxidoreductases (abst) ... 296, 304, 421
Oxygen
(abst) ... 346
consumption (abst) ... 217, 445, 448
metabolites in glomerular disease ... 1093
species, glomerulonephritis ... 778
Oxytocin (abst) ... 503

P-31 nuclear magnetic resonance, dehydrated kidney ... 830
P-glycoprotein (abst) ... 158
Pancreas, transplantation (abst) ... 738
Pancreatic diseases (abst) ... 190, 233
Para-aminohippuric acid
5-HIAA an alternate index for RPF ... 95
Parathyroid cell
proliferation inhibited by vitamin D3 in uremia ... 1049
Parathyroid glands
(abst) ... 389, 392, 395, 395, 397
blood (abst) ... 393
vitamin D receptors are decreased in ... 14
Parathyroid hormones
antagonists and inhibitors (abst) ... 254
drug effects on (abst) ... 390
metabolism (abst) ... 243
pharmacologic actions (abst) ... 172, 178, 180, 180, 184, 188, 193, 281, 387, 391, 392, 435
physiology (abst) ... 300, 389, 391, 393, 394, 396, 397
secretion (abst) ... 252, 261, 389, 392, 394, 394 397
therapeutic use (abst) ... 377
toxicity (abst) ... 422
Parathyroidectomy in ESRD ... 1395
Parenteral nutrition (abst) ... 222, 238
Pars convoluta (abst) ... 184, 387, 459, 462, 481, 489
Pars recta (abst) ... 160, 387
Particle arrays (abst) ... 502
Pedigrees (abst) ... 203
Pepsinogens (abst) ... 503
Peptides
(abst) ... 316, 360, 503
complement C3 fragments, hemodialysis membranes ... 576
Percutaneous angioplasty (abst) ... 192
Peritoneal dialysis
(abst) ... 270, 272, 273, 434
analysis (abst) ... 272
complications (abst) ... 275
drug therapy (abst) ... 269, 274, 276
influence of shaking ... 1145
instrumentation (abst) ... 269
metabolism (abst) ... 268
pathophysiology (abst) ... 275
physiology (abst) ... 274, 274, 276
utilization (abst) ... 270
Peritoneoscopy (abst) ... 269
Peritoneum
immunology (abst) ... 273, 277
metabolism (abst) ... 270
transport (abst) ... 269, 270, 272, 273, 275, 276, 276, 277
Peritonitis
diagnosis (abst) ... 270
drug therapy (abst) ... 272, 274
etiology (abst) ... 275
immunology (abst) ... 273, 342
in CAPD (abst) ... 744
occurrence (abst) ... 267, 268, 268
peritoneal dialysis, biofilm spread along catheter ... 614
persistence of, treatment (abst) ... 908
prevention and control (abst) ... 275
rational treatment in CAPD (abst) ... 913
Permeability
(abst) ... 246, 275, 276, 277
drug effects on (abst) ... 497
regulation (abst) ... 187, 461, 499
Permselectivity
(abst) ... 332
peritoneal pore size (abst) ... 755
pH
regulation of intracellular, Cl^-/base exchanger ... 783
variations during hemodialysis ... 871
Phase contrast microscopy (abst) ... 222
Phenytoin (abst) ... 346
Pheochromocytoma (abst) ... 332
Phloretin (abst) ... 494
Phlorhizin
(abst) ... 437
glycosuria and nephrotoxicity ... 1041
Phorbol esters (abst) ... 173
Phosphate
aluminum hydroxide alternative in HD ... 739
deficiency (abst) ... 389
depletion alters phospholipid in BBM (abst) ... 153
intracellular (abst) ... 380
metabolism (abst) ... 388
metabolism disorders (abst) ... 255, 264
metabolism, inositol phospholipid ... 1325
P-31 NMR in obstructed or dehydrated kidney ... 830
transport (abst) ... 150, 381, 383, 384, 388, 394
Phosphatidyl inositol synthase (abst) ... 155
Phosphodiesterases (abst) ... 306, 494
Phospholipases
(abst) ... 181, 297, 298
antagonists and inhibitors (abst) ... 176, 302
isolation and purification (abst) ... 292
physiology (abst) ... 182
regulation (abst) ... 168
Phospholipids (abst) ... 152, 153, 170, 179, 305
Phosphonoformic acid (abst) ... 382
Phosphorus
diet therapy (abst) ... 384, 390
deficiency (abst) ... 153
metabolism (abst) ... 338, 427, 438
pathophysiology (abst) ... 455
regulation (abst) ... 387, 395
transport (abst) ... 165, 171, 382, 385, 386, 386, 391
Phosphorylation (abst) ... 442
Pima Indians, proteinuria and diabetes ... 681
Pituitary hormones (abst) ... 427
Placenta (abst) ... 290
Plasma
factor (abst) ... 221
volume (abst) ... 251
Plasma cryoprecipitation (abst) ... 236
Plasma membrane antigens
interaction of antibodies with ... 954
Plasmapheresis (abst) ... 223, 230
Plasminogen activator in mesangial cells ... 806
Plasminogen activators (abst) ... 180, 181, 185

Platelet
aggregation (abst) ... 510
antibodies to (abst) ... 345
derived growth factor (abst) ... 170
metabolism (abst) ... 296, 305
pathology (abst) ... 368
pathophysiology (abst) ... 294
physiology (abst) ... 350, 363
secretion (abst) ... 340
Platelet activating factor
actions of CsA on mesangial cells ... 632
antagonists and inhibitors (abst) ... 408
biosynthesis (abst) ... 310
pathophysiology (abst) ... 320, 441
pharmacologic actions (abst) ... 175, 293
physiology (abst) ... 182, 185, 419
treatment of Heymann nephritis (abst) ... 760
Podocalyxin (abst) ... 164
Poly aspartic acid, nephrotoxicity (abst) ... 748
Poly-L-lysine, neutralization of anionic mesangial sites ... 817
Polyamines (abst) ... 403
Polyarteritis, microscopic (abst) ... 915
Polycations and biological membranes in MCN (abst) ... 760
Polycystic kidney disease
cell proliferation and fluid secretion ... 1384
complications (abst) ... 205
congenital in guinea pigs (abst) ... 749
cyst derived cells in vitro ... 1356
diagnosis (abst) ... 202, 206
drug therapy (abst) ... 203
familial and genetic (abst) ... 203, 205
fluoroquinolones in (abst) ... 738
immunology (abst) ... 369
occurrence (abst) ... 206
pathophysiology (abst) ... 203
renal concentrating capacity ... 675
surgery (abst) ... 204
tubular basement membrane change, cyst formation ... 1034
Polycythemia (abst) ... 524
Polymeric IgA_1 in bone marrow ... 1405
Polyols, differential regulation of (abst) ... 152
Polysulfone dialyzers, vancomycin clearance ... 1414
Polyuria, polydipsia, mineralocorticoids ... 767
Population characteristics (abst) ... 268
Potassium
adverse effects (abst) ... 214
bicarbonate improves Ca balance in healthy men ... 688
control of, during fasting, ESRD ... 90
deficiency (abst) ... 215, 455, 460, 490
diet therapy (abst) ... 324, 330
Na,K-pump regulation in skeletal muscle ... 1
pharmacologic actins (abst) ... 296
physiology (abst) ... 387
regulation (abst) ... 161, 162, 459, 482, 486, 488, 489, 491
secretion (abst) ... 482, 483, 486, 491
secretion, tubular acidosis and amiloride ... 1107
standards (abst) ... 484
transport (abst) ... 161, 161, 180, 216, 325, 466, 479, 480, 485, 487, 489
urine (abst) ... 477
Prazosin (abst) ... 200
Pre-eclampsia
glomerular features (abst) ... 742
Prednisolone
(abst) ... 506
or CWD on outcome of MGN patients (abst) ... 751
Prednisone
administration and dosage (abst) ... 201, 208, 213
therapeutic use (abst) ... 207, 209, 221
Pregnancy
angiotensin II effects (abst) ... 750
complications (abst) ... 204, 225, 338
diffuse mesangial proliferative GN (abst) ... 752
outcome between normal and GN patients ... 739
pathophysiology (abst) ... 435, 472
physiology (abst) ... 479, 494
pre-eclampsia (abst) ... 742
Prenatal diagnosis (abst) ... 206
Principle cells (abst) ... 453, 466
Prognosis (abst) ... 198, 248, 258, 260, 523
Progressive renal injury
lipid metabolism ... 40
Progressive renal insufficiency, allograft acceptance ... 1073
Prolactin (abst) ... 263
Propionates (abst) ... 495
Prostacyclin
and hyperfiltration (abst) ... 757
production, CsA toxicity ... 604
Prostaglandin
analogs and derivatives (abst) ... 415
antagonists and inhibitors (abst) ... 286, 297, 446
biosynthesis (abst) ... 157, 290, 291, 292, 293, 294, 295, 296, 297, 318, 354, 402, 409, 430, 493, 505, 508
metabolism (abst) ... 176, 179, 364
pharmacologic actions (abst) ... 168, 294, 470, 494, 496
physiology (abst) ... 298, 480
secretion (abst) ... 277, 291, 294, 297, 482
synthase (abst) ... 296, 312, 320
urine (abst) ... 292, 293, 296
Prostaglandin E_2
CsA inhibits formation in mesangial cells ... 1161
Prostanoids
renin release, macula densa ... 1138
Protamine
(abst) ... 151, 276
action, tight junction formation (abst) ... 151
Proteases (abst) ... 408
Protein
amyloid syndromes in hemodialysis ... 567
band 3 mRNA predicts ... 152
bicarbonate lost during metabolism ... 1277
C (abst) ... 226
carbonic anhydrase ... 851
catabolism (abst) ... 447, 449
content in streptozotocin diabetic rats ... 48
electrophoresis (abst) ... 333
energy intake effect on nutritional status, HD ... 704
guanine nucleotide regulatory, Na^+ channels (abst) ... 154
kinase C activation (abst) ... 154
membrane, generation of monoclonal antibodies ... 153
plasma cationic, MCNS, FGS (abst) ... 743
quantitation (abst) ... 219
restriction in CRF (abst) ... 909
S (abst) ... 226
synthesis (abst) ... 406
transport of, and neutral dextran in CAPD ... 1064
turnover (abst) ... 446
Protein A-gold
epithelial cells (abst) ... 741
immunoelectronmicroscopy (abst) ... 739

Protein kinases
antagonists and inhibitors (abst) 307, 393, 497
pathophysiology (abst) 324
pharmacologic actions (abst) 172, 464
physiology (abst) 154, 163, 174, 176, 178, 305, 394, 478, 483
regulation (abst) 170, 181, 184, 430
Proteinases (abst) 348
Proteinuria
diagnosis (abst) 219, 225, 230
drug effects on (abst) 320
drug therapy (abst) 197, 211, 227
etiology (abst) 351, 364
Heymann nephritis, renal injury 976
hyperfiltration, glycogen storage disease 1350
occurrence (abst) 224, 233
pathology of HIV associated nephropathy 1363
pathophysiology (abst) .. 221, 313, 322, 332, 353, 364, 420, 425, 433, 472
phosphate restriction, PGE_2 excretion (abst) 737
repeated steroids, nephrotic syndrome (abst) 910
thromboxane synthesis in MN 76
type 2 diabetes mellitus in Pima Indians 681
Proteoglycans
(abst) 159
adverse effects (abst) 359
analysis (abst) 420
biosynthesis (abst) 160, 164, 294, 341, 344, 352
immunology (abst) 341
isolation and purification (abst) 352
sulfated, PKD 1034
Protons, "new" bicarbonate formed during net acid excretion 1277
Proximal tubules
(abst) 389
drug effects on (abst) 381
elevated glucose alters paracellular transport 31
growth and development (abst) 167, 314
injuries (abst) .. 361, 407, 409, 410, 413, 413, 416, 418, 420, 504, 515, 525
metabolism (abst) 164, 173, 386, 390, 393, 444, 446
pathophysiology (abst) 366, 423
physiology (abst) ... 151, 152, 155, 160, 300, 317, 323, 468, 469, 489, 492, 500, 501
protein kinase C (abst) 154
secretion (abst) 322
transport (abst) 318, 402, 426, 450, 451, 452, 454, 457, 460, 476, 482, 483, 485, 487, 495, 495
ultrastructure (abst) 400, 410, 411, 457
Psychological
processes (abst) 194, 265, 267
stress (abst) 475
Psychology of transplantation (abst) 910
Pterins (abst) 192
Pulmonary edema (abst) 513
Pump,Na,K;regulation in skeletal muscle 1
Purine nucleotides (abst) 448
Puromycin aminonucleoside nephrosis
anionic charge of GBM 1410
Pyelonephritis
(abst) 194, 223, 234, 371
early cortical scarring 696
retards kidney growth 1133

Quality of health care (abst) 262
Quality of life (abst) 195, 196, 246, 247
Questionnaires (abst) 196

RNA (abst) 155, 406
Radiography (abst) 327, 414
Radioimmunoassay (abst) 510, 514, 516
Radionuclide imaging
(abst) 334, 418
diagnostic use (abst) 223, 521, 526
methods (abst) 201, 329
Radiotherapy (abst) 354
Ranitidine (abst) 398
Rapidly progressive glomerulonephritis
(abst) 210, 226, 347, 374, 374, 385, 503
autoimmunity 929
Type I (abst) 208, 345, 355, 362, 366, 441
Type II (abst) 320, 347, 350, 364
Resorption
drug effects on (abst) 413
growth and development (abst) 488
pathology (abst) 457
physiology (abst) 189, 500
regulation (abst) 499
Receptor
adenosine (abst) 314, 415
alpha adrenergic (abst) 163, 311, 317, 488
angiotensin (abst) 433, 440
beta adrenergic (abst) 162, 311
diuretic (abst) 477, 490
dopamine (abst) 172, 285, 287, 317, 320, 329, 477
EGF (abst) 417
IGF (abst) 171
immunologic (abst) 177, 263, 363, 515
immunologic, blood (abst) 523
immunologic, classification (abst) 362
immunologic, diagnostic use (abst) 374
immunologic, physiology (abst) 341, 355, 367
insulin (abst) 151, 433
leukotriene (abst) 291
lipoprotein (abst) 439
peptide (abst) .. 185, 207, 278, 279, 281, 282, 285, 288, 304, 307, 325
prostaglandin (abst) 298
steroid (abst) 169, 182
thromboxane (abst) 297, 505
vitamin D, decreased in parathyroid glands 19
Recombinant human erythropoietin
anemia of CRF 134
burst forming unit erythroid (abst) 755
Reflux nephropathy
prognosis, sex (abst) 749
Rejection
therapies to block undesired immune responses 1026
thromboxane inhibition prevents allograft 24
vascular endothelial cell expression, HLA antigens (abst) 742
Related donor transplantation (abst) . 512, 515, 518, 519, 520, 524
Renal abscesses, peri-renal (abst) 910
Renal adaptation (abst) ... 156, 176, 290, 295, 299, 304, 310, 319, 384, 424, 434, 435, 439, 450, 500
Renal allograft
thromboxane inhibition prevents rejection 24
Renal arteries (abst) 306, 428, 470, 511
Renal artery disease (abst) 192

Renal artery stenosis (abst) 224, 326, 333
Renal blood flow
adenosine induces contraction 1300
drug effects (abst) 198
drug effects on (abst) ... 304, 321, 322, 327, 332, 416, 468, 475
growth and development (abst) 473
kallikrein mRNA localization 1329
methods (abst) 228
pathophysiology (abst) 233, 332, 336, 414, 467, 471
physiology (abst) 192, 317, 470, 470
regulation (abst) 313, 317, 323, 404, 469
Renal cortex (abst) 421, 442, 473
Renal failure
digoxin-like factors (abst) 909
iron overload, children, deferoxamine therapy 1335
ischemic, antioxidant therapy 1282
moderate, vitamin D administration 661
pathology of HIV associated 1363
Tasmanian 1987 survey (abst) 748
Renal function in uninephrectomized humans (abst) 737
Renal growth
ureteral obstruction, gene expression 1320
Renal hypertrophy (abst) 225
Renal infarction (abst) 204
Renal insterstitial pressure (abst) 287
Renal insufficiency
progression, role of BP 670
Renal medulla (abst) 281, 311, 421, 455
Renal nerves (abst) 196, 404
Renal osteodystrophy (abst) 377, 378, 379
Renal papillary necrosis
CIN and NSAIDS (abst) 752
Renal plasma flow
delayed effect of growth hormone 865
plasma 5-hydroxyindoleacetic acid and index of 95
Renal tubular acidosis (abst) 199, 461
Renal tubules
injuries (abst) 504
metabolism (abst) 397, 447
pathophysiology (abst) 213, 359, 387
physiology (abst) 154, 413, 438
transport (abst) 444
Renin
analogs and derivatives (abst) 301
analysis (abst) 303
antagonists and inhibitors (abst) 304
biosynthesis (abst) 290, 300, 333
blood (abst) 405
deficiency (abst) 216
diagnostic use (abst) 335
drug effects on (abst) 331
kallikrein mRNA localization 1329
measured with monoclonal antibodies (abst) 757
physiology (abst) 423
regulation (abst) 206, 302, 317
release, prostanoids 1138
secretion (abst) . 264, 299, 301, 323, 324, 325, 326, 338, 475
stimulation of secretion by sulfhydryl reagents 812
Renotropic factor (abst) 295
Renovascular diseases (abst) 314
Renovascular hypertension
complications (abst) 357
diagnosis (abst) 323, 329, 331, 335
drug effects on (abst) 327
etiology (abst) 330, 333, 334, 334, 473
occurrence (abst) 331, 333
pathophysiology (abst) 278, 324, 337
therapy (abst) 325
Respiratory acidosis (abst) 457
Retinoic acid (abst) 429
Retroviral gp70 antigen in GN 638
Retroviruses (abst) 522
Rhabdomyolysis (abst) 225
Rheumatoid factor (abst) 202, 365
Rifampin (abst) 271, 274
Risk factors (abst) 198, 242, 245, 246, 247, 269

S-protein, SP-40,40 in renal biopsies (abst) 746
SIADH (abst) 216
Salicylates (abst) 421
Saline solution, hypertonic (abst) 280
Salmonella infection (abst) 343
Sangivamycin (abst) 497
Scarring (abst) 371
Scarring in acute primary pyelonephritis 696
Schistosoma mansoni, glomerulonephritis 1227
Secondary hyperparathyroidism
vitamin D receptors decreased in uremia 19
Selenium (abst) 414, 434
Septicemia (abst) 253
Serine proteases (abst) 310
Serotonin
5-HIAA an alternate index for RPF 95
(abst) 163
Sex differences (abst) 423, 519
Sexual function (abst) 203
Shaking, peritoneal transfer 1145
Shiga-like toxins (abst) 230
Shock
(abst) 401
protein (abst) 506
Shwartzman reaction 14
Skeletal muscle, Na,K-pump regulation 1
Skin (abst) 238
Skin bleeding time, DDAVP (abst) 751
Sleep apnea syndrome (abst) 224
Snake bite induced ARF in India 891
Snake venoms (abst) 340
Sodium
administration and dosage (abst) 227, 303
adverse effects (abst) 218
antagonists and inhibitors (abst) 465
blood (abst) 289
brain dehydration after rapid correction of hyponatremia 69
channel regulation by guanine nucleotide (abst) 154
channel, A6 cell RNA encoding (abst) 155
deficiency (abst) 300, 452
diet therapy (abst) 323, 324, 325, 327, 328, 337, 430
escape from Na-retaining effects of mineralocorticoids 767
glomerulo-tubular balance, natriuresis (abst) 747
glucose cotransporter in gallbladder (abst) 151
lithium clearance in humans 1183
metabolism (abst) 326, 329
myo-inositol influx/efflux (abst) 151
Na,K pump regulation in skeletal muscle 1
pharmacologic actions (abst) 151, 313
physiology (abst) 322, 336

reduced in cystinuria (abst) 912
regulation (abst) ... 167, 303, 327, 328, 337, 386, 456, 475, 479, 481, 482, 483, 483, 485, 486, 488, 488, 492
secretion (abst) 484, 488
transport (abst) 151, 156, 158, 171, 174, 181, 186, 186, 189, 282, 288, 299, 302, 312, 314, 317, 318, 322, 323, 325, 328, 329, 330, 332, 386, 388, 394, 429, 442, 451, 451, 453, 454, 455, 455, 457, 458, 460, 464, 464, 468, 471, 477, 478, 479, 480, 482, 483, 489, 490, 493
urine (abst) 189, 279, 280, 286, 298, 300, 423, 441, 477
Soluble immune response suppressor (abst) 373
Solute removal (abst) 240, 246, 251, 274
Somatomedins (abst) 312, 315
Somatostatin (abst) 459
Sorbitol (abst) 438, 496
Sorginil (abst) 433
Spermine (abst) 403
Sphingosine (abst) 174
Splanchnic nerves (abst) 476
Statistics (abst) 200
Stem cells (abst) 321
Stereoisomers (abst) 298
Stilbene (abst) 464, 498
Stone
calcium stone disease, metabolic abnormalities (abst) . 749
kinetics of immune deposits in MGN 1418
urate crystals interact with tubular cells (abst) 747
Stone former
dietary factors in recurrent (abst) 912
Streptozotocin (abst) 469
Streptozotocin-diabetic rats, dietary protein 48
Substance abuse (abst) 192, 225, 248
Substrate specificity (abst) 416
Succinylacetone (abst) 501
Sucralfate (abst) 383
Sulfate
Ca and Mg homeostasis following urinary diversion ... 105
Sulfhydryl groups (abst) 165, 384
Sulfhydryl reagents, renin secretion 812
Sulfonamides (abst) 210
Sulindac (abst) 291
Superficial nephrons (abst) 453, 473
Superoxide dismutase (abst) 399, 402
Surgical wound infection (abst) 511
Sympathomimetics (abst) 238, 445, 476

T cells
antoimmunity and the kidney 923
biosynthesis (abst) 505
cross match, chromium release (abst) 909
drug effects on (abst) 508
immunology (abst) 210, 370, 508
interleukin-2 and IL-2 receptors in IGAN 875
physiology (abst) 358, 506
regulation (abst) 352, 371
therapies to block undesired immune responses 1026
Takayasus arteritis, mycobacteria (abst) 913
Tasmanian renal failure survey 1987 (abst) 748
Taurine, amino acids in CAPD 1219
Temperature (abst) 248
Testosterone (abst) 193
Theophylline (abst) 403
Thiazide diuretics (abst) 477, 490
Threshold trait (abst) 205
Thrombin
(abst) 177, 185
effect on cAMP in glomeruli 824
Thrombosis
(abst) 226, 359
renal vein in childhood (abst) 751
Thromboxane
analogs and derivatives (abst) 291, 294, 295, 402
antagonists and inhibitors (abst) ... 207, 297, 416, 508, 510
biosynthesis (abst) 296, 320, 354, 505, 508
inhibition, allograft rejection 24
physiology (abst) 347
secretion (abst) 425
synthetase (abst) 354
synthesis inhibition in membranous nephropathy 76
Thromboxane A_2
human mesangial cells (abst) 759
vasoconstrictors, GFR in postobstruction 1311
Thymosin (abst) 198, 362
Thyroid hormones (abst) 167, 168, 234
Tight junction formation, gallbladder (abst) 151
Tissue adhesive, catheter implantation (abst) 757
Tissue plasminogen activator therapy 14
Tobramycin (abst) 244, 416
Tomography, computed (abst) 191, 270, 329
Toxic
Csa in microvascular endothelial cells 604
Toxic/metabolic nephropathies (abst) 357, 410, 417, 508
Toxicity
actions of CsA on mesangial cells 632
cyclosporine (abst) 741
oxygen metabolites in glomerular disease 1093
pathology of HIV associated nephropathy 1363
PGE_2 inhibited by CsA 1161
UMR 106-01, Al levels, ^{3}H-thymidine 1119
Transcription, genetic (abst) 170, 183, 415, 431, 441
Transforming growth factors (abst) 186, 341, 432
Transplantation
adenosine triphosphate, magnesium (abst) 738
adverse effects (abst) 514
allograft accepance 1073
allopurinol superoxide dismutase, catalase (abst) 746
anemia of CRF, rHuEpo 134
anti-Ia monoclonal antibody (abst) 745
B_2-m levels (abst) 745
blood transfusion, CsA (abst) 739
cadaveric renal, CsA (abst) 745
complications (abst) 513, 516, 519, 522, 525
convertion from triple therapy to AZA/prednisolone (abst) 745
cytomegalovirus infection (abst) 908
delayed renal failure, bone marrow 1341
dialysis in children (abst) 753
differential psychological response (abst) 910
donor-specific transfusion, CsA and antibody 1057
drug therapy (abst) 511, 511, 517, 524
elective total parathyroidectomy in ESRD 1395
hypogammaglobulinemia (abst) 739
immunology (abst) 506, 514, 526
improved biopsy technique (abst) 745
in South Africa (abst) 911
islet, prevents glycosylation in diabetes (abst) 748
lack of xenoantibody response (abst) 746
metabolism (abst) 526
OKT3 therapy (abst) 742

outcome (abst) ... 194, 204, 522
pathology (abst) ... 515
pathophysiology (abst) ... 517, 521
PGE_2 inhibited by CsA ... 1161
problems in aboriginal population (abst) ... 738
rehabilitation (abst) ... 510
results of cadavaric (abst) ... 911
synchronous pancreas (abst) ... 738
therapeutic use (abst) ... 376
therapy (abst) ... 506
thromboxane inhibition prevents rejection ... 24
triple therapy in 114 cadaveric donor (abst) ... 738
utilization (abst) ... 513, 514, 516, 519, 521, 521, 523
Transport
alcohol and renal water (abst) ... 750
ANP effect on (abst) ... 751
circulating immune complexes ... 993
cytochalasin B binding ... 1290
glomerular solute, nephrectomy ... 589
lithium clearance in humans ... 1183
Na,K-pump regulation in skeletal muscle ... 1
net acid excretion, "new" bicarbonate ... 1277
oxalate, RBC anomaly (abst) ... 754
paracellular, elevated glucose ... 31
peritoneal pore size (abst) ... 755
peritoneal solute, two-pore formalism ... 1234
Pi, cholesterol modulates BBM fluidity and (abst) ... 150
red cell cation, uremia ... 595
serum proteins, neutral dextran, CAPD ... 1064
stimulation of renin secretion, sulfhydryl reagents ... 812
Triazolam (abst) ... 252
Triglycerides (abst) ... 266, 315
Trimethoprim (abst) ... 222
Triple therapy
in 114 cadaveric renal transplants (abst) ... 738
Trypsinogen (abst) ... 233
Tubular absorption (abst) ... 498
Tubular secretion (abst) ... 222, 338
Tubuloglomerular feedback (abst) ... 453, 467, 468, 469, 473
Tubulointerstitial disease
(abst) ... 345, 349, 368, 418
pathology of HIV associated ... 1363
Tubulointerstitial nephritis
immunopathogenesis ... 938
Tumor lysis syndrome (abst) ... 215
Tumor necrosis factor
adverse effects (abst) ... 367
biosynthesis (abst) ... 309
immunology (abst) ... 186
pathophysiology (abst) ... 173, 179
pharmacologic actions (abst) ... 297, 310, 318
production, baterial lipopolysaccharide ... 1111
regulation (abst) ... 344
secretion (abst) ... 270
Type IV collagen
abnormalities in NC1 domain, hereditary nephritis ... 843
a3 chain (abst) ... 746
Tyrosine (abst) ... 225

UMR 106-01, Al levels ... 1119
Ultrafiltration
CAPD (abst) ... 752
math model of CAVH ... 125
Ultrasound imaging (abst) ... 191, 270, 526
Ultrastructure, changes with IgAN ... 880
Uninephrectomized humans, renal function (abst) ... 737
Uninephrectomy
CsA toxicity ... 1175
vascular effects of antihypertensive therapy ... 790
United States (abst) ... 200
Urea
(abst) ... 196, 228, 494, 501
kinetic modeling relevance to CAPD (abst) ... 744
math model of CAVH ... 125
Uremia
(abst) ... 196
AVP secretion, CHD (abst) ... 755
adverse effects (abst) ... 157
amino acid dialysis solution ... 1189
calcitriol, metabolic clearance rate ... 860
complications (abst) ... 201
diagnosis (abst) ... 399
growth and development (abst) ... 385
hemodialysis, red cell cation transport ... 595
intestinal absorption of Al ... 1306
metabolism (abst) ... 391, 392, 396, 427, 498
pathophysiology (abst) ... 201
physiology (abst) ... 376
vitamin D receptors decreased ... 19
vitamin D_3 and parathyroid cell proliferation ... 1049
Uremic encephalopathy (abst) ... 273
Ureter (abst) ... 344
Ureteral obstruction
(abst) ... 461
gene expression in response to ... 1320
vasoconstrictors normalize GFR ... 1311
Uric acid disorders (abst) ... 208
Uric acid nephropathy (abst) ... 219
Urinalysis (abst) ... 191, 225, 236, 369
Urinary abnormalities (abst) ... 232, 236
Urinary diversion, Ca and Mg homeostasis ... 105
Urinary obstruction
P-31 NMR in dehydrated or obstructed kidney ... 830
Urinary pH (abst) ... 220
Urinary schistosomiasis mimics GN (abst) ... 909
Urinary stone disease
arterial pressure in Italian population (abst) ... 754
Urinary tract infection, malnourished children (abst) ... 910
Urinary tract obstruction
complications (abst) ... 217, 442
pathophysiology (abst) ... 227, 287, 299, 431
therapy (abst) ... 228
Urine
chemical composition, South African patients (abst) ... 912
cyst formation, DPT, tubular basement membrane change ... 1034
glyceraldehyde excretion, Fanconi syndrome ... 99
lithium clearance in humans ... 1183
renal concentrating capacity in PKD ... 675
urate crystals interact with tubular cells (abst) ... 747
Urodynamics (abst) ... 232
Urolithiasis (abst) ... 232, 325, 382, 400

Vacuolization (abst) ... 374, 504
Vancomycin
(abst) ... 220, 253
clearance in HD with polysulfone dialyzers ... 1414
Vasa recta (abst) ... 500
Vascular access, permanent with silicone rubber catheters ... 887

Vascular injury, cytokines 969
Vascular renal disease
  thrombin effect on cAMP 824
Vascular resistance
  ACTH-induced hypertension (abst) 750
  drug effects on (abst) ... 280, 284, 289, 297, 302, 321, 328, 331, 336, 428, 472, 474, 504, 512
  etiology (abst) 511
  pathophysiology (abst) 414
  physiology (abst) 306, 325, 330
  regulation (abst) ... 257, 296, 307, 314, 317, 319, 324 335, 472
Vascular smooth muscle
  drug effects on (abst) 331
  pathophysiology (abst) 324, 333, 335
  pharmacologic actions (abst) 162, 326
  physiology (abst) 183, 306, 329, 331
  transport (abst) 330
Vascular surgery (abst) 228, 232
Vasculitis
  (abst) 208, 226
  ELISA detects antibodies (abst) 743
Vasoactive intestinal peptide (abst) 215
Vasoconstriction (abst) 412
Vasoconstrictors
  GFR in postobstruction 1311
Vasopressins
  administration and dosage (abst) 235, 305, 307
  analogs and derivatives (abst) 286
  antagonists and inhibitors (abst) 202, 206, 305
  drug effects on (abst) 293
  pharmacologic actions (abst) . 152, 158, 169, 171, 172, 181, 188, 301, 307, 311, 444, 445, 480, 489, 493, 495, 497, 499, 501, 503
  physiology (abst) 173, 175, 305, 307, 307, 480, 501
  regulation (abst) 217, 465
  secretion (abst) 324, 333
  therapeutic use (abst) 229
Vena cava (abst) 278
Venom, snake-bite-induced ARF in India 891
Ventricular function (abst) 334
Verapamil
  (abst) 363, 366, 403, 427, 440, 474
Visual evoked potentials (abst) 189
Vitamin A (abst) 429
Vitamin C (abst) 244, 261, 275, 276, 434, 435, 435
Vitamin D
  administration and dosage (abst) 395
  adverse effects (abst) 350
  analogs and derivatives (abst) 175, 254, 282, 338, 393, 393, 397
  calcitriol in uremia 860
  deficiency (abst) 377, 385
  drug therapy (abst) 276
  moderate renal failure 661
  pathophysiology (abst) 215
  pharmacologic actions (abst) 358
  physiology (abst) 384, 390
  receptors decreased in parathyroid glands, uremia 19
  regulation (abst) 390
  therapeutic use (abst) 220, 390, 400
  uremia, parathyroid cell proliferation 1049
Vitamin E (abst) 414, 434, 435
Voltage dependent tubular acidosis, amiloride 1107
Volume
  acute post-streptococcal GN (abst) 915
  mechanisms of regulatory decrease (abst) 155
  Na-retaining effects of mineralocorticoids 767
  osmolality, Na+K+ATPase (abst) 741
Volume expansion (abst) 280, 281, 318, 472, 478, 488
Von Willebrand factor (abst) 235

Water
  channels (abst) 152, 157, 188, 305, 497, 502
  endosomes containing channels (abst) 152
  expansion (abst) 280
  immersion (abst) 283, 287
  metabolism (abst) 305
  regulation (abst) 158
  transport (abst) 187, 293, 305, 312, 490, 492, 495, 497, 498, 499, 500, 501, 502
Water-electrolyte balance (abst) 215, 239, 261, 283, 289, 289, 482
Wegener's granulomatosis (abst) 370

Xanthine oxidase (abst) 412

Z-riboside (abst) 448
Zinc (abst) 399

KIDNEY INTERNATIONAL

Volume 35, Number 1, January 1989

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Regulation of the Na,K-pump in skeletal muscle. *Torben Clausen and Maria E. Everts* 1

LABORATORY INVESTIGATION

Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction. *Jerry M. Bergstein, with the technical assistance of Mark Riley* 14

1,25-$(OH)_2$D receptors are decreased in parathyroid glands from chronically uremic dogs. *Alex J. Brown, Adriana Dusso, Silvia Lopez-Hilker, Jane Lewis-Finch, Patricia Grooms, and Eduardo Slatopolsky* 19

Chronic thromboxane inhibition preserves function of rejecting rat renal allografts. *Thomas M. Coffman, Phillip Ruiz, Fred Sanfilippo, and Paul E. Klotman* 24

Elevated glucose alters paracellular transport of cultured human proximal tubule cells. *Debra J. Hazen-Martin, Mary Ann Sens, Carol J. Detrisac, John G. Blackburn, and Donald A. Sens* 31

Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. *Bertram L. Kasiske, Michael P. O'Donnell, Margot P. Cleary, and William F. Keane, with the technical assistance of Fred Phillips* 40

Effects of dietary protein content in streptozotocin-diabetic rats. *S. Michael Mauer, Michael W. Steffes, Silvia Azar, and David M. Brown* 48

Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. *Matthias Schulze, Patricia J. Baker, Diana T. Perkinson, Richard J. Johnson, Rex F. Ochi, Rolf A. K. Stahl, and William G. Couser* 60

Brain dehydration and neurologic deterioration after rapid correction of hyponatremia. *Richard H. Sterns, Darbbie J. Thomas, and Robert M. Herndon* 69

Effect of thromboxane synthesis inhibition in a model of membranous nephropathy. *Friedrich Thaiss, Peter J. Germann, Sabine Kahf, Wilhelm Schoeppe, Udo Helmchen, and Rolf A. K. Stahl.* 76

CLINICAL INVESTIGATION

Renal function following acute renal failure in childhood: A long term follow-up study. *Helen N. Georgaki-Angelaki, David B. Steed, Cyril Chantler, and George B. Haycock* 84

Control of serum potassium during fasting in patients with end-stage renal disease. *James D. Gifford, Edwin A. Rutsky, Katharine A. Kirk, and Huey G. McDaniel* 90

Plasma 5-hydroxyindoleacetic acid as an endogenous index of renal plasma flow. *Thierry Hannedouche, Dominique Laude, Michèle Déchaux, Jean-Pierre Grünfeld, and Jean-Luc Elghozi..* 95

Urine glyceraldehyde excretion is elevated in the renal Fanconi syndrome. *Adam J. Jonas, Shen-Nan Lin, Susan B. Conley, Jerry A. Schneider, Julian C. Williams, and Richard C. Caprioli .* 99

Effect of sulfate on calcium and magnesium homeostasis following urinary diversion. *W. Scott McDougal and Michael O. Koch* 105

Expression of HLA-DQ, -DR, and -DP antigens in normal kidney and glomerulonephritis. *Claudia A. Müller, Jasmina Markovic-Lipkovski, Teut Risler, Adalbert Bohle, and Gerhard A. Müller...* 116

The simulation of continuous arteriovenous hemodialysis with a mathematical model. *Thomas L. Pallone, Scott Hyver, and Jeffrey Petersen* 125

Contents continued on next page

NEPHROLOGY FORUM

The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. *Joseph W. Eschbach* 134

ABSTRACTS

American Society of Nephrology 149

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 561

Awards and Grants 564

Instructions for Authors on pages xix–xxi

KIDNEY INTERNATIONAL

Volume 35, Number 2, February 1989

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Amyloid syndromes associated with hemodialysis. *Kenneth S. Kleinman and Jack W. Coburn* .. 567

LABORATORY INVESTIGATION

Analysis of the complement C3 fragments associated with hemodialysis membranes. *Alfred K. Cheung, Charles J. Parker, and Jarmila Janatova* 576

Unilateral nephrectomy and glomerular solute transport in the dog. *Lee W. Henderson and John K. Leypoldt* 589

Hemodialysis and red cell cation transport in uremia: Role of membrane free fatty acids. *Ralph A. Kelly, Mitzy L. Canessa, Theodore I. Steinman, and William E. Mitch* 595

Cyclosporine toxicity on cultured rat microvascular endothelial cells. *David C.W. Lau, Kar-Lit Wong, and Wei Sek Hwang* 604

Peritonitis in peritoneal dialysis: Bacterial colonization by biofilm spread along the catheter surface. *Ronald R. Read, Parker Eberwein, Mrinal K. Dasgupta, Stacey K. Grant, Kan Lam, J. Curtis Nickel, and J. William Costerton* 614

Functional changes of monocytes due to dialysis membranes. *Dario Roccatello, Gianna Mazzucco, Rosanna Coppo, Giuseppe Piccoli, Cristiana Rollino, Berta Scalzo, Maria Grazia Guerra, Guido Cavalli, Osvaldo Giachino, Alessandro Amore, Fabio Malavasi, and Luigi Massimino Sena* 622

Actions of cyclosporin A on cultured rat mesangial cells. *Diego Rodríguez-Puyol, Santiago Lamas, Ana Olivera, Antonio López-Farré, Gonzalo Ortega, Luis Hernando, and José M. López-Novoa.* 632

Retroviral gp70 antigen in spontaneous mesangial glomerulonephritis of ddY mice. *Eiji Takeuchi, Toshio Doi, Toshihide Shimada, Eri Muso, Naoki Maruyama, and Haruyoshi Yoshida* 638

Adrenergic control of cAMP generation in rat inner medullary collecting tubule cells. *Isaac Teitelbaum, Alexis Strasheim, and Tomas Berl* 647

Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. *Yoshiyuki Yoshida, Agnes Fogo, and Iekuni Ichikawa* 654

CLINICAL INVESTIGATION

$1,25(OH)_2D_3$ administration in moderate renal failure: A prospective double-blind trial. *Laurence R.I. Baker, S.M. Louise Abrams, Christopher J. Roe, Marie-Claude Faugere, Paolo Fanti, Yahya Subayti, and Hartmut H. Malluche* 661

Progression of renal insufficiency: Role of blood pressure. *Peter C. Brazy, William W. Stead, and James F. Fitzwilliam* 670

The clinical utility of renal concentrating capacity in polycystic kidney disease. *Patricia A. Gabow, William D. Kaehny, Ann M. Johnson, Irene T. Duley, Michael Manco-Johnson, Dennis C. Lezotte, and Robert W. Schrier* 675

Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. *Charles L. Kunzelman, William C. Knowler, David J. Pettitt, and Peter H. Bennett* 681

Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men. *Jacob Lemann, Jr., Richard W. Gray, and Joan A. Pleuss* 688

Contents continued on next page

Frequency of development of early cortical scarring in acute primary pyelonephritis. *Alain Meyrier, Marie-Claude Condamin, Marc Fernet, Agnès Labigne-Roussel, Pierre Simon, Patrice Callard, Muriel Rainfray, Marc Soilleux, and Arlette Groc* 696

Effect of energy intake on nutritional status in maintenance hemodialysis patients. *Larry A. Slomowitz, Francisco J. Monteon, Mary Grosvenor, Steward A. Laidlaw, and Joel D. Kopple* .. 704

Iron status in patients receiving erythropoietin for dialysis-associated anemia. *David B. Van Wyck, John C. Stivelman, Joaquin Ruiz, Linda F. Kirlin, Murray A. Katz, and David A. Ogden* 712

NEPHROLOGY FORUM

Calcium metabolism and hypertension. *David A. McCarron* 717

ABSTRACTS

The Australasian Society of Nephrology 737

Italian Society of Nephrology 754

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 762

Awards and Grants 764

Erratum 765

Instructions for Authors on p. xii

KIDNEY INTERNATIONAL

Volume 35, Number 3, March 1989

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Escape from the sodium-retaining effects of mineralocorticoids: Role of ANF and intrarenal hormone systems. *J. Michael Gonzalez-Campoy, J. Carlos Romero, and Franklyn G. Knox* 767

LABORATORY INVESTIGATION

Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. *Neil W. Boyce, Peter G. Tipping, and Stephen R. Holdsworth* 778

Cl^-/base exchange in rat mesangial cells: Regulation of intracellular pH. *Majdeldin Ferdows, Keivan Golchini, Sharon G. Adler, and Ira Kurtz* 783

Renal vascular effects of antihypertensive therapy in uninephrectomized SHR. *Lance D. Dworkin, Mayer Grosser, Helen D. Feiner, Michael Ullian, and Miriam Parker* 790

Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. *Jin K. Kim, Sandra N. Summer, Jacques Durr, and Robert W. Schrier* 799

Characterization of a plasminogen activator and its inhibitor in human mesangial cells. *Roger Lacave, Eric Rondeau, Satochi Ochi, Françoise Delarue, Wolf Dieter Schleuning, and Jean-Daniel Sraer* 806

Stimulation of renin secretion by non-diuretic sulfhydryl reagents. *Doo Yun Lee, Kyung Woo Cho, Jae Seung Lee, Thomas W. Honeyman, and Chun Sik Park* 812

Neutralization of the anionic sites of cultured rat mesangial cells by poly-L-lysine. *Francesco Pugliese, Paolo Mené, Maria Cristina Anania, and Giulio A. Cinotti* 817

Effect of thrombin on cyclic AMP content in glomeruli isolated from rat kidney. *Sudhir V. Shah.* 824

P-31 nuclear magnetic resonance spectral changes in obstructed or dehydrated kidney. *Joseph I. Shapiro, Robert L. Cosby, and Laurence Chan* 830

Antibody to a cryptic, solid phase C1Q antigen in membranoproliferative nephritis. *C. Frederic Strife, Anne E. Leahy, and Clark D. West* 836

Abnormalities in the NCl domain of collagen type IV in GBM in canine hereditary nephritis. *Paul Thorner, Reuben Baumal, Victor E.O. Valli, Don Mahuran, Roderick McInnes, and Paula Marrano* 843

Renal membrane-bound carbonic anhydrase. Purification and properties. *Per J. Wistrand and Karl-Gustav Knuuttila* 851

CLINICAL INVESTIGATION

Metabolic clearance rate and production rate of calcitriol in uremia. *Adriana Dusso, Silvia Lopez-Hilker, Jane Lewis-Finch, Patricia Grooms, Alex Brown, Kevin Martin, and Eduardo Slatopolsky* 860

The delayed effect of growth hormone on renal function in humans. *Raimund Hirschberg, Hamid Rabb, Ronaldo Bergamo, and Joel D. Kopple* 865

Intraerythrocytic pH variations during hemodialysis: A ^{31}P NMR study. *J.P. Monti, P. Gallice, M. Baz, A. Murisasco, A. Crevat, and R. Elsen* 871

Increased production of interleukin-2 and IL-2 receptor in primary IgA nephropathy. *F. Paolo Schena, Giovanna Mastrolitti, Emilio Jirillo, Irene Munno, Nelli Pellegrino, A. Rita Fracasso, and Lucia Aventaggiato* 875

Contents continued on next page

Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. *Hyun Soon Lee, Yong Choi, Jung Sang Lee, Byung Hee Yu, and Haeng Il Koh* 880

TECHNICAL NOTE

Successful use of double-lumen, silicone rubber catheters for permanent hemodialysis access. *Neil H. Shusterman, Kathleen Kloss, and James L. Mullen* 887

NEPHROLOGY FORUM

Snake-bite-induced acute renal failure in India. *K.S. Chugh* 891

ABSTRACTS

South African Renal Congress 908

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 917

Awards and Grants 920

Instructions for Authors on p. xiv

KIDNEY INTERNATIONAL

Volume 35, Number 4, April 1989

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

SYMPOSIUM ON THE PATHOGENETIC MECHANISMS IN NEPHRITIS

Introduction. *Andrew J. Rees, Guiseppe A. Andres, and D. Keith Peters* 921

Autoimmunity and the kidney. *David B.G. Oliveira and D. Keith Peters* 923

Autoimmunity in rapidly progressive glomerulonephritis. *Charles D. Pusey and C. Martin Lockwood* 929

Study of the immunopathogenesis of tubulointerstitial nephritis using model systems. *Curtis B. Wilson* 938

Interaction of antibodies with renal cell surface antigens. *Jan R. Brentjens and Giuseppe Andres* .. 954

Effects of cytokines on vascular endothelium: Their role in vascular and immune injury. *Ramzi S. Cotran and Jordan S. Pober* 969

Heymann nephritis: Mechanisms of renal injury. *David J. Salant, Richard J. Quigg, and Andrey V. Cybulsky* 976

Eicosanoids and the modulation of glomerular immune injury. *Elias A. Lianos* 985

Physiological and pathological aspects of circulating immune complexes. *Jürg A. Schifferli and Ronald P. Taylor* 993

Renal involvement in essential mixed cryoglobulinemia. *Giuseppe D'Amico, G. Colasanti, F. Ferrario and R.A. Sinico* 1004

Relevance of experimental models for human nephropathology. *Philip J. Hoedemaeker and Jan J. Weening* 1015

Toward more selective therapies to block undesired immune responses. *Terry B. Strom and Vicki E. Kelley* 1026

LABORATORY INVESTIGATION

Tubular basement membrane change occurs pari passu with the development of cyst formation. *Frank A. Carone, Paul F. Hollenberg, Sakie Nakamura, Phaibul Punyarit, Walter Glogowski, and George Flouret* 1034

Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats. *Walter L. Gouvea, Helen C. Alpert, Jan Kelley, Victoriano Pardo, and Carlos A. Vaamonde* 1041

$1,25(OH)_2$ vitamin D_3 inhibits parathyroid cell proliferation in experimental uremia. *Andras Szabo, Jürgen Merke, Eric Beier, Gerhard Mall, and Eberhard Ritz* 1049

CLINICAL INVESTIGATION

Renal transplantation: Cyclosporin A and antibody development after donor-specific transfusion. *Ibrahim A. Al-Muzairai, Andrew Innes, Andrew Hillis, Keith N. Stewart, John M. Bone, Graeme R.D. Catto, and Alison M. Macleod* 1057

The peritoneal transport of serum proteins and neutral dextran in CAPD patients. *Raymond T. Krediet, Gerardus C.M. Koomen, Marion G. Koopman, Franciscus J. Hoek, Dirk G. Struijk, Elisabeth W. Boeschoten, and Lambertus Arisz* 1064

NEPHROLOGY FORUM

The role of adaptation in allograft acceptance. *Robert A.P. Koene* 1073

Contents continued on next page

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 1088
Awards and Grants 1091

Instructions for Authors on p. xvi

KIDNEY INTERNATIONAL

Volume 35, Number 5, May 1989

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Role of reactive oxygen metabolites in experimental glomerular disease. *Sudhir V. Shah* 1093

LABORATORY INVESTIGATION

An in vivo study of voltage-dependent renal tubular acidosis induced by amiloride. *Glen G. Allen and Lindsay J. Barratt* 1107

Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. *Laurent Baud, Jean-Paul Oudinet, Marcelle Bens, Lydie Noe, Marie-Noëlle Peraldi, Eric Rondeau, Jacqueline Etienne, and Raymond Ardaillou* 1111

Micromolar aluminum levels reduce ^{3}H-thymidine incorporation by cell line UMR 106-01. *Harry C. Blair, Jane L. Finch, Richard Avioli, Edmond C. Crouch, Eduardo Slatopolsky, and Steven L. Teitelbaum* 1119

Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure. *John D. Conger, Sandor A. Falk, Brad H. Yuan, and Robert W. Schrier* 1126

Ascending pyelonephritis in young rats retards kidney growth. *Lars Hannerz, Gianni Celsi, Ann-Christine Eklöf, Sante Olling, Ingrid Wikstad, and Anita Aperia* 1133

Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. *Sadayoshi Ito, Oscar A. Carretero, Keishi Abe, William H. Beierwaltes, and Kaoru Yoshinaga* 1138

Influence of shaking on peritoneal transfer in rats. *Michael D. Levitt, Julie M. Kneip, and Michael C. Overdahl* 1145

Visualization of renal autoregulation in the split hydronephrotic kidney of rats. *Michael Steinhausen, Marcus Blum, John T. Fleming, Frank G. Holz, Niranjan Parekh, and David L. Wiegman, with the technical assistance of R. Dussel* 1151

Cyclosporin A inhibits prostaglandin E_2 formation by rat mesangial cells in culture. *Rolf A.K. Stahl, Stephen Adler, Patricia J. Baker, Richard J. Johnson, Yi-Pu Chen, Pam Pritzl, and William G. Couser* 1161

Interactions of low density lipoprotein with rat mesangial cells. *James Wasserman, Arthur Santiago, Vincent Rifici, Harry Holthofer, Linda Scharschmidt, Margaret Epstein, and Detlef Schlondorff* 1168

Glomerular hemodynamics in cyclosporine nephrotoxicity following uninephrectomy. *Jonathan A. Winston, Robert Feingold, and Robert Safirstein* 1175

CLINICAL INVESTIGATION

Small intra- and large inter-individual variability in lithium clearance in humans. *Walther H. Boer, Hein A. Koomans, Jaap J. Beutler, Carlo A. Gaillard, Anton J. Rabelink, and Evert J. Dorhout Mees* 1183

CAPD with an amino acid dialysis solution: A long-term, cross-over study. *Michele Bruno, Cristiana Bagnis, Martino Marangella, Lidia Rovera, Alberto Cantaluppi, and Franco Linari* .. 1189

Basement membrane collagen in the kidney: Regional localization of novel chains related to collagen IV. *Ralph J. Butkowski, Jörgen Wieslander, Mary Kleppel, Alfred F. Michael, and Alfred J. Fish* 1195

Contents continued on next page

Contents continued

Glomerular localization of type III collagen in human kidney disease. *Kazuo Yoshioka, Tsukasa Takemura, Machi Tohda, Norihisa Akano, Hiroyuki Miyamoto, Akira Ooshima, and Sunao Maki.* 1203

In vivo induction of interleukin-1 during hemodialysis. *Nicole Haeffner-Cavaillon, Jean-Marc Cavaillon, Christian Ciancioni, Francoise Bacle, Simone Delons, and Michel D. Kazatchkine..* 1212

Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis. *Bengt Lindholm, Anders Alvestrand, Peter Fürst, and Jonas Bergström* 1219

Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: Influence of therapy. *Reinaldo Martinelli, Antônio Carlos B. Noblat, Edilson Brito, and Heonir Rocha*..... 1227

Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism. *Bengt Rippe and Gunnar Stelin*..... 1234

TECHNICAL NOTES

Hepatoma G2 conditioned medium facilitates early outgrowth of endothelial cells from isolated glomeruli. *Sharon Elliot, Liliane J. Striker, Toshio Doi, W. Marston Linehan, and Gary E. Striker.* 1245

87-Rubidium NMR: A novel method of measuring cation flux in intact kidney. *Zoltan H. Endre, Jonathan L. Allis, Peter J. Ratcliffe, and George K. Radda* 1249

NEPHROLOGY FORUM

Pathogenesis and therapy of interstitial nephritis. *Eric G. Neilson*..... 1257

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings..... 1272

Awards and Grants 1275

Instructions for Authors on p. 1276

KIDNEY INTERNATIONAL

Volume 35, Number 6, June 1989

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

How much "new" bicarbonate is formed in the distal nephron in the process of net acid excretion? *Mitchell L. Halperin* 1277

LABORATORY INVESTIGATION

Early events in ischemic renal failure in the rat: Effects of antioxidant therapy. *Joan E. Bird, Andrew P. Evan, Orjan W. Peterson, and Roland C. Blantz* 1282

Cytochalasin B binding to rabbit proximal tubular basolateral membranes. *Peter T. Cheung and Marc R. Hammerman* 1290

Comparative studies of two acid β-galactosidases from rabbit and bovine kidney. *Vicenta S. Martínez-Zorzano, Francisco J. Rodríguez Berrocal, José A. Cabezas, and María Páez de la Cadena* 1295

Adenosine induces mesangial cell contraction by an A_1-type receptor. *Ana Olivera, Santiago Lamas, Diego Rodriguez-Puyol, and José M. López-Novoa* 1300

Prior inhibition of vasoconstrictors normalizes GFR in postobstructed kidneys. *Mabel L. Purkerson and Saulo Klahr* 1306

Gene expression in response to acute unilateral ureteral obstruction. *Ihor S. Sawczuk, Gerald Hoke, Carl A. Olsson, John Connor, and Ralph Buttyan* 1315

Analysis of inositol tris- and tetrakisphosphate in mesangial cells by HPLC. *SungHyo Shin, Yoshihiro Fujiwara, Toshiro Takama, Satoshi Ochi, Akira Wada, Megumu Fukunaga, Yoshimasa Orita, Takenobu Kamada, and Kunio Tagawa* 1320

Renal kallikrein mRNA localization by in situ hybridization. *William Xiong, Lee Chao, and Julie Chao* 1324

CLINICAL INVESTIGATION

Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD. *Sharon P. Andreoli and Mervyn Cohen* 1330

Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. *Corinne Antignac, Marie-Claire Gubler, Guy Leverger, Michel Broyer, Renée Habib, with the technical assistance of Mireille Lacoste, Agnès Beziau, and Colette Naizot* 1336

Hyperfiltration and renal disease in glycogen storage disease, type I. *Lester Baker, Stephen Dahlem, Stanley Goldfarb, Elizabeth F.O. Kern, Charles A. Stanley, Joseph Egler, Jerrold S. Olshan, and Sidney Heyman* 1345

Cyst-derived cells do not exhibit accelerated growth or features of transformed cells in vitro. *Frank A. Carone, Sakie Nakamura, Barbara S. Schumacher, Phaibul Punyarit, and Kenneth D. Bauer* 1351

Pathology of HIV-associated nephropathy: A detailed morphologic and comparative study. *Vivette D'Agati, Jung-Il Suh, Laura Carbone, Jen-Tse Cheng, and Gerald Appel* 1358

Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. *Arnold J. Felsenfeld, Mariano Rodriguez, Michael Coleman, Dennis Ross, and Francisco Llach* 1371

Contents continued on next page

Chemical modification of cell proliferation and fluid secretion in renal cysts. *Jared J. Grantham, Marie Uchic, E.J. Cragoe, Jr., James Kornhaus, J. Aaron Grantham, Vicki Donoso, Roberto Mangoo-Karim, Andrew Evan, and James McAteer* 1379

Elective total parathyroidectomy without autotransplant in end-stage renal disease. *Michael Kaye, Pierre D'Amour, and Janet Henderson* 1390

Elevated production of polymeric and monomeric IgA1 by the bone marrow in IgA nephropathy. *A. Warmold L. van den Wall Bake, Mohamed R. Daha, Joost J. Haaijman, Jiri Radl, Arno van der Ark, and Leendert A. van Es* 1400

TECHNICAL NOTE

Analysis of anionic charge of the glomerular basement membrane in aminonucleoside nephrosis. *Shuzo Kobayashi, Mitsumasa Nagase, Nishio Honda, Kyoko Adachi, Norio Ichinose, and Akira Hishida* 1405

Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. *Diane M. Lanese, Patricia S. Alfrey, and Bruce A. Molitoris* 1409

Influence of dietary constituents on intestinal absorption of aluminum. *Neil A. Partridge, Fred E. Regnier, Joe L. White, and Stanley L. Hem* 1413

NEPHROLOGY FORUM

Kinetics of immune deposits in membranous nephropathy. *Pierre J. Verroust* 1418

ABSTRACTS

Dutch Society of Nephrology 1429

Fifth Hellenic Congress of Nephrology 1436

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 1450

Awards and Grants 1453

ACKNOWLEDGMENT OF REFEREES 1456

INDEX TO VOLUME 35

Instructions for Authors on pp. xxxi–xxxiii